# PeptideScanner evidence objects: Tirzepatide

Every published version of the records placed with Tirzepatide, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json. Selected public evidence only; not medical advice.

- Objects: 211
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct03940742-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT03940742

> PeptideScanner retained ClinicalTrials.gov record NCT03940742 at 2026-07-30T19:15:14.510Z. Its registry update date was 2023-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct03940742-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-03-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03940742-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct03940742-tirzepatide-v1
- Content SHA-256: `ac892cf781efa3a13156d45466b8b691d43f942505a2089aece32782cc003040`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03940742 ([`ctg-observation-nct03940742-2023-03-24-e847bffefdf5`](#source-ctg-observation-nct03940742-2023-03-24-e847bffefdf5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03940742 at 2026-07-30T19:15:14.510Z. Its registry update date was 2023-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct03940742-2023-03-24-e847bffefdf5`](#source-ctg-observation-nct03940742-2023-03-24-e847bffefdf5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03940742 at 2026-07-30T19:15:14.510Z. Its registry update date was 2023-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct03940742-2023-03-24-e847bffefdf5`](#source-ctg-observation-nct03940742-2023-03-24-e847bffefdf5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03940742-2023-03-24-e847bffefdf5`](#source-ctg-observation-nct03940742-2023-03-24-e847bffefdf5))

### Sources

<a id="source-ctg-observation-nct03940742-2023-03-24-e847bffefdf5"></a>
- **ClinicalTrials.gov record NCT03940742 · retained source version 2023-03-24:e847bffefdf5c1fd8ed94a964cd6e7ffb27effeb05b8cb86b53bdde09328f465** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03940742) (`ctg-observation-nct03940742-2023-03-24-e847bffefdf5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03940742." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct03940742-tirzepatide-v1 SHA-256: ac892cf781efa3a13156d45466b8b691d43f942505a2089aece32782cc003040.

---

<a id="clinicaltrials-gov-nct04081337-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT04081337

> PeptideScanner retained ClinicalTrials.gov record NCT04081337 at 2026-07-30T18:48:25.645Z. Its registry update date was 2024-02-08, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct04081337-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-02-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04081337-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct04081337-tirzepatide-v1
- Content SHA-256: `49ac490c5b23c6c0109e9b3cf406be464754432c682367ffaa7513bf9dbea37e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04081337 ([`ctg-observation-nct04081337-2024-02-08-de8b30f54424`](#source-ctg-observation-nct04081337-2024-02-08-de8b30f54424))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04081337 at 2026-07-30T18:48:25.645Z. Its registry update date was 2024-02-08, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct04081337-2024-02-08-de8b30f54424`](#source-ctg-observation-nct04081337-2024-02-08-de8b30f54424))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04081337 at 2026-07-30T18:48:25.645Z. Its registry update date was 2024-02-08, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct04081337-2024-02-08-de8b30f54424`](#source-ctg-observation-nct04081337-2024-02-08-de8b30f54424))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04081337-2024-02-08-de8b30f54424`](#source-ctg-observation-nct04081337-2024-02-08-de8b30f54424))

### Sources

<a id="source-ctg-observation-nct04081337-2024-02-08-de8b30f54424"></a>
- **ClinicalTrials.gov record NCT04081337 · retained source version 2024-02-08:de8b30f54424c2c8bc007576bcc007c02fbef58223386c10d10466ed596dee92** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04081337) (`ctg-observation-nct04081337-2024-02-08-de8b30f54424`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04081337." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct04081337-tirzepatide-v1 SHA-256: 49ac490c5b23c6c0109e9b3cf406be464754432c682367ffaa7513bf9dbea37e.

---

<a id="clinicaltrials-gov-nct04172987-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT04172987

> PeptideScanner retained ClinicalTrials.gov record NCT04172987 at 2026-07-30T19:15:14.513Z. Its registry update date was 2023-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct04172987-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2023-03-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04172987-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct04172987-tirzepatide-v1
- Content SHA-256: `79d865197f5beaff46955daceee0b562164ffeedaeddc53d6f46acec4a3f42ed`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04172987 ([`ctg-observation-nct04172987-2023-03-27-442266bc5854`](#source-ctg-observation-nct04172987-2023-03-27-442266bc5854))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04172987 at 2026-07-30T19:15:14.513Z. Its registry update date was 2023-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct04172987-2023-03-27-442266bc5854`](#source-ctg-observation-nct04172987-2023-03-27-442266bc5854))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04172987 at 2026-07-30T19:15:14.513Z. Its registry update date was 2023-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct04172987-2023-03-27-442266bc5854`](#source-ctg-observation-nct04172987-2023-03-27-442266bc5854))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04172987-2023-03-27-442266bc5854`](#source-ctg-observation-nct04172987-2023-03-27-442266bc5854))

### Sources

<a id="source-ctg-observation-nct04172987-2023-03-27-442266bc5854"></a>
- **ClinicalTrials.gov record NCT04172987 · retained source version 2023-03-27:442266bc5854436231baa0cbfd25f72eef49216a2c2234f3c2e0033ef18301e2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04172987) (`ctg-observation-nct04172987-2023-03-27-442266bc5854`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04172987." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct04172987-tirzepatide-v1 SHA-256: 79d865197f5beaff46955daceee0b562164ffeedaeddc53d6f46acec4a3f42ed.

---

<a id="clinicaltrials-gov-nct04407234-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT04407234

> PeptideScanner retained ClinicalTrials.gov record NCT04407234 at 2026-07-30T18:49:14.741Z. Its registry update date was 2024-01-08, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct04407234-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-01-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04407234-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct04407234-tirzepatide-v1
- Content SHA-256: `95f246c2a704261f35fa35e7c643e58d79e339e2a4e9b2030d9c3f27cf6adbfb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04407234 ([`ctg-observation-nct04407234-2024-01-08-d370bfac5047`](#source-ctg-observation-nct04407234-2024-01-08-d370bfac5047))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04407234 at 2026-07-30T18:49:14.741Z. Its registry update date was 2024-01-08, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct04407234-2024-01-08-d370bfac5047`](#source-ctg-observation-nct04407234-2024-01-08-d370bfac5047))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04407234 at 2026-07-30T18:49:14.741Z. Its registry update date was 2024-01-08, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct04407234-2024-01-08-d370bfac5047`](#source-ctg-observation-nct04407234-2024-01-08-d370bfac5047))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04407234-2024-01-08-d370bfac5047`](#source-ctg-observation-nct04407234-2024-01-08-d370bfac5047))

### Sources

<a id="source-ctg-observation-nct04407234-2024-01-08-d370bfac5047"></a>
- **ClinicalTrials.gov record NCT04407234 · retained source version 2024-01-08:d370bfac504714396df5ada86c8141f483a4c81692784b1a89a269ebcdfb66df** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04407234) (`ctg-observation-nct04407234-2024-01-08-d370bfac5047`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04407234." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct04407234-tirzepatide-v1 SHA-256: 95f246c2a704261f35fa35e7c643e58d79e339e2a4e9b2030d9c3f27cf6adbfb.

---

<a id="clinicaltrials-gov-nct05433584-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT05433584

> PeptideScanner retained ClinicalTrials.gov record NCT05433584 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct05433584-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05433584-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05433584-tirzepatide-v1
- Content SHA-256: `7b8b8f29b34dbe0bffa654a90baeb3cb1cc980bd36b7cee13757952a35eb7a68`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05433584 ([`ctg-observation-nct05433584-2026-11-12-b1cec8b1847e`](#source-ctg-observation-nct05433584-2026-11-12-b1cec8b1847e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05433584 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05433584-2026-11-12-b1cec8b1847e`](#source-ctg-observation-nct05433584-2026-11-12-b1cec8b1847e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05433584 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05433584-2026-11-12-b1cec8b1847e`](#source-ctg-observation-nct05433584-2026-11-12-b1cec8b1847e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05433584-2026-11-12-b1cec8b1847e`](#source-ctg-observation-nct05433584-2026-11-12-b1cec8b1847e))

### Sources

<a id="source-ctg-observation-nct05433584-2026-11-12-b1cec8b1847e"></a>
- **ClinicalTrials.gov record NCT05433584 · retained source version 2026-11-12:b1cec8b1847e2896a3236f1a2da832c76759540b0965ac931553af0103d7f923** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05433584) (`ctg-observation-nct05433584-2026-11-12-b1cec8b1847e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05433584." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05433584-tirzepatide-v1 SHA-256: 7b8b8f29b34dbe0bffa654a90baeb3cb1cc980bd36b7cee13757952a35eb7a68.

---

<a id="clinicaltrials-gov-nct05536804-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT05536804

> PeptideScanner retained ClinicalTrials.gov record NCT05536804 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct05536804-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-11
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05536804-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05536804-tirzepatide-v1
- Content SHA-256: `8740e7e365c170c50d4c4de6b0e2f39a503c0e7f44c00cb1a017615a58ab3151`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05536804 ([`ctg-observation-nct05536804-2026-09-11-d971b7bb79be`](#source-ctg-observation-nct05536804-2026-09-11-d971b7bb79be))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05536804 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05536804-2026-09-11-d971b7bb79be`](#source-ctg-observation-nct05536804-2026-09-11-d971b7bb79be))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05536804 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-11, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05536804-2026-09-11-d971b7bb79be`](#source-ctg-observation-nct05536804-2026-09-11-d971b7bb79be))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05536804-2026-09-11-d971b7bb79be`](#source-ctg-observation-nct05536804-2026-09-11-d971b7bb79be))

### Sources

<a id="source-ctg-observation-nct05536804-2026-09-11-d971b7bb79be"></a>
- **ClinicalTrials.gov record NCT05536804 · retained source version 2026-09-11:d971b7bb79be9f8e90a2080a3a5228aed2b0a76c14956d95b9f1ea1f3385fab7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05536804) (`ctg-observation-nct05536804-2026-09-11-d971b7bb79be`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05536804." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05536804-tirzepatide-v1 SHA-256: 8740e7e365c170c50d4c4de6b0e2f39a503c0e7f44c00cb1a017615a58ab3151.

---

<a id="clinicaltrials-gov-nct05556512-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT05556512

> PeptideScanner retained ClinicalTrials.gov record NCT05556512 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct05556512-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05556512-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05556512-tirzepatide-v1
- Content SHA-256: `a1f1d7c070ae34dfbb90c032daf4f85111331b7724bf07321405b658130e770a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05556512 ([`ctg-observation-nct05556512-2026-11-12-f30748f0be37`](#source-ctg-observation-nct05556512-2026-11-12-f30748f0be37))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05556512 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05556512-2026-11-12-f30748f0be37`](#source-ctg-observation-nct05556512-2026-11-12-f30748f0be37))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05556512 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05556512-2026-11-12-f30748f0be37`](#source-ctg-observation-nct05556512-2026-11-12-f30748f0be37))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05556512-2026-11-12-f30748f0be37`](#source-ctg-observation-nct05556512-2026-11-12-f30748f0be37))

### Sources

<a id="source-ctg-observation-nct05556512-2026-11-12-f30748f0be37"></a>
- **ClinicalTrials.gov record NCT05556512 · retained source version 2026-11-12:f30748f0be37cac1f901273c9014b511f66735c19bf0e5cc0abc5ea9af10875e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05556512) (`ctg-observation-nct05556512-2026-11-12-f30748f0be37`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05556512." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05556512-tirzepatide-v1 SHA-256: a1f1d7c070ae34dfbb90c032daf4f85111331b7724bf07321405b658130e770a.

---

<a id="clinicaltrials-gov-nct05708859-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT05708859

> PeptideScanner retained ClinicalTrials.gov record NCT05708859 at 2026-07-30T18:39:33.781Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct05708859-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-10-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05708859-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05708859-tirzepatide-v1
- Content SHA-256: `cca3310a5256b108f4caab17706c5c6dbfb63f672fc96fed72213322a935aa68`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05708859 ([`ctg-observation-nct05708859-2024-10-15-478162d3fc33`](#source-ctg-observation-nct05708859-2024-10-15-478162d3fc33))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05708859 at 2026-07-30T18:39:33.781Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05708859-2024-10-15-478162d3fc33`](#source-ctg-observation-nct05708859-2024-10-15-478162d3fc33))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05708859 at 2026-07-30T18:39:33.781Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05708859-2024-10-15-478162d3fc33`](#source-ctg-observation-nct05708859-2024-10-15-478162d3fc33))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05708859-2024-10-15-478162d3fc33`](#source-ctg-observation-nct05708859-2024-10-15-478162d3fc33))

### Sources

<a id="source-ctg-observation-nct05708859-2024-10-15-478162d3fc33"></a>
- **ClinicalTrials.gov record NCT05708859 · retained source version 2024-10-15:478162d3fc339a9977a6d9a0031bfb44ab021205b9168ca15667542928d01081** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05708859) (`ctg-observation-nct05708859-2024-10-15-478162d3fc33`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05708859." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05708859-tirzepatide-v1 SHA-256: cca3310a5256b108f4caab17706c5c6dbfb63f672fc96fed72213322a935aa68.

---

<a id="clinicaltrials-gov-nct05766358-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT05766358

> PeptideScanner retained ClinicalTrials.gov record NCT05766358 at 2026-07-30T18:43:56.186Z. Its registry update date was 2024-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct05766358-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-06-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05766358-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05766358-tirzepatide-v1
- Content SHA-256: `109f59e745858d4be57b9d61791155e32e5e24df7fecc4d4ab984883eaecac31`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05766358 ([`ctg-observation-nct05766358-2024-06-10-e23b21c5417b`](#source-ctg-observation-nct05766358-2024-06-10-e23b21c5417b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05766358 at 2026-07-30T18:43:56.186Z. Its registry update date was 2024-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05766358-2024-06-10-e23b21c5417b`](#source-ctg-observation-nct05766358-2024-06-10-e23b21c5417b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05766358 at 2026-07-30T18:43:56.186Z. Its registry update date was 2024-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05766358-2024-06-10-e23b21c5417b`](#source-ctg-observation-nct05766358-2024-06-10-e23b21c5417b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05766358-2024-06-10-e23b21c5417b`](#source-ctg-observation-nct05766358-2024-06-10-e23b21c5417b))

### Sources

<a id="source-ctg-observation-nct05766358-2024-06-10-e23b21c5417b"></a>
- **ClinicalTrials.gov record NCT05766358 · retained source version 2024-06-10:e23b21c5417bc1885ea51f38b4f5cfa120158ad67e9fadfc7919d8a537843942** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05766358) (`ctg-observation-nct05766358-2024-06-10-e23b21c5417b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05766358." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05766358-tirzepatide-v1 SHA-256: 109f59e745858d4be57b9d61791155e32e5e24df7fecc4d4ab984883eaecac31.

---

<a id="clinicaltrials-gov-nct05912621-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT05912621

> PeptideScanner retained ClinicalTrials.gov record NCT05912621 at 2026-07-30T18:37:14.695Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct05912621-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2024-12-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05912621-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05912621-tirzepatide-v1
- Content SHA-256: `39c727465251d261db2d3d6af9d07388dc9659e4ac765d7acd99ee9659625ac2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05912621 ([`ctg-observation-nct05912621-2024-12-04-b3a8034cf873`](#source-ctg-observation-nct05912621-2024-12-04-b3a8034cf873))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05912621 at 2026-07-30T18:37:14.695Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05912621-2024-12-04-b3a8034cf873`](#source-ctg-observation-nct05912621-2024-12-04-b3a8034cf873))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05912621 at 2026-07-30T18:37:14.695Z. Its registry update date was 2024-12-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05912621-2024-12-04-b3a8034cf873`](#source-ctg-observation-nct05912621-2024-12-04-b3a8034cf873))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05912621-2024-12-04-b3a8034cf873`](#source-ctg-observation-nct05912621-2024-12-04-b3a8034cf873))

### Sources

<a id="source-ctg-observation-nct05912621-2024-12-04-b3a8034cf873"></a>
- **ClinicalTrials.gov record NCT05912621 · retained source version 2024-12-04:b3a8034cf873b7a28d167ad6c499777901357e39df21578316b822bdb6ca47a7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05912621) (`ctg-observation-nct05912621-2024-12-04-b3a8034cf873`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05912621." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05912621-tirzepatide-v1 SHA-256: 39c727465251d261db2d3d6af9d07388dc9659e4ac765d7acd99ee9659625ac2.

---

<a id="clinicaltrials-gov-nct05933499-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT05933499

> PeptideScanner retained ClinicalTrials.gov record NCT05933499 at 2026-07-30T16:22:22.327Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct05933499-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05933499-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05933499-tirzepatide-v1
- Content SHA-256: `7067324de200300a545962e7eb8b881123628b8a4fd1f5d159fd7a5a8bad6e33`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05933499 ([`ctg-observation-nct05933499-2026-03-27-bb4a74e33427`](#source-ctg-observation-nct05933499-2026-03-27-bb4a74e33427))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05933499 at 2026-07-30T16:22:22.327Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05933499-2026-03-27-bb4a74e33427`](#source-ctg-observation-nct05933499-2026-03-27-bb4a74e33427))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05933499 at 2026-07-30T16:22:22.327Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct05933499-2026-03-27-bb4a74e33427`](#source-ctg-observation-nct05933499-2026-03-27-bb4a74e33427))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05933499-2026-03-27-bb4a74e33427`](#source-ctg-observation-nct05933499-2026-03-27-bb4a74e33427))

### Sources

<a id="source-ctg-observation-nct05933499-2026-03-27-bb4a74e33427"></a>
- **ClinicalTrials.gov record NCT05933499 · retained source version 2026-03-27:bb4a74e33427dab5f659f601eb8d1158b1a2f44e7fe3d50ba8a932555bbf5d62** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05933499) (`ctg-observation-nct05933499-2026-03-27-bb4a74e33427`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05933499." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct05933499-tirzepatide-v1 SHA-256: 7067324de200300a545962e7eb8b881123628b8a4fd1f5d159fd7a5a8bad6e33.

---

<a id="clinicaltrials-gov-nct06073184-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06073184

> PeptideScanner retained ClinicalTrials.gov record NCT06073184 at 2026-07-30T18:26:04.258Z. Its registry update date was 2025-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06073184-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-06-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06073184-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06073184-tirzepatide-v1
- Content SHA-256: `13310fbc2806677c45bc751c543c64262fbbfd3d156c61b15779274cab909705`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06073184 ([`ctg-observation-nct06073184-2025-06-10-f1e2526395f8`](#source-ctg-observation-nct06073184-2025-06-10-f1e2526395f8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06073184 at 2026-07-30T18:26:04.258Z. Its registry update date was 2025-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06073184-2025-06-10-f1e2526395f8`](#source-ctg-observation-nct06073184-2025-06-10-f1e2526395f8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06073184 at 2026-07-30T18:26:04.258Z. Its registry update date was 2025-06-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06073184-2025-06-10-f1e2526395f8`](#source-ctg-observation-nct06073184-2025-06-10-f1e2526395f8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06073184-2025-06-10-f1e2526395f8`](#source-ctg-observation-nct06073184-2025-06-10-f1e2526395f8))

### Sources

<a id="source-ctg-observation-nct06073184-2025-06-10-f1e2526395f8"></a>
- **ClinicalTrials.gov record NCT06073184 · retained source version 2025-06-10:f1e2526395f8049e2ac0ea81d322d7c4ac1d1f92858bed9c57ac756d8afe1bf2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06073184) (`ctg-observation-nct06073184-2025-06-10-f1e2526395f8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06073184." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06073184-tirzepatide-v1 SHA-256: 13310fbc2806677c45bc751c543c64262fbbfd3d156c61b15779274cab909705.

---

<a id="clinicaltrials-gov-nct06162715-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06162715

> PeptideScanner retained ClinicalTrials.gov record NCT06162715 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06162715-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-10
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06162715-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06162715-tirzepatide-v1
- Content SHA-256: `2ddfc0961de63f570f2d4d4221fe09da108b41b05d9095b2ddab1ca2c96183ca`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06162715 ([`ctg-observation-nct06162715-2026-11-10-d0af41597257`](#source-ctg-observation-nct06162715-2026-11-10-d0af41597257))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06162715 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06162715-2026-11-10-d0af41597257`](#source-ctg-observation-nct06162715-2026-11-10-d0af41597257))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06162715 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06162715-2026-11-10-d0af41597257`](#source-ctg-observation-nct06162715-2026-11-10-d0af41597257))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06162715-2026-11-10-d0af41597257`](#source-ctg-observation-nct06162715-2026-11-10-d0af41597257))

### Sources

<a id="source-ctg-observation-nct06162715-2026-11-10-d0af41597257"></a>
- **ClinicalTrials.gov record NCT06162715 · retained source version 2026-11-10:d0af415972575b0f764aa53d9cfb0cb83e9cd40198133d52724fdd00bd9fc2b5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06162715) (`ctg-observation-nct06162715-2026-11-10-d0af41597257`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06162715." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06162715-tirzepatide-v1 SHA-256: 2ddfc0961de63f570f2d4d4221fe09da108b41b05d9095b2ddab1ca2c96183ca.

---

<a id="clinicaltrials-gov-nct06191848-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06191848

> PeptideScanner retained ClinicalTrials.gov record NCT06191848 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06191848-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06191848-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06191848-tirzepatide-v1
- Content SHA-256: `8a843bb496eccce742aa2e744da84196e5add4e1e42d9d959c38cfee8f3b10cf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06191848 ([`ctg-observation-nct06191848-2026-10-13-ba5076ff0f9a`](#source-ctg-observation-nct06191848-2026-10-13-ba5076ff0f9a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06191848 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06191848-2026-10-13-ba5076ff0f9a`](#source-ctg-observation-nct06191848-2026-10-13-ba5076ff0f9a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06191848 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06191848-2026-10-13-ba5076ff0f9a`](#source-ctg-observation-nct06191848-2026-10-13-ba5076ff0f9a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06191848-2026-10-13-ba5076ff0f9a`](#source-ctg-observation-nct06191848-2026-10-13-ba5076ff0f9a))

### Sources

<a id="source-ctg-observation-nct06191848-2026-10-13-ba5076ff0f9a"></a>
- **ClinicalTrials.gov record NCT06191848 · retained source version 2026-10-13:ba5076ff0f9aff7f4ed5ebe6aa2ea1af427d49ae22ea596734c878be9cc55f29** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06191848) (`ctg-observation-nct06191848-2026-10-13-ba5076ff0f9a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06191848." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06191848-tirzepatide-v1 SHA-256: 8a843bb496eccce742aa2e744da84196e5add4e1e42d9d959c38cfee8f3b10cf.

---

<a id="clinicaltrials-gov-nct06439277-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06439277

> PeptideScanner retained ClinicalTrials.gov record NCT06439277 at 2026-09-09T19:17:17.406Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06439277-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-04
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06439277-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06439277-tirzepatide-v1
- Content SHA-256: `06d8c3448bb2ecc594198337ffe8447bf08ab8b39f16140f9dff7733c7099ea4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06439277 ([`ctg-observation-nct06439277-2026-09-04-8c8df4f1d6dd`](#source-ctg-observation-nct06439277-2026-09-04-8c8df4f1d6dd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06439277 at 2026-09-09T19:17:17.406Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06439277-2026-09-04-8c8df4f1d6dd`](#source-ctg-observation-nct06439277-2026-09-04-8c8df4f1d6dd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06439277 at 2026-09-09T19:17:17.406Z. Its registry update date was 2026-09-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06439277-2026-09-04-8c8df4f1d6dd`](#source-ctg-observation-nct06439277-2026-09-04-8c8df4f1d6dd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06439277-2026-09-04-8c8df4f1d6dd`](#source-ctg-observation-nct06439277-2026-09-04-8c8df4f1d6dd))

### Sources

<a id="source-ctg-observation-nct06439277-2026-09-04-8c8df4f1d6dd"></a>
- **ClinicalTrials.gov record NCT06439277 · retained source version 2026-09-04:8c8df4f1d6dd8e03a5bfcd7d796ee02ec00890c8387e370739e3274073dc3064** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06439277) (`ctg-observation-nct06439277-2026-09-04-8c8df4f1d6dd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06439277." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06439277-tirzepatide-v1 SHA-256: 06d8c3448bb2ecc594198337ffe8447bf08ab8b39f16140f9dff7733c7099ea4.

---

<a id="clinicaltrials-gov-nct06445075-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06445075

> PeptideScanner retained ClinicalTrials.gov record NCT06445075 at 2026-07-30T16:25:18.017Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06445075-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06445075-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06445075-tirzepatide-v1
- Content SHA-256: `4c1c0d2d92f452f2371c7522771e61e10f3729c6494779d1ac5a251138b57188`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06445075 ([`ctg-observation-nct06445075-2026-01-23-263be8f36b29`](#source-ctg-observation-nct06445075-2026-01-23-263be8f36b29))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06445075 at 2026-07-30T16:25:18.017Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06445075-2026-01-23-263be8f36b29`](#source-ctg-observation-nct06445075-2026-01-23-263be8f36b29))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06445075 at 2026-07-30T16:25:18.017Z. Its registry update date was 2026-01-23, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06445075-2026-01-23-263be8f36b29`](#source-ctg-observation-nct06445075-2026-01-23-263be8f36b29))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06445075-2026-01-23-263be8f36b29`](#source-ctg-observation-nct06445075-2026-01-23-263be8f36b29))

### Sources

<a id="source-ctg-observation-nct06445075-2026-01-23-263be8f36b29"></a>
- **ClinicalTrials.gov record NCT06445075 · retained source version 2026-01-23:263be8f36b29016c742285892ecf1468cd73d97dd102c3f27d97917aea41a0c2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06445075) (`ctg-observation-nct06445075-2026-01-23-263be8f36b29`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06445075." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06445075-tirzepatide-v1 SHA-256: 4c1c0d2d92f452f2371c7522771e61e10f3729c6494779d1ac5a251138b57188.

---

<a id="clinicaltrials-gov-nct06485089-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06485089

> PeptideScanner retained ClinicalTrials.gov record NCT06485089 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-28, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06485089-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06485089-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06485089-tirzepatide-v1
- Content SHA-256: `b2931c4733c3783a1ac2b8ef698db1d71db7ee2e9cfdcb728964e7ceb13d6c48`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06485089 ([`ctg-observation-nct06485089-2026-05-28-b1f207434664`](#source-ctg-observation-nct06485089-2026-05-28-b1f207434664))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06485089 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06485089-2026-05-28-b1f207434664`](#source-ctg-observation-nct06485089-2026-05-28-b1f207434664))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06485089 at 2026-07-30T16:19:36.906Z. Its registry update date was 2026-05-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06485089-2026-05-28-b1f207434664`](#source-ctg-observation-nct06485089-2026-05-28-b1f207434664))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06485089-2026-05-28-b1f207434664`](#source-ctg-observation-nct06485089-2026-05-28-b1f207434664))

### Sources

<a id="source-ctg-observation-nct06485089-2026-05-28-b1f207434664"></a>
- **ClinicalTrials.gov record NCT06485089 · retained source version 2026-05-28:b1f207434664c978691f353fc48ab39d00b7e09b116872b48dda3ef6dc455662** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06485089) (`ctg-observation-nct06485089-2026-05-28-b1f207434664`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06485089." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06485089-tirzepatide-v1 SHA-256: b2931c4733c3783a1ac2b8ef698db1d71db7ee2e9cfdcb728964e7ceb13d6c48.

---

<a id="clinicaltrials-gov-nct06517212-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06517212

> PeptideScanner retained ClinicalTrials.gov record NCT06517212 at 2026-07-30T16:23:45.659Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06517212-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06517212-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06517212-tirzepatide-v1
- Content SHA-256: `4079113334e916c463341984143eb9cac8f17db6f790a5c4723e21718765b299`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06517212 ([`ctg-observation-nct06517212-2026-02-12-108e8f67fefa`](#source-ctg-observation-nct06517212-2026-02-12-108e8f67fefa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06517212 at 2026-07-30T16:23:45.659Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06517212-2026-02-12-108e8f67fefa`](#source-ctg-observation-nct06517212-2026-02-12-108e8f67fefa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06517212 at 2026-07-30T16:23:45.659Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06517212-2026-02-12-108e8f67fefa`](#source-ctg-observation-nct06517212-2026-02-12-108e8f67fefa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06517212-2026-02-12-108e8f67fefa`](#source-ctg-observation-nct06517212-2026-02-12-108e8f67fefa))

### Sources

<a id="source-ctg-observation-nct06517212-2026-02-12-108e8f67fefa"></a>
- **ClinicalTrials.gov record NCT06517212 · retained source version 2026-02-12:108e8f67fefaf28633c4188389f7d978caf4f23d6114d328f22f9bb8aeb51955** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06517212) (`ctg-observation-nct06517212-2026-02-12-108e8f67fefa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06517212." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06517212-tirzepatide-v1 SHA-256: 4079113334e916c463341984143eb9cac8f17db6f790a5c4723e21718765b299.

---

<a id="clinicaltrials-gov-nct06603571-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06603571

> PeptideScanner retained ClinicalTrials.gov record NCT06603571 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06603571-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-29
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06603571-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06603571-tirzepatide-v1
- Content SHA-256: `6b262c9fe8ad18e271cee70ba4d1d819b38c7343d894369ed6d4e320ca48751b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06603571 ([`ctg-observation-nct06603571-2026-09-29-cc3b6f8d332d`](#source-ctg-observation-nct06603571-2026-09-29-cc3b6f8d332d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06603571 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06603571-2026-09-29-cc3b6f8d332d`](#source-ctg-observation-nct06603571-2026-09-29-cc3b6f8d332d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06603571 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06603571-2026-09-29-cc3b6f8d332d`](#source-ctg-observation-nct06603571-2026-09-29-cc3b6f8d332d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06603571-2026-09-29-cc3b6f8d332d`](#source-ctg-observation-nct06603571-2026-09-29-cc3b6f8d332d))

### Sources

<a id="source-ctg-observation-nct06603571-2026-09-29-cc3b6f8d332d"></a>
- **ClinicalTrials.gov record NCT06603571 · retained source version 2026-09-29:cc3b6f8d332dff545d7afc3a50439cffe879f207e42fac2fd7bd5448283db117** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06603571) (`ctg-observation-nct06603571-2026-09-29-cc3b6f8d332d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06603571." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06603571-tirzepatide-v1 SHA-256: 6b262c9fe8ad18e271cee70ba4d1d819b38c7343d894369ed6d4e320ca48751b.

---

<a id="clinicaltrials-gov-nct06606821-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06606821

> PeptideScanner retained ClinicalTrials.gov record NCT06606821 at 2026-07-30T18:27:14.157Z. Its registry update date was 2025-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06606821-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-05-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06606821-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06606821-tirzepatide-v1
- Content SHA-256: `4776f9365ccd828a90d6ba350c640ae384a0ff308cee4d7ebb32d23c75f63134`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06606821 ([`ctg-observation-nct06606821-2025-05-22-ce937143bf9d`](#source-ctg-observation-nct06606821-2025-05-22-ce937143bf9d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06606821 at 2026-07-30T18:27:14.157Z. Its registry update date was 2025-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06606821-2025-05-22-ce937143bf9d`](#source-ctg-observation-nct06606821-2025-05-22-ce937143bf9d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06606821 at 2026-07-30T18:27:14.157Z. Its registry update date was 2025-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06606821-2025-05-22-ce937143bf9d`](#source-ctg-observation-nct06606821-2025-05-22-ce937143bf9d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06606821-2025-05-22-ce937143bf9d`](#source-ctg-observation-nct06606821-2025-05-22-ce937143bf9d))

### Sources

<a id="source-ctg-observation-nct06606821-2025-05-22-ce937143bf9d"></a>
- **ClinicalTrials.gov record NCT06606821 · retained source version 2025-05-22:ce937143bf9dd9a8760a4bf86b9416b11384fdbdd8a64ddf83d37a54c7d61c7b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06606821) (`ctg-observation-nct06606821-2025-05-22-ce937143bf9d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06606821." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06606821-tirzepatide-v1 SHA-256: 4776f9365ccd828a90d6ba350c640ae384a0ff308cee4d7ebb32d23c75f63134.

---

<a id="clinicaltrials-gov-nct06651177-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06651177

> PeptideScanner retained ClinicalTrials.gov record NCT06651177 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06651177-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-11
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06651177-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06651177-tirzepatide-v1
- Content SHA-256: `73643e2c016c416ad21ad1c89124790a6188cf8414c60927289f7b1cd151dc7a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06651177 ([`ctg-observation-nct06651177-2026-08-11-690d2eafdef8`](#source-ctg-observation-nct06651177-2026-08-11-690d2eafdef8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06651177 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06651177-2026-08-11-690d2eafdef8`](#source-ctg-observation-nct06651177-2026-08-11-690d2eafdef8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06651177 at 2026-08-13T05:52:27.017Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06651177-2026-08-11-690d2eafdef8`](#source-ctg-observation-nct06651177-2026-08-11-690d2eafdef8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06651177-2026-08-11-690d2eafdef8`](#source-ctg-observation-nct06651177-2026-08-11-690d2eafdef8))

### Sources

<a id="source-ctg-observation-nct06651177-2026-08-11-690d2eafdef8"></a>
- **ClinicalTrials.gov record NCT06651177 · retained source version 2026-08-11:690d2eafdef825dc0cbea75a13cd7e6d6eeff55cb328d7622a670d9a81cbe70f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06651177) (`ctg-observation-nct06651177-2026-08-11-690d2eafdef8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06651177." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06651177-tirzepatide-v1 SHA-256: 73643e2c016c416ad21ad1c89124790a6188cf8414c60927289f7b1cd151dc7a.

---

<a id="clinicaltrials-gov-nct06657209-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06657209

> PeptideScanner retained ClinicalTrials.gov record NCT06657209 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06657209-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06657209-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06657209-tirzepatide-v1
- Content SHA-256: `4b3b19af364883b10faeb7aa7995cfdd1c15f56019238007e751f4d0ec1366dd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06657209 ([`ctg-observation-nct06657209-2026-04-20-d7c369a3b74c`](#source-ctg-observation-nct06657209-2026-04-20-d7c369a3b74c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06657209 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06657209-2026-04-20-d7c369a3b74c`](#source-ctg-observation-nct06657209-2026-04-20-d7c369a3b74c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06657209 at 2026-07-30T16:20:49.310Z. Its registry update date was 2026-04-20, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06657209-2026-04-20-d7c369a3b74c`](#source-ctg-observation-nct06657209-2026-04-20-d7c369a3b74c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06657209-2026-04-20-d7c369a3b74c`](#source-ctg-observation-nct06657209-2026-04-20-d7c369a3b74c))

### Sources

<a id="source-ctg-observation-nct06657209-2026-04-20-d7c369a3b74c"></a>
- **ClinicalTrials.gov record NCT06657209 · retained source version 2026-04-20:d7c369a3b74ca46334148f19feef7d598aaf5d77c0d81c238a827bea01f5a44c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06657209) (`ctg-observation-nct06657209-2026-04-20-d7c369a3b74c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06657209." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06657209-tirzepatide-v1 SHA-256: 4b3b19af364883b10faeb7aa7995cfdd1c15f56019238007e751f4d0ec1366dd.

---

<a id="clinicaltrials-gov-nct06700538-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06700538

> PeptideScanner retained ClinicalTrials.gov record NCT06700538 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06700538-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-30
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06700538-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06700538-tirzepatide-v1
- Content SHA-256: `20da17398f67e5cc9db00d05ffb8e99ed75a9bcc921726014ab85c4015b5fef3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06700538 ([`ctg-observation-nct06700538-2026-10-30-db2820923f99`](#source-ctg-observation-nct06700538-2026-10-30-db2820923f99))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06700538 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06700538-2026-10-30-db2820923f99`](#source-ctg-observation-nct06700538-2026-10-30-db2820923f99))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06700538 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-30, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06700538-2026-10-30-db2820923f99`](#source-ctg-observation-nct06700538-2026-10-30-db2820923f99))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06700538-2026-10-30-db2820923f99`](#source-ctg-observation-nct06700538-2026-10-30-db2820923f99))

### Sources

<a id="source-ctg-observation-nct06700538-2026-10-30-db2820923f99"></a>
- **ClinicalTrials.gov record NCT06700538 · retained source version 2026-10-30:db2820923f9995efc32b1b5a1aabe3bac02eb033b492d53e46c9ada31867cbde** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06700538) (`ctg-observation-nct06700538-2026-10-30-db2820923f99`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06700538." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06700538-tirzepatide-v1 SHA-256: 20da17398f67e5cc9db00d05ffb8e99ed75a9bcc921726014ab85c4015b5fef3.

---

<a id="clinicaltrials-gov-nct06727331-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06727331

> PeptideScanner retained ClinicalTrials.gov record NCT06727331 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06727331-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06727331-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06727331-tirzepatide-v1
- Content SHA-256: `5ff671c42ab50fbcc4e79fc3dd63bc65d03c876261c439494bcdaa425f0eb720`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06727331 ([`ctg-observation-nct06727331-2026-07-09-09715248765b`](#source-ctg-observation-nct06727331-2026-07-09-09715248765b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06727331 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06727331-2026-07-09-09715248765b`](#source-ctg-observation-nct06727331-2026-07-09-09715248765b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06727331 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06727331-2026-07-09-09715248765b`](#source-ctg-observation-nct06727331-2026-07-09-09715248765b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06727331-2026-07-09-09715248765b`](#source-ctg-observation-nct06727331-2026-07-09-09715248765b))

### Sources

<a id="source-ctg-observation-nct06727331-2026-07-09-09715248765b"></a>
- **ClinicalTrials.gov record NCT06727331 · retained source version 2026-07-09:09715248765b4e7d805f72f82c51c50ddaa39f2c2a6ad85fd1329b070d961df8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06727331) (`ctg-observation-nct06727331-2026-07-09-09715248765b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06727331." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06727331-tirzepatide-v1 SHA-256: 5ff671c42ab50fbcc4e79fc3dd63bc65d03c876261c439494bcdaa425f0eb720.

---

<a id="clinicaltrials-gov-nct06734273-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06734273

> PeptideScanner retained ClinicalTrials.gov record NCT06734273 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-08, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06734273-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-08
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06734273-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06734273-tirzepatide-v1
- Content SHA-256: `858df821b7fdd2a4f6d90fbac2728c7635955dc2c0f0b1d27b457e97949a584c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06734273 ([`ctg-observation-nct06734273-2026-05-08-e60f05200efe`](#source-ctg-observation-nct06734273-2026-05-08-e60f05200efe))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06734273 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-08, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06734273-2026-05-08-e60f05200efe`](#source-ctg-observation-nct06734273-2026-05-08-e60f05200efe))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06734273 at 2026-07-30T16:19:36.910Z. Its registry update date was 2026-05-08, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06734273-2026-05-08-e60f05200efe`](#source-ctg-observation-nct06734273-2026-05-08-e60f05200efe))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06734273-2026-05-08-e60f05200efe`](#source-ctg-observation-nct06734273-2026-05-08-e60f05200efe))

### Sources

<a id="source-ctg-observation-nct06734273-2026-05-08-e60f05200efe"></a>
- **ClinicalTrials.gov record NCT06734273 · retained source version 2026-05-08:e60f05200efe03fee2a87c0f816d0bff263315a8b9c5f7b6f6f46dcd554b8f42** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06734273) (`ctg-observation-nct06734273-2026-05-08-e60f05200efe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06734273." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06734273-tirzepatide-v1 SHA-256: 858df821b7fdd2a4f6d90fbac2728c7635955dc2c0f0b1d27b457e97949a584c.

---

<a id="clinicaltrials-gov-nct06745128-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06745128

> PeptideScanner retained ClinicalTrials.gov record NCT06745128 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06745128-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-06-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06745128-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06745128-tirzepatide-v1
- Content SHA-256: `dbfcf15c125d1986660981abea12afb203b997e6513a6b92f00eabc25ce543fc`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06745128 ([`ctg-observation-nct06745128-2025-06-12-ee59a7748249`](#source-ctg-observation-nct06745128-2025-06-12-ee59a7748249))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06745128 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06745128-2025-06-12-ee59a7748249`](#source-ctg-observation-nct06745128-2025-06-12-ee59a7748249))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06745128 at 2026-07-30T18:26:04.261Z. Its registry update date was 2025-06-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06745128-2025-06-12-ee59a7748249`](#source-ctg-observation-nct06745128-2025-06-12-ee59a7748249))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06745128-2025-06-12-ee59a7748249`](#source-ctg-observation-nct06745128-2025-06-12-ee59a7748249))

### Sources

<a id="source-ctg-observation-nct06745128-2025-06-12-ee59a7748249"></a>
- **ClinicalTrials.gov record NCT06745128 · retained source version 2025-06-12:ee59a77482491a9833d15caa7ddc4c9ed8a276860a84ec6d146dced239a9a91a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06745128) (`ctg-observation-nct06745128-2025-06-12-ee59a7748249`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06745128." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06745128-tirzepatide-v1 SHA-256: dbfcf15c125d1986660981abea12afb203b997e6513a6b92f00eabc25ce543fc.

---

<a id="clinicaltrials-gov-nct06751589-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06751589

> PeptideScanner retained ClinicalTrials.gov record NCT06751589 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06751589-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06751589-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06751589-tirzepatide-v1
- Content SHA-256: `4c4ed5519122a722d6fa42b0d3848c928a40bb2b97ea400feb56255667503dd0`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06751589 ([`ctg-observation-nct06751589-2026-04-13-fb42de1bcb98`](#source-ctg-observation-nct06751589-2026-04-13-fb42de1bcb98))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06751589 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06751589-2026-04-13-fb42de1bcb98`](#source-ctg-observation-nct06751589-2026-04-13-fb42de1bcb98))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06751589 at 2026-07-30T16:20:49.318Z. Its registry update date was 2026-04-13, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06751589-2026-04-13-fb42de1bcb98`](#source-ctg-observation-nct06751589-2026-04-13-fb42de1bcb98))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06751589-2026-04-13-fb42de1bcb98`](#source-ctg-observation-nct06751589-2026-04-13-fb42de1bcb98))

### Sources

<a id="source-ctg-observation-nct06751589-2026-04-13-fb42de1bcb98"></a>
- **ClinicalTrials.gov record NCT06751589 · retained source version 2026-04-13:fb42de1bcb9836522dc655795b6833facb3779fa89c7433a4164d5952f8d99c1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06751589) (`ctg-observation-nct06751589-2026-04-13-fb42de1bcb98`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06751589." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06751589-tirzepatide-v1 SHA-256: 4c4ed5519122a722d6fa42b0d3848c928a40bb2b97ea400feb56255667503dd0.

---

<a id="clinicaltrials-gov-nct06759701-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06759701

> PeptideScanner retained ClinicalTrials.gov record NCT06759701 at 2026-07-30T16:23:45.658Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06759701-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06759701-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06759701-tirzepatide-v1
- Content SHA-256: `1f54fce7851570f5ceeb284404d03f748c8dae3118403f10f0ff1a4ca5d481b1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06759701 ([`ctg-observation-nct06759701-2026-02-27-0785a9b2ffc2`](#source-ctg-observation-nct06759701-2026-02-27-0785a9b2ffc2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06759701 at 2026-07-30T16:23:45.658Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06759701-2026-02-27-0785a9b2ffc2`](#source-ctg-observation-nct06759701-2026-02-27-0785a9b2ffc2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06759701 at 2026-07-30T16:23:45.658Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06759701-2026-02-27-0785a9b2ffc2`](#source-ctg-observation-nct06759701-2026-02-27-0785a9b2ffc2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06759701-2026-02-27-0785a9b2ffc2`](#source-ctg-observation-nct06759701-2026-02-27-0785a9b2ffc2))

### Sources

<a id="source-ctg-observation-nct06759701-2026-02-27-0785a9b2ffc2"></a>
- **ClinicalTrials.gov record NCT06759701 · retained source version 2026-02-27:0785a9b2ffc2737cf81a254a0c9e8bbcce10721dd35d379fdacae6e9962b5693** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06759701) (`ctg-observation-nct06759701-2026-02-27-0785a9b2ffc2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06759701." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06759701-tirzepatide-v1 SHA-256: 1f54fce7851570f5ceeb284404d03f748c8dae3118403f10f0ff1a4ca5d481b1.

---

<a id="clinicaltrials-gov-nct06774079-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06774079

> PeptideScanner retained ClinicalTrials.gov record NCT06774079 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-29, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06774079-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-29
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06774079-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06774079-tirzepatide-v1
- Content SHA-256: `b9e82e9474233cc142ec5ddc7c40cf7d562b26bf8aa5745adab5b290619dbae4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06774079 ([`ctg-observation-nct06774079-2026-10-29-5b55e2d37702`](#source-ctg-observation-nct06774079-2026-10-29-5b55e2d37702))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06774079 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-29, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06774079-2026-10-29-5b55e2d37702`](#source-ctg-observation-nct06774079-2026-10-29-5b55e2d37702))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06774079 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-29, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06774079-2026-10-29-5b55e2d37702`](#source-ctg-observation-nct06774079-2026-10-29-5b55e2d37702))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06774079-2026-10-29-5b55e2d37702`](#source-ctg-observation-nct06774079-2026-10-29-5b55e2d37702))

### Sources

<a id="source-ctg-observation-nct06774079-2026-10-29-5b55e2d37702"></a>
- **ClinicalTrials.gov record NCT06774079 · retained source version 2026-10-29:5b55e2d37702f5bd5713c5400b8731729799a6f0f20cb621d8b4dd98e8f000f3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06774079) (`ctg-observation-nct06774079-2026-10-29-5b55e2d37702`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06774079." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06774079-tirzepatide-v1 SHA-256: b9e82e9474233cc142ec5ddc7c40cf7d562b26bf8aa5745adab5b290619dbae4.

---

<a id="clinicaltrials-gov-nct06802081-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06802081

> PeptideScanner retained ClinicalTrials.gov record NCT06802081 at 2026-07-30T16:25:18.015Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06802081-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-13
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06802081-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06802081-tirzepatide-v1
- Content SHA-256: `4648febcf54fe7e28772bbed17cb94c342610706ea9584dcaef407f190f039f3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06802081 ([`ctg-observation-nct06802081-2026-01-13-9c7503932c6e`](#source-ctg-observation-nct06802081-2026-01-13-9c7503932c6e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06802081 at 2026-07-30T16:25:18.015Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06802081-2026-01-13-9c7503932c6e`](#source-ctg-observation-nct06802081-2026-01-13-9c7503932c6e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06802081 at 2026-07-30T16:25:18.015Z. Its registry update date was 2026-01-13, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06802081-2026-01-13-9c7503932c6e`](#source-ctg-observation-nct06802081-2026-01-13-9c7503932c6e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06802081-2026-01-13-9c7503932c6e`](#source-ctg-observation-nct06802081-2026-01-13-9c7503932c6e))

### Sources

<a id="source-ctg-observation-nct06802081-2026-01-13-9c7503932c6e"></a>
- **ClinicalTrials.gov record NCT06802081 · retained source version 2026-01-13:9c7503932c6e2e972b4ea054197656ec20286ac2ae7f341343e5f2ca47e38584** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06802081) (`ctg-observation-nct06802081-2026-01-13-9c7503932c6e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06802081." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06802081-tirzepatide-v1 SHA-256: 4648febcf54fe7e28772bbed17cb94c342610706ea9584dcaef407f190f039f3.

---

<a id="clinicaltrials-gov-nct06811324-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06811324

> PeptideScanner retained ClinicalTrials.gov record NCT06811324 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06811324-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06811324-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06811324-tirzepatide-v1
- Content SHA-256: `b26b19f05aba8001ccc8e8086cf74153aa002233440f175b834f70e00fe41c8f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06811324 ([`ctg-observation-nct06811324-2026-04-15-214e4e82afe6`](#source-ctg-observation-nct06811324-2026-04-15-214e4e82afe6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06811324 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06811324-2026-04-15-214e4e82afe6`](#source-ctg-observation-nct06811324-2026-04-15-214e4e82afe6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06811324 at 2026-07-30T16:20:49.320Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06811324-2026-04-15-214e4e82afe6`](#source-ctg-observation-nct06811324-2026-04-15-214e4e82afe6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06811324-2026-04-15-214e4e82afe6`](#source-ctg-observation-nct06811324-2026-04-15-214e4e82afe6))

### Sources

<a id="source-ctg-observation-nct06811324-2026-04-15-214e4e82afe6"></a>
- **ClinicalTrials.gov record NCT06811324 · retained source version 2026-04-15:214e4e82afe65f4be341938f60172f009ad9a4b900b2b9a941e3c4f6652dc67c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06811324) (`ctg-observation-nct06811324-2026-04-15-214e4e82afe6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06811324." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06811324-tirzepatide-v1 SHA-256: b26b19f05aba8001ccc8e8086cf74153aa002233440f175b834f70e00fe41c8f.

---

<a id="clinicaltrials-gov-nct06847399-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06847399

> PeptideScanner retained ClinicalTrials.gov record NCT06847399 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-22, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06847399-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06847399-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06847399-tirzepatide-v1
- Content SHA-256: `82d105031a0e414932b0dae92092033335852dec03629eaec49aeaba77703bde`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06847399 ([`ctg-observation-nct06847399-2025-09-22-540136a7fc2a`](#source-ctg-observation-nct06847399-2025-09-22-540136a7fc2a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06847399 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06847399-2025-09-22-540136a7fc2a`](#source-ctg-observation-nct06847399-2025-09-22-540136a7fc2a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06847399 at 2026-07-30T18:22:04.915Z. Its registry update date was 2025-09-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06847399-2025-09-22-540136a7fc2a`](#source-ctg-observation-nct06847399-2025-09-22-540136a7fc2a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06847399-2025-09-22-540136a7fc2a`](#source-ctg-observation-nct06847399-2025-09-22-540136a7fc2a))

### Sources

<a id="source-ctg-observation-nct06847399-2025-09-22-540136a7fc2a"></a>
- **ClinicalTrials.gov record NCT06847399 · retained source version 2025-09-22:540136a7fc2a0c9453c123de99b9484952d467e963952d12a388b36f8515234b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06847399) (`ctg-observation-nct06847399-2025-09-22-540136a7fc2a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06847399." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06847399-tirzepatide-v1 SHA-256: 82d105031a0e414932b0dae92092033335852dec03629eaec49aeaba77703bde.

---

<a id="clinicaltrials-gov-nct06854614-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06854614

> PeptideScanner retained ClinicalTrials.gov record NCT06854614 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06854614-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-30
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06854614-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06854614-tirzepatide-v1
- Content SHA-256: `cb0c2c10a20e3a8493630bc9aa255f7f07a335e9100425e69f176fb0336a958b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06854614 ([`ctg-observation-nct06854614-2026-09-30-0de2bcbbd5e5`](#source-ctg-observation-nct06854614-2026-09-30-0de2bcbbd5e5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06854614 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06854614-2026-09-30-0de2bcbbd5e5`](#source-ctg-observation-nct06854614-2026-09-30-0de2bcbbd5e5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06854614 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-30, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06854614-2026-09-30-0de2bcbbd5e5`](#source-ctg-observation-nct06854614-2026-09-30-0de2bcbbd5e5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06854614-2026-09-30-0de2bcbbd5e5`](#source-ctg-observation-nct06854614-2026-09-30-0de2bcbbd5e5))

### Sources

<a id="source-ctg-observation-nct06854614-2026-09-30-0de2bcbbd5e5"></a>
- **ClinicalTrials.gov record NCT06854614 · retained source version 2026-09-30:0de2bcbbd5e5a411431a5b2873c9810ff287c6650c14ce2965fcf9a370e6a1c5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06854614) (`ctg-observation-nct06854614-2026-09-30-0de2bcbbd5e5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06854614." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06854614-tirzepatide-v1 SHA-256: cb0c2c10a20e3a8493630bc9aa255f7f07a335e9100425e69f176fb0336a958b.

---

<a id="clinicaltrials-gov-nct06857942-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06857942

> PeptideScanner retained ClinicalTrials.gov record NCT06857942 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06857942-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06857942-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06857942-tirzepatide-v1
- Content SHA-256: `ba295a06fc3387d330a122ab2328cdcf47f2bb651e39823d2d124ab266e51210`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06857942 ([`ctg-observation-nct06857942-2026-11-04-72dee6ab4ec9`](#source-ctg-observation-nct06857942-2026-11-04-72dee6ab4ec9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06857942 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06857942-2026-11-04-72dee6ab4ec9`](#source-ctg-observation-nct06857942-2026-11-04-72dee6ab4ec9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06857942 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06857942-2026-11-04-72dee6ab4ec9`](#source-ctg-observation-nct06857942-2026-11-04-72dee6ab4ec9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06857942-2026-11-04-72dee6ab4ec9`](#source-ctg-observation-nct06857942-2026-11-04-72dee6ab4ec9))

### Sources

<a id="source-ctg-observation-nct06857942-2026-11-04-72dee6ab4ec9"></a>
- **ClinicalTrials.gov record NCT06857942 · retained source version 2026-11-04:72dee6ab4ec9e6072dbd20a1a417ddeae9cf94a5efd875dae187d07396d974ea** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06857942) (`ctg-observation-nct06857942-2026-11-04-72dee6ab4ec9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06857942." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06857942-tirzepatide-v1 SHA-256: ba295a06fc3387d330a122ab2328cdcf47f2bb651e39823d2d124ab266e51210.

---

<a id="clinicaltrials-gov-nct06861439-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06861439

> PeptideScanner retained ClinicalTrials.gov record NCT06861439 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06861439-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-02
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06861439-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06861439-tirzepatide-v1
- Content SHA-256: `134fa3657e68ab2266483552eca7c56e8e8ee8502637783d58d323fb6e9c5483`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06861439 ([`ctg-observation-nct06861439-2026-10-02-bdf5828baacd`](#source-ctg-observation-nct06861439-2026-10-02-bdf5828baacd))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06861439 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06861439-2026-10-02-bdf5828baacd`](#source-ctg-observation-nct06861439-2026-10-02-bdf5828baacd))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06861439 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-02, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06861439-2026-10-02-bdf5828baacd`](#source-ctg-observation-nct06861439-2026-10-02-bdf5828baacd))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06861439-2026-10-02-bdf5828baacd`](#source-ctg-observation-nct06861439-2026-10-02-bdf5828baacd))

### Sources

<a id="source-ctg-observation-nct06861439-2026-10-02-bdf5828baacd"></a>
- **ClinicalTrials.gov record NCT06861439 · retained source version 2026-10-02:bdf5828baacd24da9945896a2c4036b5603ed45a73b1fa303d64ea5989d9bd18** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06861439) (`ctg-observation-nct06861439-2026-10-02-bdf5828baacd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06861439." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06861439-tirzepatide-v1 SHA-256: 134fa3657e68ab2266483552eca7c56e8e8ee8502637783d58d323fb6e9c5483.

---

<a id="clinicaltrials-gov-nct06864026-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06864026

> PeptideScanner retained ClinicalTrials.gov record NCT06864026 at 2026-07-30T16:19:03.062Z. Its registry update date was 2026-06-11, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06864026-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-11
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06864026-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06864026-tirzepatide-v1
- Content SHA-256: `9c823c6c54cf1cbbf18390966c0d3625ba1f97e1f5d2c311f338592bb4775680`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06864026 ([`ctg-observation-nct06864026-2026-06-11-efbb4c5cab69`](#source-ctg-observation-nct06864026-2026-06-11-efbb4c5cab69))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06864026 at 2026-07-30T16:19:03.062Z. Its registry update date was 2026-06-11, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06864026-2026-06-11-efbb4c5cab69`](#source-ctg-observation-nct06864026-2026-06-11-efbb4c5cab69))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06864026 at 2026-07-30T16:19:03.062Z. Its registry update date was 2026-06-11, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06864026-2026-06-11-efbb4c5cab69`](#source-ctg-observation-nct06864026-2026-06-11-efbb4c5cab69))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06864026-2026-06-11-efbb4c5cab69`](#source-ctg-observation-nct06864026-2026-06-11-efbb4c5cab69))

### Sources

<a id="source-ctg-observation-nct06864026-2026-06-11-efbb4c5cab69"></a>
- **ClinicalTrials.gov record NCT06864026 · retained source version 2026-06-11:efbb4c5cab6910febccd52e752e91dbc84bdc56e4b1c8a38fc4133c7cad68c93** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06864026) (`ctg-observation-nct06864026-2026-06-11-efbb4c5cab69`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06864026." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06864026-tirzepatide-v1 SHA-256: 9c823c6c54cf1cbbf18390966c0d3625ba1f97e1f5d2c311f338592bb4775680.

---

<a id="clinicaltrials-gov-nct06893211-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06893211

> PeptideScanner retained ClinicalTrials.gov record NCT06893211 at 2026-08-10T18:10:03.966Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06893211-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06893211-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06893211-tirzepatide-v1
- Content SHA-256: `52795bdbd5a06fe60fa1061dc222214fdfc17ebd5384b1e7e41ea2479443a420`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06893211 ([`ctg-observation-nct06893211-2026-07-07-6ca8a3e5605d`](#source-ctg-observation-nct06893211-2026-07-07-6ca8a3e5605d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06893211 at 2026-08-10T18:10:03.966Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06893211-2026-07-07-6ca8a3e5605d`](#source-ctg-observation-nct06893211-2026-07-07-6ca8a3e5605d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06893211 at 2026-08-10T18:10:03.966Z. Its registry update date was 2026-07-07, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06893211-2026-07-07-6ca8a3e5605d`](#source-ctg-observation-nct06893211-2026-07-07-6ca8a3e5605d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06893211-2026-07-07-6ca8a3e5605d`](#source-ctg-observation-nct06893211-2026-07-07-6ca8a3e5605d))

### Sources

<a id="source-ctg-observation-nct06893211-2026-07-07-6ca8a3e5605d"></a>
- **ClinicalTrials.gov record NCT06893211 · retained source version 2026-07-07:6ca8a3e5605da9a773bfdea0d6977dbd531d8d45e04e2e53d4049d717563d6f0** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06893211) (`ctg-observation-nct06893211-2026-07-07-6ca8a3e5605d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06893211." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06893211-tirzepatide-v1 SHA-256: 52795bdbd5a06fe60fa1061dc222214fdfc17ebd5384b1e7e41ea2479443a420.

---

<a id="clinicaltrials-gov-nct06901245-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06901245

> PeptideScanner retained ClinicalTrials.gov record NCT06901245 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-16, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06901245-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-09-16
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06901245-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06901245-tirzepatide-v1
- Content SHA-256: `11576729d39a50f4b10ba411c6b35b89b4f1dbdd48d4fd43ed7b137518d381f2`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06901245 ([`ctg-observation-nct06901245-2025-09-16-debeccd02441`](#source-ctg-observation-nct06901245-2025-09-16-debeccd02441))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06901245 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-16, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06901245-2025-09-16-debeccd02441`](#source-ctg-observation-nct06901245-2025-09-16-debeccd02441))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06901245 at 2026-07-30T18:22:04.914Z. Its registry update date was 2025-09-16, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06901245-2025-09-16-debeccd02441`](#source-ctg-observation-nct06901245-2025-09-16-debeccd02441))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06901245-2025-09-16-debeccd02441`](#source-ctg-observation-nct06901245-2025-09-16-debeccd02441))

### Sources

<a id="source-ctg-observation-nct06901245-2025-09-16-debeccd02441"></a>
- **ClinicalTrials.gov record NCT06901245 · retained source version 2025-09-16:debeccd024415a8f0e148aa34665c786d367ca7ad42fd171f517c56076cc54b7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06901245) (`ctg-observation-nct06901245-2025-09-16-debeccd02441`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06901245." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06901245-tirzepatide-v1 SHA-256: 11576729d39a50f4b10ba411c6b35b89b4f1dbdd48d4fd43ed7b137518d381f2.

---

<a id="clinicaltrials-gov-nct06911203-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06911203

> PeptideScanner retained ClinicalTrials.gov record NCT06911203 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06911203-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-13
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06911203-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06911203-tirzepatide-v1
- Content SHA-256: `b48658975b858f8d322b62ee0af6ac164129658f373df037a46f6f7579590d33`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06911203 ([`ctg-observation-nct06911203-2026-10-13-3d1b7004b0c2`](#source-ctg-observation-nct06911203-2026-10-13-3d1b7004b0c2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06911203 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06911203-2026-10-13-3d1b7004b0c2`](#source-ctg-observation-nct06911203-2026-10-13-3d1b7004b0c2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06911203 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06911203-2026-10-13-3d1b7004b0c2`](#source-ctg-observation-nct06911203-2026-10-13-3d1b7004b0c2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06911203-2026-10-13-3d1b7004b0c2`](#source-ctg-observation-nct06911203-2026-10-13-3d1b7004b0c2))

### Sources

<a id="source-ctg-observation-nct06911203-2026-10-13-3d1b7004b0c2"></a>
- **ClinicalTrials.gov record NCT06911203 · retained source version 2026-10-13:3d1b7004b0c23008f907880873b19f00d5c364af9e3804b590e96b133532e5d1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06911203) (`ctg-observation-nct06911203-2026-10-13-3d1b7004b0c2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06911203." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06911203-tirzepatide-v1 SHA-256: b48658975b858f8d322b62ee0af6ac164129658f373df037a46f6f7579590d33.

---

<a id="clinicaltrials-gov-nct06914154-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06914154

> PeptideScanner retained ClinicalTrials.gov record NCT06914154 at 2026-07-30T16:25:18.014Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06914154-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-30
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06914154-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06914154-tirzepatide-v1
- Content SHA-256: `a934ce95c6728dd8d4505ba884f276781875750e1a7023c8a55d2cc4856c3983`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06914154 ([`ctg-observation-nct06914154-2026-01-30-46144a9bc44a`](#source-ctg-observation-nct06914154-2026-01-30-46144a9bc44a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06914154 at 2026-07-30T16:25:18.014Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06914154-2026-01-30-46144a9bc44a`](#source-ctg-observation-nct06914154-2026-01-30-46144a9bc44a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06914154 at 2026-07-30T16:25:18.014Z. Its registry update date was 2026-01-30, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06914154-2026-01-30-46144a9bc44a`](#source-ctg-observation-nct06914154-2026-01-30-46144a9bc44a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06914154-2026-01-30-46144a9bc44a`](#source-ctg-observation-nct06914154-2026-01-30-46144a9bc44a))

### Sources

<a id="source-ctg-observation-nct06914154-2026-01-30-46144a9bc44a"></a>
- **ClinicalTrials.gov record NCT06914154 · retained source version 2026-01-30:46144a9bc44a51d6db183f182b4e407bedaf662c8e5f503252e3427f6552c161** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06914154) (`ctg-observation-nct06914154-2026-01-30-46144a9bc44a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06914154." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06914154-tirzepatide-v1 SHA-256: a934ce95c6728dd8d4505ba884f276781875750e1a7023c8a55d2cc4856c3983.

---

<a id="clinicaltrials-gov-nct06918405-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06918405

> PeptideScanner retained ClinicalTrials.gov record NCT06918405 at 2026-07-30T18:29:04.229Z. Its registry update date was 2025-04-09, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06918405-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-04-09
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06918405-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06918405-tirzepatide-v1
- Content SHA-256: `6d2fd6cd6681b7a2da0cf740ae645dce6eb5d610f306a014ac6b3394b537bfca`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06918405 ([`ctg-observation-nct06918405-2025-04-09-b819227ff0a9`](#source-ctg-observation-nct06918405-2025-04-09-b819227ff0a9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06918405 at 2026-07-30T18:29:04.229Z. Its registry update date was 2025-04-09, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06918405-2025-04-09-b819227ff0a9`](#source-ctg-observation-nct06918405-2025-04-09-b819227ff0a9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06918405 at 2026-07-30T18:29:04.229Z. Its registry update date was 2025-04-09, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06918405-2025-04-09-b819227ff0a9`](#source-ctg-observation-nct06918405-2025-04-09-b819227ff0a9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06918405-2025-04-09-b819227ff0a9`](#source-ctg-observation-nct06918405-2025-04-09-b819227ff0a9))

### Sources

<a id="source-ctg-observation-nct06918405-2025-04-09-b819227ff0a9"></a>
- **ClinicalTrials.gov record NCT06918405 · retained source version 2025-04-09:b819227ff0a98705ae8f37b1c57c05453d8bf5715026fd00bad422fd09d4a448** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06918405) (`ctg-observation-nct06918405-2025-04-09-b819227ff0a9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06918405." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06918405-tirzepatide-v1 SHA-256: 6d2fd6cd6681b7a2da0cf740ae645dce6eb5d610f306a014ac6b3394b537bfca.

---

<a id="clinicaltrials-gov-nct06934642-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06934642

> PeptideScanner retained ClinicalTrials.gov record NCT06934642 at 2026-08-10T18:10:03.939Z. Its registry update date was 2026-07-15, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06934642-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-15
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06934642-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06934642-tirzepatide-v1
- Content SHA-256: `767630b7aaa3166d59dc3a485da9bb2b220dd2ab58e16a4a6e89c5d45ccf748d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06934642 ([`ctg-observation-nct06934642-2026-07-15-ea694ee9a887`](#source-ctg-observation-nct06934642-2026-07-15-ea694ee9a887))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06934642 at 2026-08-10T18:10:03.939Z. Its registry update date was 2026-07-15, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06934642-2026-07-15-ea694ee9a887`](#source-ctg-observation-nct06934642-2026-07-15-ea694ee9a887))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06934642 at 2026-08-10T18:10:03.939Z. Its registry update date was 2026-07-15, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06934642-2026-07-15-ea694ee9a887`](#source-ctg-observation-nct06934642-2026-07-15-ea694ee9a887))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06934642-2026-07-15-ea694ee9a887`](#source-ctg-observation-nct06934642-2026-07-15-ea694ee9a887))

### Sources

<a id="source-ctg-observation-nct06934642-2026-07-15-ea694ee9a887"></a>
- **ClinicalTrials.gov record NCT06934642 · retained source version 2026-07-15:ea694ee9a887e110a5b2ebe5969e8429cfa7f3020cb898c99c2c89efbd20a3a7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06934642) (`ctg-observation-nct06934642-2026-07-15-ea694ee9a887`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06934642." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06934642-tirzepatide-v1 SHA-256: 767630b7aaa3166d59dc3a485da9bb2b220dd2ab58e16a4a6e89c5d45ccf748d.

---

<a id="clinicaltrials-gov-nct06935838-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06935838

> PeptideScanner retained ClinicalTrials.gov record NCT06935838 at 2026-08-10T18:10:03.949Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06935838-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06935838-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06935838-tirzepatide-v1
- Content SHA-256: `56c28bf60b1f0f5fac836fc3603af9cf455887309e7c2f63125604d43ecc5852`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06935838 ([`ctg-observation-nct06935838-2026-07-08-f2d7f6021fa6`](#source-ctg-observation-nct06935838-2026-07-08-f2d7f6021fa6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06935838 at 2026-08-10T18:10:03.949Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06935838-2026-07-08-f2d7f6021fa6`](#source-ctg-observation-nct06935838-2026-07-08-f2d7f6021fa6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06935838 at 2026-08-10T18:10:03.949Z. Its registry update date was 2026-07-08, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06935838-2026-07-08-f2d7f6021fa6`](#source-ctg-observation-nct06935838-2026-07-08-f2d7f6021fa6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06935838-2026-07-08-f2d7f6021fa6`](#source-ctg-observation-nct06935838-2026-07-08-f2d7f6021fa6))

### Sources

<a id="source-ctg-observation-nct06935838-2026-07-08-f2d7f6021fa6"></a>
- **ClinicalTrials.gov record NCT06935838 · retained source version 2026-07-08:f2d7f6021fa6af2b87fae9e19bb293f422df86a91e607fad647c30fe801d3c3e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06935838) (`ctg-observation-nct06935838-2026-07-08-f2d7f6021fa6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06935838." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06935838-tirzepatide-v1 SHA-256: 56c28bf60b1f0f5fac836fc3603af9cf455887309e7c2f63125604d43ecc5852.

---

<a id="clinicaltrials-gov-nct06937086-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06937086

> PeptideScanner retained ClinicalTrials.gov record NCT06937086 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06937086-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06937086-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06937086-tirzepatide-v1
- Content SHA-256: `f2693b87262088c02536de292674e115994d3b4c5d044b3bc5d2af0f258ae10c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06937086 ([`ctg-observation-nct06937086-2026-11-04-2d100b3f97f3`](#source-ctg-observation-nct06937086-2026-11-04-2d100b3f97f3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06937086 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06937086-2026-11-04-2d100b3f97f3`](#source-ctg-observation-nct06937086-2026-11-04-2d100b3f97f3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06937086 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06937086-2026-11-04-2d100b3f97f3`](#source-ctg-observation-nct06937086-2026-11-04-2d100b3f97f3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06937086-2026-11-04-2d100b3f97f3`](#source-ctg-observation-nct06937086-2026-11-04-2d100b3f97f3))

### Sources

<a id="source-ctg-observation-nct06937086-2026-11-04-2d100b3f97f3"></a>
- **ClinicalTrials.gov record NCT06937086 · retained source version 2026-11-04:2d100b3f97f37936e0b521b123a0a0706ef38f2b476fdf7a5e779f0d447d1a9e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06937086) (`ctg-observation-nct06937086-2026-11-04-2d100b3f97f3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06937086." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06937086-tirzepatide-v1 SHA-256: f2693b87262088c02536de292674e115994d3b4c5d044b3bc5d2af0f258ae10c.

---

<a id="clinicaltrials-gov-nct06937099-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06937099

> PeptideScanner retained ClinicalTrials.gov record NCT06937099 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06937099-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06937099-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06937099-tirzepatide-v1
- Content SHA-256: `a41175bfc72e690c28589e9ac52ee78f077fc45dd43b949c90d24d24cb9c4a26`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06937099 ([`ctg-observation-nct06937099-2026-11-04-c60315ecfecb`](#source-ctg-observation-nct06937099-2026-11-04-c60315ecfecb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06937099 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06937099-2026-11-04-c60315ecfecb`](#source-ctg-observation-nct06937099-2026-11-04-c60315ecfecb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06937099 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06937099-2026-11-04-c60315ecfecb`](#source-ctg-observation-nct06937099-2026-11-04-c60315ecfecb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06937099-2026-11-04-c60315ecfecb`](#source-ctg-observation-nct06937099-2026-11-04-c60315ecfecb))

### Sources

<a id="source-ctg-observation-nct06937099-2026-11-04-c60315ecfecb"></a>
- **ClinicalTrials.gov record NCT06937099 · retained source version 2026-11-04:c60315ecfecb4b93ff785cf5d2c0c4d3145ea8f64f3fd889bc5c29a5a1858082** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06937099) (`ctg-observation-nct06937099-2026-11-04-c60315ecfecb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06937099." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06937099-tirzepatide-v1 SHA-256: a41175bfc72e690c28589e9ac52ee78f077fc45dd43b949c90d24d24cb9c4a26.

---

<a id="clinicaltrials-gov-nct06939088-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06939088

> PeptideScanner retained ClinicalTrials.gov record NCT06939088 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-10, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06939088-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-10
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06939088-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06939088-tirzepatide-v1
- Content SHA-256: `0219147c0670fc49ff3ee555d5f5e33ca3be2ed6869cb8fa0884b13847169eaf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06939088 ([`ctg-observation-nct06939088-2026-02-10-2b2c68882774`](#source-ctg-observation-nct06939088-2026-02-10-2b2c68882774))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06939088 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06939088-2026-02-10-2b2c68882774`](#source-ctg-observation-nct06939088-2026-02-10-2b2c68882774))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06939088 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06939088-2026-02-10-2b2c68882774`](#source-ctg-observation-nct06939088-2026-02-10-2b2c68882774))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06939088-2026-02-10-2b2c68882774`](#source-ctg-observation-nct06939088-2026-02-10-2b2c68882774))

### Sources

<a id="source-ctg-observation-nct06939088-2026-02-10-2b2c68882774"></a>
- **ClinicalTrials.gov record NCT06939088 · retained source version 2026-02-10:2b2c68882774e7b179eabb09f43f4325425608303065ed4894afe9024a6d8292** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06939088) (`ctg-observation-nct06939088-2026-02-10-2b2c68882774`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06939088." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06939088-tirzepatide-v1 SHA-256: 0219147c0670fc49ff3ee555d5f5e33ca3be2ed6869cb8fa0884b13847169eaf.

---

<a id="clinicaltrials-gov-nct06965413-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06965413

> PeptideScanner retained ClinicalTrials.gov record NCT06965413 at 2026-08-13T05:52:27.007Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06965413-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-11
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06965413-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06965413-tirzepatide-v1
- Content SHA-256: `c60fabd87dff19d191a1c8c090c0ab5ee1e075f3072e4a4f03202544425b3201`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06965413 ([`ctg-observation-nct06965413-2026-08-11-04ab92740e99`](#source-ctg-observation-nct06965413-2026-08-11-04ab92740e99))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06965413 at 2026-08-13T05:52:27.007Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06965413-2026-08-11-04ab92740e99`](#source-ctg-observation-nct06965413-2026-08-11-04ab92740e99))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06965413 at 2026-08-13T05:52:27.007Z. Its registry update date was 2026-08-11, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06965413-2026-08-11-04ab92740e99`](#source-ctg-observation-nct06965413-2026-08-11-04ab92740e99))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06965413-2026-08-11-04ab92740e99`](#source-ctg-observation-nct06965413-2026-08-11-04ab92740e99))

### Sources

<a id="source-ctg-observation-nct06965413-2026-08-11-04ab92740e99"></a>
- **ClinicalTrials.gov record NCT06965413 · retained source version 2026-08-11:04ab92740e998970b1bd66d4dda461c1de9db4219906e276ce3ca5fc1946b162** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06965413) (`ctg-observation-nct06965413-2026-08-11-04ab92740e99`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06965413." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06965413-tirzepatide-v1 SHA-256: c60fabd87dff19d191a1c8c090c0ab5ee1e075f3072e4a4f03202544425b3201.

---

<a id="clinicaltrials-gov-nct06976853-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06976853

> PeptideScanner retained ClinicalTrials.gov record NCT06976853 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06976853-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06976853-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06976853-tirzepatide-v1
- Content SHA-256: `17a07b0770db45551bbd8a96518c4332c7973426ca217f42e430546c9f85d85c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06976853 ([`ctg-observation-nct06976853-2026-06-05-d5edfc4b6396`](#source-ctg-observation-nct06976853-2026-06-05-d5edfc4b6396))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06976853 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06976853-2026-06-05-d5edfc4b6396`](#source-ctg-observation-nct06976853-2026-06-05-d5edfc4b6396))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06976853 at 2026-07-30T16:19:03.055Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06976853-2026-06-05-d5edfc4b6396`](#source-ctg-observation-nct06976853-2026-06-05-d5edfc4b6396))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06976853-2026-06-05-d5edfc4b6396`](#source-ctg-observation-nct06976853-2026-06-05-d5edfc4b6396))

### Sources

<a id="source-ctg-observation-nct06976853-2026-06-05-d5edfc4b6396"></a>
- **ClinicalTrials.gov record NCT06976853 · retained source version 2026-06-05:d5edfc4b6396bd61eb3b5da78a7da99ee950b4c01fee44fb208abc110f2029c3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06976853) (`ctg-observation-nct06976853-2026-06-05-d5edfc4b6396`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06976853." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06976853-tirzepatide-v1 SHA-256: 17a07b0770db45551bbd8a96518c4332c7973426ca217f42e430546c9f85d85c.

---

<a id="clinicaltrials-gov-nct06994338-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT06994338

> PeptideScanner retained ClinicalTrials.gov record NCT06994338 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-14, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct06994338-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-10-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06994338-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06994338-tirzepatide-v1
- Content SHA-256: `38c6888666f1eba162acba593c7e94e8e44d1b838d4cf31fef3a7388ebf450f9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06994338 ([`ctg-observation-nct06994338-2025-10-14-a5ec3b86cdb7`](#source-ctg-observation-nct06994338-2025-10-14-a5ec3b86cdb7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06994338 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-14, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06994338-2025-10-14-a5ec3b86cdb7`](#source-ctg-observation-nct06994338-2025-10-14-a5ec3b86cdb7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06994338 at 2026-07-30T18:20:54.428Z. Its registry update date was 2025-10-14, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct06994338-2025-10-14-a5ec3b86cdb7`](#source-ctg-observation-nct06994338-2025-10-14-a5ec3b86cdb7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06994338-2025-10-14-a5ec3b86cdb7`](#source-ctg-observation-nct06994338-2025-10-14-a5ec3b86cdb7))

### Sources

<a id="source-ctg-observation-nct06994338-2025-10-14-a5ec3b86cdb7"></a>
- **ClinicalTrials.gov record NCT06994338 · retained source version 2025-10-14:a5ec3b86cdb716f6517c38c4556eafca2a98da760b72dd47a73a4ab2fd4338eb** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06994338) (`ctg-observation-nct06994338-2025-10-14-a5ec3b86cdb7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06994338." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct06994338-tirzepatide-v1 SHA-256: 38c6888666f1eba162acba593c7e94e8e44d1b838d4cf31fef3a7388ebf450f9.

---

<a id="clinicaltrials-gov-nct07046819-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07046819

> PeptideScanner retained ClinicalTrials.gov record NCT07046819 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07046819-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-12
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07046819-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07046819-tirzepatide-v1
- Content SHA-256: `c695acdea809b6efd13b54a22fa16060272d7862d43728ffa18efd7681b6c88e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07046819 ([`ctg-observation-nct07046819-2026-08-12-5b39883d5ea8`](#source-ctg-observation-nct07046819-2026-08-12-5b39883d5ea8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07046819 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07046819-2026-08-12-5b39883d5ea8`](#source-ctg-observation-nct07046819-2026-08-12-5b39883d5ea8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07046819 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07046819-2026-08-12-5b39883d5ea8`](#source-ctg-observation-nct07046819-2026-08-12-5b39883d5ea8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07046819-2026-08-12-5b39883d5ea8`](#source-ctg-observation-nct07046819-2026-08-12-5b39883d5ea8))

### Sources

<a id="source-ctg-observation-nct07046819-2026-08-12-5b39883d5ea8"></a>
- **ClinicalTrials.gov record NCT07046819 · retained source version 2026-08-12:5b39883d5ea884b5145845563dd0234f104c44b733bea8c8bfe503a0c1058c3b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07046819) (`ctg-observation-nct07046819-2026-08-12-5b39883d5ea8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07046819." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07046819-tirzepatide-v1 SHA-256: c695acdea809b6efd13b54a22fa16060272d7862d43728ffa18efd7681b6c88e.

---

<a id="clinicaltrials-gov-nct07065552-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07065552

> PeptideScanner retained ClinicalTrials.gov record NCT07065552 at 2026-07-30T16:20:49.313Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07065552-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-04-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07065552-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07065552-tirzepatide-v1
- Content SHA-256: `c1eac16bf819492d333dc38e57c752afe1e1fc91f0e4cf3dffec593815f871b6`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07065552 ([`ctg-observation-nct07065552-2026-04-28-88f1abe15610`](#source-ctg-observation-nct07065552-2026-04-28-88f1abe15610))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07065552 at 2026-07-30T16:20:49.313Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07065552-2026-04-28-88f1abe15610`](#source-ctg-observation-nct07065552-2026-04-28-88f1abe15610))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07065552 at 2026-07-30T16:20:49.313Z. Its registry update date was 2026-04-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07065552-2026-04-28-88f1abe15610`](#source-ctg-observation-nct07065552-2026-04-28-88f1abe15610))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07065552-2026-04-28-88f1abe15610`](#source-ctg-observation-nct07065552-2026-04-28-88f1abe15610))

### Sources

<a id="source-ctg-observation-nct07065552-2026-04-28-88f1abe15610"></a>
- **ClinicalTrials.gov record NCT07065552 · retained source version 2026-04-28:88f1abe156102845151b730bf2c1d73fe5fd339982143a5a6587a9cef54b9d7f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07065552) (`ctg-observation-nct07065552-2026-04-28-88f1abe15610`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07065552." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07065552-tirzepatide-v1 SHA-256: c1eac16bf819492d333dc38e57c752afe1e1fc91f0e4cf3dffec593815f871b6.

---

<a id="clinicaltrials-gov-nct07078838-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07078838

> PeptideScanner retained ClinicalTrials.gov record NCT07078838 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07078838-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-28
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07078838-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07078838-tirzepatide-v1
- Content SHA-256: `d20d1e536605384172213d882912d3469d80b51669af16f925bf9364e7b27148`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07078838 ([`ctg-observation-nct07078838-2026-09-28-a22b91f9415a`](#source-ctg-observation-nct07078838-2026-09-28-a22b91f9415a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07078838 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07078838-2026-09-28-a22b91f9415a`](#source-ctg-observation-nct07078838-2026-09-28-a22b91f9415a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07078838 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07078838-2026-09-28-a22b91f9415a`](#source-ctg-observation-nct07078838-2026-09-28-a22b91f9415a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07078838-2026-09-28-a22b91f9415a`](#source-ctg-observation-nct07078838-2026-09-28-a22b91f9415a))

### Sources

<a id="source-ctg-observation-nct07078838-2026-09-28-a22b91f9415a"></a>
- **ClinicalTrials.gov record NCT07078838 · retained source version 2026-09-28:a22b91f9415ac0c7cb7380e9b7d45a6341fe56be3b234aabee566c69204245cc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07078838) (`ctg-observation-nct07078838-2026-09-28-a22b91f9415a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07078838." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07078838-tirzepatide-v1 SHA-256: d20d1e536605384172213d882912d3469d80b51669af16f925bf9364e7b27148.

---

<a id="clinicaltrials-gov-nct07095517-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07095517

> PeptideScanner retained ClinicalTrials.gov record NCT07095517 at 2026-07-30T16:23:45.642Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07095517-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07095517-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07095517-tirzepatide-v1
- Content SHA-256: `d4b7f6abdef8ed7cf835e32e905c1cf415e8d20d3c9bae5ce4e212107ab11f99`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07095517 ([`ctg-observation-nct07095517-2026-02-27-71fe8d9973a1`](#source-ctg-observation-nct07095517-2026-02-27-71fe8d9973a1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07095517 at 2026-07-30T16:23:45.642Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07095517-2026-02-27-71fe8d9973a1`](#source-ctg-observation-nct07095517-2026-02-27-71fe8d9973a1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07095517 at 2026-07-30T16:23:45.642Z. Its registry update date was 2026-02-27, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07095517-2026-02-27-71fe8d9973a1`](#source-ctg-observation-nct07095517-2026-02-27-71fe8d9973a1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07095517-2026-02-27-71fe8d9973a1`](#source-ctg-observation-nct07095517-2026-02-27-71fe8d9973a1))

### Sources

<a id="source-ctg-observation-nct07095517-2026-02-27-71fe8d9973a1"></a>
- **ClinicalTrials.gov record NCT07095517 · retained source version 2026-02-27:71fe8d9973a14e974f7e1f0dedc8d9659b84824ab2d38e31bc0d01d3ae69873d** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07095517) (`ctg-observation-nct07095517-2026-02-27-71fe8d9973a1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07095517." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07095517-tirzepatide-v1 SHA-256: d4b7f6abdef8ed7cf835e32e905c1cf415e8d20d3c9bae5ce4e212107ab11f99.

---

<a id="clinicaltrials-gov-nct07099742-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07099742

> PeptideScanner retained ClinicalTrials.gov record NCT07099742 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07099742-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-07
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07099742-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07099742-tirzepatide-v1
- Content SHA-256: `8c49fb0cd6348d8ede95977fcdce17a64de49c7e3451ca61e6096ca9702b5d97`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07099742 ([`ctg-observation-nct07099742-2026-10-07-2e0938645518`](#source-ctg-observation-nct07099742-2026-10-07-2e0938645518))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07099742 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07099742-2026-10-07-2e0938645518`](#source-ctg-observation-nct07099742-2026-10-07-2e0938645518))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07099742 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-07, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07099742-2026-10-07-2e0938645518`](#source-ctg-observation-nct07099742-2026-10-07-2e0938645518))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07099742-2026-10-07-2e0938645518`](#source-ctg-observation-nct07099742-2026-10-07-2e0938645518))

### Sources

<a id="source-ctg-observation-nct07099742-2026-10-07-2e0938645518"></a>
- **ClinicalTrials.gov record NCT07099742 · retained source version 2026-10-07:2e0938645518f8f4f40d3ef8cbc51223b64ba15e982251ac8063afad9e17d557** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07099742) (`ctg-observation-nct07099742-2026-10-07-2e0938645518`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07099742." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07099742-tirzepatide-v1 SHA-256: 8c49fb0cd6348d8ede95977fcdce17a64de49c7e3451ca61e6096ca9702b5d97.

---

<a id="clinicaltrials-gov-nct07128082-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07128082

> PeptideScanner retained ClinicalTrials.gov record NCT07128082 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-23, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07128082-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07128082-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07128082-tirzepatide-v1
- Content SHA-256: `7a63be5bab3a2d6c964c5a8b125057340cea69a215f8cdad502a68e9b0c54a3e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07128082 ([`ctg-observation-nct07128082-2025-12-23-80513130dcb6`](#source-ctg-observation-nct07128082-2025-12-23-80513130dcb6))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07128082 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-23, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07128082-2025-12-23-80513130dcb6`](#source-ctg-observation-nct07128082-2025-12-23-80513130dcb6))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07128082 at 2026-07-30T18:18:33.504Z. Its registry update date was 2025-12-23, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07128082-2025-12-23-80513130dcb6`](#source-ctg-observation-nct07128082-2025-12-23-80513130dcb6))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07128082-2025-12-23-80513130dcb6`](#source-ctg-observation-nct07128082-2025-12-23-80513130dcb6))

### Sources

<a id="source-ctg-observation-nct07128082-2025-12-23-80513130dcb6"></a>
- **ClinicalTrials.gov record NCT07128082 · retained source version 2025-12-23:80513130dcb65e61aa274fd1e2e7aa4e0e2decff2a7f5d77d68885c79f72ba7b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07128082) (`ctg-observation-nct07128082-2025-12-23-80513130dcb6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07128082." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07128082-tirzepatide-v1 SHA-256: 7a63be5bab3a2d6c964c5a8b125057340cea69a215f8cdad502a68e9b0c54a3e.

---

<a id="clinicaltrials-gov-nct07176663-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07176663

> PeptideScanner retained ClinicalTrials.gov record NCT07176663 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-15, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07176663-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07176663-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07176663-tirzepatide-v1
- Content SHA-256: `80d02613c5100c077ccdb0d188b991a9b39e49d0eee9214a39dbb68c4898f6c7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07176663 ([`ctg-observation-nct07176663-2025-12-15-dc981bd79f9c`](#source-ctg-observation-nct07176663-2025-12-15-dc981bd79f9c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07176663 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-15, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07176663-2025-12-15-dc981bd79f9c`](#source-ctg-observation-nct07176663-2025-12-15-dc981bd79f9c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07176663 at 2026-07-30T18:18:33.508Z. Its registry update date was 2025-12-15, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07176663-2025-12-15-dc981bd79f9c`](#source-ctg-observation-nct07176663-2025-12-15-dc981bd79f9c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07176663-2025-12-15-dc981bd79f9c`](#source-ctg-observation-nct07176663-2025-12-15-dc981bd79f9c))

### Sources

<a id="source-ctg-observation-nct07176663-2025-12-15-dc981bd79f9c"></a>
- **ClinicalTrials.gov record NCT07176663 · retained source version 2025-12-15:dc981bd79f9c7041572f1f0fdeaa343c934d19b15ee76d86d8eec113de4e3871** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07176663) (`ctg-observation-nct07176663-2025-12-15-dc981bd79f9c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07176663." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07176663-tirzepatide-v1 SHA-256: 80d02613c5100c077ccdb0d188b991a9b39e49d0eee9214a39dbb68c4898f6c7.

---

<a id="clinicaltrials-gov-nct07191873-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07191873

> PeptideScanner retained ClinicalTrials.gov record NCT07191873 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07191873-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07191873-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07191873-tirzepatide-v1
- Content SHA-256: `7e09db71c73f7cf03fdab3bacb98bd10ae5f5167db0ad3b4ed1a4d0d929320b3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07191873 ([`ctg-observation-nct07191873-2026-07-28-fde7aa23d599`](#source-ctg-observation-nct07191873-2026-07-28-fde7aa23d599))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07191873 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07191873-2026-07-28-fde7aa23d599`](#source-ctg-observation-nct07191873-2026-07-28-fde7aa23d599))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07191873 at 2026-08-10T18:10:04.225Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07191873-2026-07-28-fde7aa23d599`](#source-ctg-observation-nct07191873-2026-07-28-fde7aa23d599))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07191873-2026-07-28-fde7aa23d599`](#source-ctg-observation-nct07191873-2026-07-28-fde7aa23d599))

### Sources

<a id="source-ctg-observation-nct07191873-2026-07-28-fde7aa23d599"></a>
- **ClinicalTrials.gov record NCT07191873 · retained source version 2026-07-28:fde7aa23d599cd01613729a0c5a9b7e43505438fa1406584ee4b94ce563c5e38** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07191873) (`ctg-observation-nct07191873-2026-07-28-fde7aa23d599`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07191873." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07191873-tirzepatide-v1 SHA-256: 7e09db71c73f7cf03fdab3bacb98bd10ae5f5167db0ad3b4ed1a4d0d929320b3.

---

<a id="clinicaltrials-gov-nct07218445-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07218445

> PeptideScanner retained ClinicalTrials.gov record NCT07218445 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07218445-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07218445-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07218445-tirzepatide-v1
- Content SHA-256: `0e0f249436f59ade84e681657d4b26de6dc98ffeefcc23a3a4a39c99ab28327b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07218445 ([`ctg-observation-nct07218445-2026-06-05-bd82ac885dbc`](#source-ctg-observation-nct07218445-2026-06-05-bd82ac885dbc))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07218445 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07218445-2026-06-05-bd82ac885dbc`](#source-ctg-observation-nct07218445-2026-06-05-bd82ac885dbc))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07218445 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07218445-2026-06-05-bd82ac885dbc`](#source-ctg-observation-nct07218445-2026-06-05-bd82ac885dbc))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07218445-2026-06-05-bd82ac885dbc`](#source-ctg-observation-nct07218445-2026-06-05-bd82ac885dbc))

### Sources

<a id="source-ctg-observation-nct07218445-2026-06-05-bd82ac885dbc"></a>
- **ClinicalTrials.gov record NCT07218445 · retained source version 2026-06-05:bd82ac885dbcbff5aeb87fe184c4f1ccc2a820e5c1ebb8cd4ff21a1042de7401** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07218445) (`ctg-observation-nct07218445-2026-06-05-bd82ac885dbc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07218445." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07218445-tirzepatide-v1 SHA-256: 0e0f249436f59ade84e681657d4b26de6dc98ffeefcc23a3a4a39c99ab28327b.

---

<a id="clinicaltrials-gov-nct07220473-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07220473

> PeptideScanner retained ClinicalTrials.gov record NCT07220473 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07220473-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-24
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07220473-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07220473-tirzepatide-v1
- Content SHA-256: `0af2a26ff0bb9fb8071a9ae6df00e83d09d997fcb4367879737596f740554b3e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07220473 ([`ctg-observation-nct07220473-2026-03-24-4ededd10b2f5`](#source-ctg-observation-nct07220473-2026-03-24-4ededd10b2f5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07220473 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07220473-2026-03-24-4ededd10b2f5`](#source-ctg-observation-nct07220473-2026-03-24-4ededd10b2f5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07220473 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-24, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07220473-2026-03-24-4ededd10b2f5`](#source-ctg-observation-nct07220473-2026-03-24-4ededd10b2f5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07220473-2026-03-24-4ededd10b2f5`](#source-ctg-observation-nct07220473-2026-03-24-4ededd10b2f5))

### Sources

<a id="source-ctg-observation-nct07220473-2026-03-24-4ededd10b2f5"></a>
- **ClinicalTrials.gov record NCT07220473 · retained source version 2026-03-24:4ededd10b2f55be9688505b69054163e2e29f2ba023c2712f2639c658769a45a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07220473) (`ctg-observation-nct07220473-2026-03-24-4ededd10b2f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07220473." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07220473-tirzepatide-v1 SHA-256: 0af2a26ff0bb9fb8071a9ae6df00e83d09d997fcb4367879737596f740554b3e.

---

<a id="clinicaltrials-gov-nct07228741-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07228741

> PeptideScanner retained ClinicalTrials.gov record NCT07228741 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07228741-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07228741-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07228741-tirzepatide-v1
- Content SHA-256: `a25f51ccbb444443f7837ac76be2a44bb424eda30a69117b0483c482cac1cf4e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07228741 ([`ctg-observation-nct07228741-2026-06-04-a567604ab461`](#source-ctg-observation-nct07228741-2026-06-04-a567604ab461))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07228741 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07228741-2026-06-04-a567604ab461`](#source-ctg-observation-nct07228741-2026-06-04-a567604ab461))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07228741 at 2026-07-30T16:19:03.065Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07228741-2026-06-04-a567604ab461`](#source-ctg-observation-nct07228741-2026-06-04-a567604ab461))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07228741-2026-06-04-a567604ab461`](#source-ctg-observation-nct07228741-2026-06-04-a567604ab461))

### Sources

<a id="source-ctg-observation-nct07228741-2026-06-04-a567604ab461"></a>
- **ClinicalTrials.gov record NCT07228741 · retained source version 2026-06-04:a567604ab4616d37d7ba2d77f34f7b98f9439aa525e958556bbc386d49ec715c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07228741) (`ctg-observation-nct07228741-2026-06-04-a567604ab461`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07228741." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07228741-tirzepatide-v1 SHA-256: a25f51ccbb444443f7837ac76be2a44bb424eda30a69117b0483c482cac1cf4e.

---

<a id="clinicaltrials-gov-nct07247084-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07247084

> PeptideScanner retained ClinicalTrials.gov record NCT07247084 at 2026-09-09T19:17:17.101Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07247084-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-09
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07247084-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07247084-tirzepatide-v1
- Content SHA-256: `2a49eaa661897ac01b40f1dff2efcb94470f7bb16e77dd45f84c1adcd77561e5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07247084 ([`ctg-observation-nct07247084-2026-09-09-05c2d5f3f7f4`](#source-ctg-observation-nct07247084-2026-09-09-05c2d5f3f7f4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07247084 at 2026-09-09T19:17:17.101Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07247084-2026-09-09-05c2d5f3f7f4`](#source-ctg-observation-nct07247084-2026-09-09-05c2d5f3f7f4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07247084 at 2026-09-09T19:17:17.101Z. Its registry update date was 2026-09-09, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07247084-2026-09-09-05c2d5f3f7f4`](#source-ctg-observation-nct07247084-2026-09-09-05c2d5f3f7f4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07247084-2026-09-09-05c2d5f3f7f4`](#source-ctg-observation-nct07247084-2026-09-09-05c2d5f3f7f4))

### Sources

<a id="source-ctg-observation-nct07247084-2026-09-09-05c2d5f3f7f4"></a>
- **ClinicalTrials.gov record NCT07247084 · retained source version 2026-09-09:05c2d5f3f7f4365bc2ebe038556042438fc43452f3bb67e041843f418eb8c44a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07247084) (`ctg-observation-nct07247084-2026-09-09-05c2d5f3f7f4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07247084." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07247084-tirzepatide-v1 SHA-256: 2a49eaa661897ac01b40f1dff2efcb94470f7bb16e77dd45f84c1adcd77561e5.

---

<a id="clinicaltrials-gov-nct07257484-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07257484

> PeptideScanner retained ClinicalTrials.gov record NCT07257484 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07257484-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-22
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07257484-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07257484-tirzepatide-v1
- Content SHA-256: `d8a2141303388d304d8623008728d3b0e25b9e1ed299d58061825879706bba64`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07257484 ([`ctg-observation-nct07257484-2026-07-22-431e62a387c5`](#source-ctg-observation-nct07257484-2026-07-22-431e62a387c5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07257484 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07257484-2026-07-22-431e62a387c5`](#source-ctg-observation-nct07257484-2026-07-22-431e62a387c5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07257484 at 2026-08-10T18:10:04.223Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07257484-2026-07-22-431e62a387c5`](#source-ctg-observation-nct07257484-2026-07-22-431e62a387c5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07257484-2026-07-22-431e62a387c5`](#source-ctg-observation-nct07257484-2026-07-22-431e62a387c5))

### Sources

<a id="source-ctg-observation-nct07257484-2026-07-22-431e62a387c5"></a>
- **ClinicalTrials.gov record NCT07257484 · retained source version 2026-07-22:431e62a387c501fc79bcbead63f0ed19f35a8ac16b1b6bce55f9ebc66d39acc8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07257484) (`ctg-observation-nct07257484-2026-07-22-431e62a387c5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07257484." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07257484-tirzepatide-v1 SHA-256: d8a2141303388d304d8623008728d3b0e25b9e1ed299d58061825879706bba64.

---

<a id="clinicaltrials-gov-nct07265752-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07265752

> PeptideScanner retained ClinicalTrials.gov record NCT07265752 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07265752-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07265752-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07265752-tirzepatide-v1
- Content SHA-256: `2b941a8d98de2fba0c0848fd4b01c7511808017ce2c09fc8e16904b28f8f9fea`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07265752 ([`ctg-observation-nct07265752-2025-12-18-bf2241ee6265`](#source-ctg-observation-nct07265752-2025-12-18-bf2241ee6265))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07265752 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07265752-2025-12-18-bf2241ee6265`](#source-ctg-observation-nct07265752-2025-12-18-bf2241ee6265))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07265752 at 2026-07-30T18:18:33.524Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07265752-2025-12-18-bf2241ee6265`](#source-ctg-observation-nct07265752-2025-12-18-bf2241ee6265))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07265752-2025-12-18-bf2241ee6265`](#source-ctg-observation-nct07265752-2025-12-18-bf2241ee6265))

### Sources

<a id="source-ctg-observation-nct07265752-2025-12-18-bf2241ee6265"></a>
- **ClinicalTrials.gov record NCT07265752 · retained source version 2025-12-18:bf2241ee62654e8abada53ef13a11e73d5bab216a8143274e345235ca2a4105b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07265752) (`ctg-observation-nct07265752-2025-12-18-bf2241ee6265`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07265752." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07265752-tirzepatide-v1 SHA-256: 2b941a8d98de2fba0c0848fd4b01c7511808017ce2c09fc8e16904b28f8f9fea.

---

<a id="clinicaltrials-gov-nct07292519-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07292519

> PeptideScanner retained ClinicalTrials.gov record NCT07292519 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07292519-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-12-18
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07292519-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07292519-tirzepatide-v1
- Content SHA-256: `498f47cfcfdb029eae6ea0e42d5e4289777f9768a8544fe6d949b2343ba5ceb4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07292519 ([`ctg-observation-nct07292519-2025-12-18-eca8d3ce7259`](#source-ctg-observation-nct07292519-2025-12-18-eca8d3ce7259))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07292519 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07292519-2025-12-18-eca8d3ce7259`](#source-ctg-observation-nct07292519-2025-12-18-eca8d3ce7259))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07292519 at 2026-07-30T18:18:33.513Z. Its registry update date was 2025-12-18, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07292519-2025-12-18-eca8d3ce7259`](#source-ctg-observation-nct07292519-2025-12-18-eca8d3ce7259))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07292519-2025-12-18-eca8d3ce7259`](#source-ctg-observation-nct07292519-2025-12-18-eca8d3ce7259))

### Sources

<a id="source-ctg-observation-nct07292519-2025-12-18-eca8d3ce7259"></a>
- **ClinicalTrials.gov record NCT07292519 · retained source version 2025-12-18:eca8d3ce725914f9dfba4b62b979e12c5778e2e0769b00eab4dc1127646e30b6** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07292519) (`ctg-observation-nct07292519-2025-12-18-eca8d3ce7259`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07292519." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07292519-tirzepatide-v1 SHA-256: 498f47cfcfdb029eae6ea0e42d5e4289777f9768a8544fe6d949b2343ba5ceb4.

---

<a id="clinicaltrials-gov-nct07298915-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07298915

> PeptideScanner retained ClinicalTrials.gov record NCT07298915 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07298915-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07298915-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07298915-tirzepatide-v1
- Content SHA-256: `b54ce4664fce189a0e406e68c83c72fabc5b4f2c42eda9b1156a986b9c6f81bb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07298915 ([`ctg-observation-nct07298915-2026-05-06-2e5b1e9c4e97`](#source-ctg-observation-nct07298915-2026-05-06-2e5b1e9c4e97))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07298915 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07298915-2026-05-06-2e5b1e9c4e97`](#source-ctg-observation-nct07298915-2026-05-06-2e5b1e9c4e97))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07298915 at 2026-07-30T16:19:36.919Z. Its registry update date was 2026-05-06, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07298915-2026-05-06-2e5b1e9c4e97`](#source-ctg-observation-nct07298915-2026-05-06-2e5b1e9c4e97))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07298915-2026-05-06-2e5b1e9c4e97`](#source-ctg-observation-nct07298915-2026-05-06-2e5b1e9c4e97))

### Sources

<a id="source-ctg-observation-nct07298915-2026-05-06-2e5b1e9c4e97"></a>
- **ClinicalTrials.gov record NCT07298915 · retained source version 2026-05-06:2e5b1e9c4e970ce7bd779383c7896b769c95542e99275fa2a464f39808149074** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07298915) (`ctg-observation-nct07298915-2026-05-06-2e5b1e9c4e97`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07298915." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07298915-tirzepatide-v1 SHA-256: b54ce4664fce189a0e406e68c83c72fabc5b4f2c42eda9b1156a986b9c6f81bb.

---

<a id="clinicaltrials-gov-nct07364175-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07364175

> PeptideScanner retained ClinicalTrials.gov record NCT07364175 at 2026-07-30T16:25:18.007Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07364175-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07364175-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07364175-tirzepatide-v1
- Content SHA-256: `af62a7eb4ac17a27983c85fcdeeb09ab411dc39466a7f8ff45032d9a7a7b5d71`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07364175 ([`ctg-observation-nct07364175-2026-01-29-760b785eb355`](#source-ctg-observation-nct07364175-2026-01-29-760b785eb355))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07364175 at 2026-07-30T16:25:18.007Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07364175-2026-01-29-760b785eb355`](#source-ctg-observation-nct07364175-2026-01-29-760b785eb355))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07364175 at 2026-07-30T16:25:18.007Z. Its registry update date was 2026-01-29, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07364175-2026-01-29-760b785eb355`](#source-ctg-observation-nct07364175-2026-01-29-760b785eb355))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07364175-2026-01-29-760b785eb355`](#source-ctg-observation-nct07364175-2026-01-29-760b785eb355))

### Sources

<a id="source-ctg-observation-nct07364175-2026-01-29-760b785eb355"></a>
- **ClinicalTrials.gov record NCT07364175 · retained source version 2026-01-29:760b785eb3551f59dcbdaba1520614b35d3ad0bdda765096ea0a22f0a118155a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07364175) (`ctg-observation-nct07364175-2026-01-29-760b785eb355`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07364175." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07364175-tirzepatide-v1 SHA-256: af62a7eb4ac17a27983c85fcdeeb09ab411dc39466a7f8ff45032d9a7a7b5d71.

---

<a id="clinicaltrials-gov-nct07373834-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07373834

> PeptideScanner retained ClinicalTrials.gov record NCT07373834 at 2026-07-30T16:25:18.006Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07373834-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-28
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07373834-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07373834-tirzepatide-v1
- Content SHA-256: `a615ad5d3c24e0147e80b6b5af6e3e4464a4823a184b7c5075c0a8aae4029b0f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07373834 ([`ctg-observation-nct07373834-2026-01-28-fbb4425317a4`](#source-ctg-observation-nct07373834-2026-01-28-fbb4425317a4))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07373834 at 2026-07-30T16:25:18.006Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07373834-2026-01-28-fbb4425317a4`](#source-ctg-observation-nct07373834-2026-01-28-fbb4425317a4))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07373834 at 2026-07-30T16:25:18.006Z. Its registry update date was 2026-01-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07373834-2026-01-28-fbb4425317a4`](#source-ctg-observation-nct07373834-2026-01-28-fbb4425317a4))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07373834-2026-01-28-fbb4425317a4`](#source-ctg-observation-nct07373834-2026-01-28-fbb4425317a4))

### Sources

<a id="source-ctg-observation-nct07373834-2026-01-28-fbb4425317a4"></a>
- **ClinicalTrials.gov record NCT07373834 · retained source version 2026-01-28:fbb4425317a485a0ee6ec1fb920ce4cd17e83053b10a359bdf852c54bbfbcc47** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07373834) (`ctg-observation-nct07373834-2026-01-28-fbb4425317a4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07373834." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07373834-tirzepatide-v1 SHA-256: a615ad5d3c24e0147e80b6b5af6e3e4464a4823a184b7c5075c0a8aae4029b0f.

---

<a id="clinicaltrials-gov-nct07382024-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07382024

> PeptideScanner retained ClinicalTrials.gov record NCT07382024 at 2026-07-30T16:19:03.058Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07382024-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-08
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07382024-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07382024-tirzepatide-v1
- Content SHA-256: `00a42067fcde2af11b9e5c4a2e4d4a6c0149f2878cc2e4fc71675529506e34cd`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07382024 ([`ctg-observation-nct07382024-2026-06-12-a80b4d304541`](#source-ctg-observation-nct07382024-2026-06-12-a80b4d304541))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07382024 at 2026-07-30T16:19:03.058Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07382024-2026-06-12-a80b4d304541`](#source-ctg-observation-nct07382024-2026-06-12-a80b4d304541))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07382024 at 2026-07-30T16:19:03.058Z. Its registry update date was 2026-06-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07382024-2026-06-12-a80b4d304541`](#source-ctg-observation-nct07382024-2026-06-12-a80b4d304541))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07382024-2026-06-12-a80b4d304541`](#source-ctg-observation-nct07382024-2026-06-12-a80b4d304541))

### Sources

<a id="source-ctg-observation-nct07382024-2026-06-12-a80b4d304541"></a>
- **ClinicalTrials.gov record NCT07382024 · retained source version 2026-06-12:a80b4d3045417dc3996abddafe887fa8cc6ff6cd9e5404c59a5ec2d9316b5ddf** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07382024) (`ctg-observation-nct07382024-2026-06-12-a80b4d304541`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07382024." Version 1, published 2026-08-08. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07382024-tirzepatide-v1 SHA-256: 00a42067fcde2af11b9e5c4a2e4d4a6c0149f2878cc2e4fc71675529506e34cd.

---

<a id="clinicaltrials-gov-nct07423247-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07423247

> PeptideScanner retained ClinicalTrials.gov record NCT07423247 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-20, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07423247-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-20
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07423247-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07423247-tirzepatide-v1
- Content SHA-256: `e43019d5cfed47cbaf11fdff18c792ed32de82e69f002024fbed4e465da19527`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07423247 ([`ctg-observation-nct07423247-2026-02-20-f77be8dfab9b`](#source-ctg-observation-nct07423247-2026-02-20-f77be8dfab9b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07423247 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-20, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07423247-2026-02-20-f77be8dfab9b`](#source-ctg-observation-nct07423247-2026-02-20-f77be8dfab9b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07423247 at 2026-07-30T16:23:45.670Z. Its registry update date was 2026-02-20, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07423247-2026-02-20-f77be8dfab9b`](#source-ctg-observation-nct07423247-2026-02-20-f77be8dfab9b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07423247-2026-02-20-f77be8dfab9b`](#source-ctg-observation-nct07423247-2026-02-20-f77be8dfab9b))

### Sources

<a id="source-ctg-observation-nct07423247-2026-02-20-f77be8dfab9b"></a>
- **ClinicalTrials.gov record NCT07423247 · retained source version 2026-02-20:f77be8dfab9ba43b1bb64237570b5db73025c719ed5d530ac42f834c50f4f5bd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07423247) (`ctg-observation-nct07423247-2026-02-20-f77be8dfab9b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07423247." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07423247-tirzepatide-v1 SHA-256: e43019d5cfed47cbaf11fdff18c792ed32de82e69f002024fbed4e465da19527.

---

<a id="clinicaltrials-gov-nct07443956-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07443956

> PeptideScanner retained ClinicalTrials.gov record NCT07443956 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07443956-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07443956-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07443956-tirzepatide-v1
- Content SHA-256: `7e6e31ecbcbb4baef03d5606975edab800e4789d85d82b8ffe2fc144a39df65c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07443956 ([`ctg-observation-nct07443956-2026-05-04-eaf3920a4ee9`](#source-ctg-observation-nct07443956-2026-05-04-eaf3920a4ee9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07443956 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07443956-2026-05-04-eaf3920a4ee9`](#source-ctg-observation-nct07443956-2026-05-04-eaf3920a4ee9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07443956 at 2026-07-30T16:19:36.909Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07443956-2026-05-04-eaf3920a4ee9`](#source-ctg-observation-nct07443956-2026-05-04-eaf3920a4ee9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07443956-2026-05-04-eaf3920a4ee9`](#source-ctg-observation-nct07443956-2026-05-04-eaf3920a4ee9))

### Sources

<a id="source-ctg-observation-nct07443956-2026-05-04-eaf3920a4ee9"></a>
- **ClinicalTrials.gov record NCT07443956 · retained source version 2026-05-04:eaf3920a4ee9ffbe0994754233f17dff260314d8273e6388632740d91a9f332f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07443956) (`ctg-observation-nct07443956-2026-05-04-eaf3920a4ee9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07443956." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07443956-tirzepatide-v1 SHA-256: 7e6e31ecbcbb4baef03d5606975edab800e4789d85d82b8ffe2fc144a39df65c.

---

<a id="clinicaltrials-gov-nct07463846-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07463846

> PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07463846-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-12
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07463846-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07463846-tirzepatide-v1
- Content SHA-256: `bf15dbbf03cf5a41804fc85d5548daa50ae33685a237a21315ae1c7f49aa2d7e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07463846 ([`ctg-observation-nct07463846-2026-08-12-3a462c76c655`](#source-ctg-observation-nct07463846-2026-08-12-3a462c76c655))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07463846-2026-08-12-3a462c76c655`](#source-ctg-observation-nct07463846-2026-08-12-3a462c76c655))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-08-13T05:54:14.856Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07463846-2026-08-12-3a462c76c655`](#source-ctg-observation-nct07463846-2026-08-12-3a462c76c655))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07463846-2026-08-12-3a462c76c655`](#source-ctg-observation-nct07463846-2026-08-12-3a462c76c655))

### Sources

<a id="source-ctg-observation-nct07463846-2026-08-12-3a462c76c655"></a>
- **ClinicalTrials.gov record NCT07463846 · retained source version 2026-08-12:3a462c76c655636a6f8c827ccc1df679466e5fda22800a442b527ef2e945d7df** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07463846) (`ctg-observation-nct07463846-2026-08-12-3a462c76c655`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07463846." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07463846-tirzepatide-v1 SHA-256: bf15dbbf03cf5a41804fc85d5548daa50ae33685a237a21315ae1c7f49aa2d7e.

---

<a id="clinicaltrials-gov-nct07463846-tirzepatide-v2"></a>

## ClinicalTrials.gov record NCT07463846

> PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07463846-tirzepatide:v2`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07463846-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07463846-tirzepatide-v2
- Content SHA-256: `a353749695dc9d59057ca59824cf343317cf3c92bbc8bf14253b9f151f72cb13`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07463846 ([`ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2`](#source-ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2`](#source-ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07463846 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2`](#source-ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2`](#source-ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2))

### Sources

<a id="source-ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2"></a>
- **ClinicalTrials.gov record NCT07463846 · retained source version 2026-11-12:df642b074c116cd2fb88fd57ee47c69696a51876de28b957174c71215747a8ac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07463846) (`ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2`)

### Correction lineage

updated on 2026-11-15: ClinicalTrials.gov posted a newer version of NCT07463846, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2`](#source-ctg-observation-nct07463846-2026-08-12-3a462c76c655-r2)

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07463846." Version 2, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07463846-tirzepatide-v2 SHA-256: a353749695dc9d59057ca59824cf343317cf3c92bbc8bf14253b9f151f72cb13.

---

<a id="clinicaltrials-gov-nct07468552-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07468552

> PeptideScanner retained ClinicalTrials.gov record NCT07468552 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07468552-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-12
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07468552-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07468552-tirzepatide-v1
- Content SHA-256: `b46278d2f706b9d340105bf55d51719da37350389915f16b142bb72d66a9f58e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07468552 ([`ctg-observation-nct07468552-2026-03-12-c82025d84014`](#source-ctg-observation-nct07468552-2026-03-12-c82025d84014))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07468552 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07468552-2026-03-12-c82025d84014`](#source-ctg-observation-nct07468552-2026-03-12-c82025d84014))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07468552 at 2026-07-30T16:22:22.342Z. Its registry update date was 2026-03-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07468552-2026-03-12-c82025d84014`](#source-ctg-observation-nct07468552-2026-03-12-c82025d84014))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07468552-2026-03-12-c82025d84014`](#source-ctg-observation-nct07468552-2026-03-12-c82025d84014))

### Sources

<a id="source-ctg-observation-nct07468552-2026-03-12-c82025d84014"></a>
- **ClinicalTrials.gov record NCT07468552 · retained source version 2026-03-12:c82025d840140de79ed3d70336d78f8b1d0c144a5a749577c773ae45c384e247** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07468552) (`ctg-observation-nct07468552-2026-03-12-c82025d84014`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07468552." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07468552-tirzepatide-v1 SHA-256: b46278d2f706b9d340105bf55d51719da37350389915f16b142bb72d66a9f58e.

---

<a id="clinicaltrials-gov-nct07481747-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07481747

> PeptideScanner retained ClinicalTrials.gov record NCT07481747 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07481747-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07481747-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07481747-tirzepatide-v1
- Content SHA-256: `9593542a4da755b9267523830c812c095b4682df269cdf47546641af75ad7674`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07481747 ([`ctg-observation-nct07481747-2026-11-12-783a57d13c2f`](#source-ctg-observation-nct07481747-2026-11-12-783a57d13c2f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07481747 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07481747-2026-11-12-783a57d13c2f`](#source-ctg-observation-nct07481747-2026-11-12-783a57d13c2f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07481747 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07481747-2026-11-12-783a57d13c2f`](#source-ctg-observation-nct07481747-2026-11-12-783a57d13c2f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07481747-2026-11-12-783a57d13c2f`](#source-ctg-observation-nct07481747-2026-11-12-783a57d13c2f))

### Sources

<a id="source-ctg-observation-nct07481747-2026-11-12-783a57d13c2f"></a>
- **ClinicalTrials.gov record NCT07481747 · retained source version 2026-11-12:783a57d13c2f1a6b26b4fad040d1babdff645a102f5d5f60806f9fa390efc873** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07481747) (`ctg-observation-nct07481747-2026-11-12-783a57d13c2f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07481747." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07481747-tirzepatide-v1 SHA-256: 9593542a4da755b9267523830c812c095b4682df269cdf47546641af75ad7674.

---

<a id="clinicaltrials-gov-nct07504172-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07504172

> PeptideScanner retained ClinicalTrials.gov record NCT07504172 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07504172-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-28
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07504172-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07504172-tirzepatide-v1
- Content SHA-256: `40c4c691042967efb66af0ff2906aeedf4d319e9da72c7f324dcf79b8d32080b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07504172 ([`ctg-observation-nct07504172-2026-10-28-07cc803e9f61`](#source-ctg-observation-nct07504172-2026-10-28-07cc803e9f61))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07504172 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07504172-2026-10-28-07cc803e9f61`](#source-ctg-observation-nct07504172-2026-10-28-07cc803e9f61))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07504172 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07504172-2026-10-28-07cc803e9f61`](#source-ctg-observation-nct07504172-2026-10-28-07cc803e9f61))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07504172-2026-10-28-07cc803e9f61`](#source-ctg-observation-nct07504172-2026-10-28-07cc803e9f61))

### Sources

<a id="source-ctg-observation-nct07504172-2026-10-28-07cc803e9f61"></a>
- **ClinicalTrials.gov record NCT07504172 · retained source version 2026-10-28:07cc803e9f611c4a584803001ff0437d8a11bdd68642ceccafed5232d3262537** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07504172) (`ctg-observation-nct07504172-2026-10-28-07cc803e9f61`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07504172." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07504172-tirzepatide-v1 SHA-256: 40c4c691042967efb66af0ff2906aeedf4d319e9da72c7f324dcf79b8d32080b.

---

<a id="clinicaltrials-gov-nct07527910-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07527910

> PeptideScanner retained ClinicalTrials.gov record NCT07527910 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07527910-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-29
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07527910-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07527910-tirzepatide-v1
- Content SHA-256: `98dac0315455c174f505fcfe8da506685811d98a49cb45a9cebfd9414eed6d06`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07527910 ([`ctg-observation-nct07527910-2026-09-29-82673d0b8dc0`](#source-ctg-observation-nct07527910-2026-09-29-82673d0b8dc0))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07527910 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07527910-2026-09-29-82673d0b8dc0`](#source-ctg-observation-nct07527910-2026-09-29-82673d0b8dc0))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07527910 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07527910-2026-09-29-82673d0b8dc0`](#source-ctg-observation-nct07527910-2026-09-29-82673d0b8dc0))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07527910-2026-09-29-82673d0b8dc0`](#source-ctg-observation-nct07527910-2026-09-29-82673d0b8dc0))

### Sources

<a id="source-ctg-observation-nct07527910-2026-09-29-82673d0b8dc0"></a>
- **ClinicalTrials.gov record NCT07527910 · retained source version 2026-09-29:82673d0b8dc03eea4e82429f30caa5eb9cf048d34963571dbb63b75a46216c94** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07527910) (`ctg-observation-nct07527910-2026-09-29-82673d0b8dc0`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07527910." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07527910-tirzepatide-v1 SHA-256: 98dac0315455c174f505fcfe8da506685811d98a49cb45a9cebfd9414eed6d06.

---

<a id="clinicaltrials-gov-nct07554638-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07554638

> PeptideScanner retained ClinicalTrials.gov record NCT07554638 at 2026-07-30T16:19:36.907Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07554638-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-04
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07554638-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07554638-tirzepatide-v1
- Content SHA-256: `4bb78ce7a09011f8c6b911336f337766a382c686e308a38eb4f0b14612ae13fb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07554638 ([`ctg-observation-nct07554638-2026-05-04-1236ac6dddcb`](#source-ctg-observation-nct07554638-2026-05-04-1236ac6dddcb))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07554638 at 2026-07-30T16:19:36.907Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07554638-2026-05-04-1236ac6dddcb`](#source-ctg-observation-nct07554638-2026-05-04-1236ac6dddcb))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07554638 at 2026-07-30T16:19:36.907Z. Its registry update date was 2026-05-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07554638-2026-05-04-1236ac6dddcb`](#source-ctg-observation-nct07554638-2026-05-04-1236ac6dddcb))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07554638-2026-05-04-1236ac6dddcb`](#source-ctg-observation-nct07554638-2026-05-04-1236ac6dddcb))

### Sources

<a id="source-ctg-observation-nct07554638-2026-05-04-1236ac6dddcb"></a>
- **ClinicalTrials.gov record NCT07554638 · retained source version 2026-05-04:1236ac6dddcb980fa4ad6218050bfedea82e19977d1b63f874d55618feae4f5e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07554638) (`ctg-observation-nct07554638-2026-05-04-1236ac6dddcb`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07554638." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07554638-tirzepatide-v1 SHA-256: 4bb78ce7a09011f8c6b911336f337766a382c686e308a38eb4f0b14612ae13fb.

---

<a id="clinicaltrials-gov-nct07559500-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07559500

> PeptideScanner retained ClinicalTrials.gov record NCT07559500 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07559500-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07559500-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07559500-tirzepatide-v1
- Content SHA-256: `e5259d4b8ce362c65d25ef8f01252d0dc39fa05fc8dc12cbb7d3c25a529cdea4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07559500 ([`ctg-observation-nct07559500-2026-07-28-844c25a77010`](#source-ctg-observation-nct07559500-2026-07-28-844c25a77010))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07559500 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07559500-2026-07-28-844c25a77010`](#source-ctg-observation-nct07559500-2026-07-28-844c25a77010))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07559500 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-28, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07559500-2026-07-28-844c25a77010`](#source-ctg-observation-nct07559500-2026-07-28-844c25a77010))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07559500-2026-07-28-844c25a77010`](#source-ctg-observation-nct07559500-2026-07-28-844c25a77010))

### Sources

<a id="source-ctg-observation-nct07559500-2026-07-28-844c25a77010"></a>
- **ClinicalTrials.gov record NCT07559500 · retained source version 2026-07-28:844c25a77010c2d759fb53725b01c6ea15e29d26d2659c94e5eb2ee2899cb163** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07559500) (`ctg-observation-nct07559500-2026-07-28-844c25a77010`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07559500." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07559500-tirzepatide-v1 SHA-256: e5259d4b8ce362c65d25ef8f01252d0dc39fa05fc8dc12cbb7d3c25a529cdea4.

---

<a id="clinicaltrials-gov-nct07602699-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07602699

> PeptideScanner retained ClinicalTrials.gov record NCT07602699 at 2026-08-10T18:10:03.953Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07602699-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-17
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07602699-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07602699-tirzepatide-v1
- Content SHA-256: `c42be6c55507bfc2ec2517a1ebd758779f7f97f344e9fde03590ce5cd6d4e7f8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07602699 ([`ctg-observation-nct07602699-2026-07-17-0da1179d3868`](#source-ctg-observation-nct07602699-2026-07-17-0da1179d3868))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07602699 at 2026-08-10T18:10:03.953Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07602699-2026-07-17-0da1179d3868`](#source-ctg-observation-nct07602699-2026-07-17-0da1179d3868))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07602699 at 2026-08-10T18:10:03.953Z. Its registry update date was 2026-07-17, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07602699-2026-07-17-0da1179d3868`](#source-ctg-observation-nct07602699-2026-07-17-0da1179d3868))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07602699-2026-07-17-0da1179d3868`](#source-ctg-observation-nct07602699-2026-07-17-0da1179d3868))

### Sources

<a id="source-ctg-observation-nct07602699-2026-07-17-0da1179d3868"></a>
- **ClinicalTrials.gov record NCT07602699 · retained source version 2026-07-17:0da1179d3868e8c8c3f384e77b25189b795cca0d29ad9c30279c8db3ccc76af8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07602699) (`ctg-observation-nct07602699-2026-07-17-0da1179d3868`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07602699." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07602699-tirzepatide-v1 SHA-256: c42be6c55507bfc2ec2517a1ebd758779f7f97f344e9fde03590ce5cd6d4e7f8.

---

<a id="clinicaltrials-gov-nct07605247-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07605247

> PeptideScanner retained ClinicalTrials.gov record NCT07605247 at 2026-07-30T16:19:36.902Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07605247-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-05-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07605247-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07605247-tirzepatide-v1
- Content SHA-256: `cc1d204c6bd91daebc44c5c8c934c4ad08aecb15d918c56a9f58e0bb85dafbe3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07605247 ([`ctg-observation-nct07605247-2026-05-22-fb082688bd6d`](#source-ctg-observation-nct07605247-2026-05-22-fb082688bd6d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07605247 at 2026-07-30T16:19:36.902Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07605247-2026-05-22-fb082688bd6d`](#source-ctg-observation-nct07605247-2026-05-22-fb082688bd6d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07605247 at 2026-07-30T16:19:36.902Z. Its registry update date was 2026-05-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07605247-2026-05-22-fb082688bd6d`](#source-ctg-observation-nct07605247-2026-05-22-fb082688bd6d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07605247-2026-05-22-fb082688bd6d`](#source-ctg-observation-nct07605247-2026-05-22-fb082688bd6d))

### Sources

<a id="source-ctg-observation-nct07605247-2026-05-22-fb082688bd6d"></a>
- **ClinicalTrials.gov record NCT07605247 · retained source version 2026-05-22:fb082688bd6d9c82480305983544d6482527004146cd7f8f58eeba534eb3e8a1** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07605247) (`ctg-observation-nct07605247-2026-05-22-fb082688bd6d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07605247." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07605247-tirzepatide-v1 SHA-256: cc1d204c6bd91daebc44c5c8c934c4ad08aecb15d918c56a9f58e0bb85dafbe3.

---

<a id="clinicaltrials-gov-nct07630454-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07630454

> PeptideScanner retained ClinicalTrials.gov record NCT07630454 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07630454-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-05
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-09
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07630454-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07630454-tirzepatide-v1
- Content SHA-256: `9003e909767f1ae251eb6194c18432a803b9bb5afcec6b9f5c2879e93b53da11`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07630454 ([`ctg-observation-nct07630454-2026-06-05-1b48bfa519cf`](#source-ctg-observation-nct07630454-2026-06-05-1b48bfa519cf))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07630454 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07630454-2026-06-05-1b48bfa519cf`](#source-ctg-observation-nct07630454-2026-06-05-1b48bfa519cf))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07630454 at 2026-07-30T16:19:03.064Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07630454-2026-06-05-1b48bfa519cf`](#source-ctg-observation-nct07630454-2026-06-05-1b48bfa519cf))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07630454-2026-06-05-1b48bfa519cf`](#source-ctg-observation-nct07630454-2026-06-05-1b48bfa519cf))

### Sources

<a id="source-ctg-observation-nct07630454-2026-06-05-1b48bfa519cf"></a>
- **ClinicalTrials.gov record NCT07630454 · retained source version 2026-06-05:1b48bfa519cfbcb122aa1474a40109666aa5599fed66dc999a4854577b272a55** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07630454) (`ctg-observation-nct07630454-2026-06-05-1b48bfa519cf`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07630454." Version 1, published 2026-08-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07630454-tirzepatide-v1 SHA-256: 9003e909767f1ae251eb6194c18432a803b9bb5afcec6b9f5c2879e93b53da11.

---

<a id="clinicaltrials-gov-nct07671248-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07671248

> PeptideScanner retained ClinicalTrials.gov record NCT07671248 at 2026-07-30T16:38:53.229Z. Its registry update date was 2026-07-01, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07671248-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-07-31
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07671248-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07671248-tirzepatide-v1
- Content SHA-256: `1c17695003176ada18ce6c1c1f2042069a1cd1872e1200f2230900ed801ca102`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07671248 ([`ctg-observation-nct07671248-2026-07-01-c7aa2f53914c`](#source-ctg-observation-nct07671248-2026-07-01-c7aa2f53914c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07671248 at 2026-07-30T16:38:53.229Z. Its registry update date was 2026-07-01, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07671248-2026-07-01-c7aa2f53914c`](#source-ctg-observation-nct07671248-2026-07-01-c7aa2f53914c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07671248 at 2026-07-30T16:38:53.229Z. Its registry update date was 2026-07-01, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07671248-2026-07-01-c7aa2f53914c`](#source-ctg-observation-nct07671248-2026-07-01-c7aa2f53914c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07671248-2026-07-01-c7aa2f53914c`](#source-ctg-observation-nct07671248-2026-07-01-c7aa2f53914c))

### Sources

<a id="source-ctg-observation-nct07671248-2026-07-01-c7aa2f53914c"></a>
- **ClinicalTrials.gov record NCT07671248 · retained source version 2026-07-01:c7aa2f53914cba901585fbca615cc662e3c3900823e0e335b25abe9e30f1016f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07671248) (`ctg-observation-nct07671248-2026-07-01-c7aa2f53914c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07671248." Version 1, published 2026-07-31. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07671248-tirzepatide-v1 SHA-256: 1c17695003176ada18ce6c1c1f2042069a1cd1872e1200f2230900ed801ca102.

---

<a id="clinicaltrials-gov-nct07693608-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07693608

> PeptideScanner retained ClinicalTrials.gov record NCT07693608 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07693608-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07693608-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07693608-tirzepatide-v1
- Content SHA-256: `a8527dfe84c64de16b64a17dc822def25004862ea887e204c0b1566e30981678`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07693608 ([`ctg-observation-nct07693608-2026-07-09-c547aa4a1529`](#source-ctg-observation-nct07693608-2026-07-09-c547aa4a1529))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07693608 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07693608-2026-07-09-c547aa4a1529`](#source-ctg-observation-nct07693608-2026-07-09-c547aa4a1529))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07693608 at 2026-08-10T18:10:03.920Z. Its registry update date was 2026-07-09, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07693608-2026-07-09-c547aa4a1529`](#source-ctg-observation-nct07693608-2026-07-09-c547aa4a1529))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07693608-2026-07-09-c547aa4a1529`](#source-ctg-observation-nct07693608-2026-07-09-c547aa4a1529))

### Sources

<a id="source-ctg-observation-nct07693608-2026-07-09-c547aa4a1529"></a>
- **ClinicalTrials.gov record NCT07693608 · retained source version 2026-07-09:c547aa4a1529609c99e4d84e1c6da81c2088b08cd1c367e7b451886b6f380f9e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07693608) (`ctg-observation-nct07693608-2026-07-09-c547aa4a1529`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07693608." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07693608-tirzepatide-v1 SHA-256: a8527dfe84c64de16b64a17dc822def25004862ea887e204c0b1566e30981678.

---

<a id="clinicaltrials-gov-nct07697391-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07697391

> PeptideScanner retained ClinicalTrials.gov record NCT07697391 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07697391-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07697391-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07697391-tirzepatide-v1
- Content SHA-256: `5b2a6e99545ed7bc120cc23e4802f5673a29f49d555bb3ec3c10efb558ea6eca`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07697391 ([`ctg-observation-nct07697391-2026-11-04-b8835d31aa25`](#source-ctg-observation-nct07697391-2026-11-04-b8835d31aa25))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07697391 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07697391-2026-11-04-b8835d31aa25`](#source-ctg-observation-nct07697391-2026-11-04-b8835d31aa25))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07697391 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07697391-2026-11-04-b8835d31aa25`](#source-ctg-observation-nct07697391-2026-11-04-b8835d31aa25))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07697391-2026-11-04-b8835d31aa25`](#source-ctg-observation-nct07697391-2026-11-04-b8835d31aa25))

### Sources

<a id="source-ctg-observation-nct07697391-2026-11-04-b8835d31aa25"></a>
- **ClinicalTrials.gov record NCT07697391 · retained source version 2026-11-04:b8835d31aa25866837ffa570bdef2132ff789f49a77fb7bdcfd0cd61a541db3a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07697391) (`ctg-observation-nct07697391-2026-11-04-b8835d31aa25`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07697391." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07697391-tirzepatide-v1 SHA-256: 5b2a6e99545ed7bc120cc23e4802f5673a29f49d555bb3ec3c10efb558ea6eca.

---

<a id="clinicaltrials-gov-nct07707778-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07707778

> PeptideScanner retained ClinicalTrials.gov record NCT07707778 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07707778-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-20
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07707778-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07707778-tirzepatide-v1
- Content SHA-256: `1bf8bec0821116a921742a3985f885645b844958cbfb2ec9be83928aa76f1bc4`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07707778 ([`ctg-observation-nct07707778-2026-07-20-1576d02c408f`](#source-ctg-observation-nct07707778-2026-07-20-1576d02c408f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07707778 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07707778-2026-07-20-1576d02c408f`](#source-ctg-observation-nct07707778-2026-07-20-1576d02c408f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07707778 at 2026-08-10T18:10:03.948Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07707778-2026-07-20-1576d02c408f`](#source-ctg-observation-nct07707778-2026-07-20-1576d02c408f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07707778-2026-07-20-1576d02c408f`](#source-ctg-observation-nct07707778-2026-07-20-1576d02c408f))

### Sources

<a id="source-ctg-observation-nct07707778-2026-07-20-1576d02c408f"></a>
- **ClinicalTrials.gov record NCT07707778 · retained source version 2026-07-20:1576d02c408fff800e9efa0b535807e1a3aa66af04c33582091e124b6b149099** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07707778) (`ctg-observation-nct07707778-2026-07-20-1576d02c408f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07707778." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07707778-tirzepatide-v1 SHA-256: 1bf8bec0821116a921742a3985f885645b844958cbfb2ec9be83928aa76f1bc4.

---

<a id="clinicaltrials-gov-nct07715929-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07715929

> PeptideScanner retained ClinicalTrials.gov record NCT07715929 at 2026-08-10T18:10:04.226Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07715929-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-21
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07715929-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07715929-tirzepatide-v1
- Content SHA-256: `66c87ab301ee19fc044aa25acab75bb0d65886aca079fc560532d8a453fae090`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07715929 ([`ctg-observation-nct07715929-2026-07-21-1ea2927c5ab3`](#source-ctg-observation-nct07715929-2026-07-21-1ea2927c5ab3))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07715929 at 2026-08-10T18:10:04.226Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07715929-2026-07-21-1ea2927c5ab3`](#source-ctg-observation-nct07715929-2026-07-21-1ea2927c5ab3))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07715929 at 2026-08-10T18:10:04.226Z. Its registry update date was 2026-07-21, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07715929-2026-07-21-1ea2927c5ab3`](#source-ctg-observation-nct07715929-2026-07-21-1ea2927c5ab3))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07715929-2026-07-21-1ea2927c5ab3`](#source-ctg-observation-nct07715929-2026-07-21-1ea2927c5ab3))

### Sources

<a id="source-ctg-observation-nct07715929-2026-07-21-1ea2927c5ab3"></a>
- **ClinicalTrials.gov record NCT07715929 · retained source version 2026-07-21:1ea2927c5ab3bf69730268c39cdc865fa97a21b391360856d99205d97596c9b8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07715929) (`ctg-observation-nct07715929-2026-07-21-1ea2927c5ab3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07715929." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07715929-tirzepatide-v1 SHA-256: 66c87ab301ee19fc044aa25acab75bb0d65886aca079fc560532d8a453fae090.

---

<a id="clinicaltrials-gov-nct07734792-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07734792

> PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07734792-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07734792-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07734792-tirzepatide-v1
- Content SHA-256: `1ed43c035d2a435a7542e36d5ccd67580e4a6f898fd1b18e34e6a4e8f3dbf1a7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07734792 ([`ctg-observation-nct07734792-2026-07-29-16e12449ec7c`](#source-ctg-observation-nct07734792-2026-07-29-16e12449ec7c))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07734792-2026-07-29-16e12449ec7c`](#source-ctg-observation-nct07734792-2026-07-29-16e12449ec7c))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-08-10T18:10:03.951Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07734792-2026-07-29-16e12449ec7c`](#source-ctg-observation-nct07734792-2026-07-29-16e12449ec7c))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07734792-2026-07-29-16e12449ec7c`](#source-ctg-observation-nct07734792-2026-07-29-16e12449ec7c))

### Sources

<a id="source-ctg-observation-nct07734792-2026-07-29-16e12449ec7c"></a>
- **ClinicalTrials.gov record NCT07734792 · retained source version 2026-07-29:16e12449ec7c16e6da927803b862ad70e818004c86e3c71791b515cb1f390ee2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07734792) (`ctg-observation-nct07734792-2026-07-29-16e12449ec7c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07734792." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07734792-tirzepatide-v1 SHA-256: 1ed43c035d2a435a7542e36d5ccd67580e4a6f898fd1b18e34e6a4e8f3dbf1a7.

---

<a id="clinicaltrials-gov-nct07734792-tirzepatide-v2"></a>

## ClinicalTrials.gov record NCT07734792

> PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07734792-tirzepatide:v2`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-15
- Published by PeptideScanner: 2026-11-15
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07734792-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07734792-tirzepatide-v2
- Content SHA-256: `13aebae98a491c31cef8d3d57f4309c0df889a32b57c7c372230d547aeb10576`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07734792 ([`ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2`](#source-ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2`](#source-ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07734792 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2`](#source-ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2`](#source-ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2))

### Sources

<a id="source-ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2"></a>
- **ClinicalTrials.gov record NCT07734792 · retained source version 2026-11-12:a90a7a922143986a42b26419dd275680f081cc1d0182cd882ffd7f6977a52fc3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07734792) (`ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2`)

### Correction lineage

updated on 2026-11-15: ClinicalTrials.gov posted a newer version of NCT07734792, with a registry update date of 2026-11-12. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2`](#source-ctg-observation-nct07734792-2026-07-29-16e12449ec7c-r2)

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07734792." Version 2, published 2026-11-15. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07734792-tirzepatide-v2 SHA-256: 13aebae98a491c31cef8d3d57f4309c0df889a32b57c7c372230d547aeb10576.

---

<a id="clinicaltrials-gov-nct07734870-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07734870

> PeptideScanner retained ClinicalTrials.gov record NCT07734870 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07734870-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-12
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07734870-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07734870-tirzepatide-v1
- Content SHA-256: `6b0331f7310bd22405a9a770b53e66118a634baf3379f1f37b7a1048272601f3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07734870 ([`ctg-observation-nct07734870-2026-08-12-3bb650fb7d5b`](#source-ctg-observation-nct07734870-2026-08-12-3bb650fb7d5b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07734870 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07734870-2026-08-12-3bb650fb7d5b`](#source-ctg-observation-nct07734870-2026-08-12-3bb650fb7d5b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07734870 at 2026-08-13T05:54:14.859Z. Its registry update date was 2026-08-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07734870-2026-08-12-3bb650fb7d5b`](#source-ctg-observation-nct07734870-2026-08-12-3bb650fb7d5b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07734870-2026-08-12-3bb650fb7d5b`](#source-ctg-observation-nct07734870-2026-08-12-3bb650fb7d5b))

### Sources

<a id="source-ctg-observation-nct07734870-2026-08-12-3bb650fb7d5b"></a>
- **ClinicalTrials.gov record NCT07734870 · retained source version 2026-08-12:3bb650fb7d5b8f738cf83175c1fbf13b286b241c7a7680070517bf3a61ba9538** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07734870) (`ctg-observation-nct07734870-2026-08-12-3bb650fb7d5b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07734870." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07734870-tirzepatide-v1 SHA-256: 6b0331f7310bd22405a9a770b53e66118a634baf3379f1f37b7a1048272601f3.

---

<a id="clinicaltrials-gov-nct07782359-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07782359

> PeptideScanner retained ClinicalTrials.gov record NCT07782359 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07782359-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-27
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07782359-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07782359-tirzepatide-v1
- Content SHA-256: `00d34d547621c92f41a8dcfa6e7490763470a23517c6a2cbaf28b553d9ebc672`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07782359 ([`ctg-observation-nct07782359-2026-10-27-5e2199d02134`](#source-ctg-observation-nct07782359-2026-10-27-5e2199d02134))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07782359 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07782359-2026-10-27-5e2199d02134`](#source-ctg-observation-nct07782359-2026-10-27-5e2199d02134))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07782359 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-27, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07782359-2026-10-27-5e2199d02134`](#source-ctg-observation-nct07782359-2026-10-27-5e2199d02134))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07782359-2026-10-27-5e2199d02134`](#source-ctg-observation-nct07782359-2026-10-27-5e2199d02134))

### Sources

<a id="source-ctg-observation-nct07782359-2026-10-27-5e2199d02134"></a>
- **ClinicalTrials.gov record NCT07782359 · retained source version 2026-10-27:5e2199d021340c8aa8504772efbe8e41bf79358ea67a4baa0680fbfeb01a5f97** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07782359) (`ctg-observation-nct07782359-2026-10-27-5e2199d02134`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07782359." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07782359-tirzepatide-v1 SHA-256: 00d34d547621c92f41a8dcfa6e7490763470a23517c6a2cbaf28b553d9ebc672.

---

<a id="clinicaltrials-gov-nct07803744-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07803744

> PeptideScanner retained ClinicalTrials.gov record NCT07803744 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07803744-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-23
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07803744-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07803744-tirzepatide-v1
- Content SHA-256: `f1c626f078ebe894692b4923b9372306ee4e1c7ab3c814e19d36221501039a9d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07803744 ([`ctg-observation-nct07803744-2026-09-23-f6e29c5089b8`](#source-ctg-observation-nct07803744-2026-09-23-f6e29c5089b8))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07803744 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07803744-2026-09-23-f6e29c5089b8`](#source-ctg-observation-nct07803744-2026-09-23-f6e29c5089b8))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07803744 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-23, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07803744-2026-09-23-f6e29c5089b8`](#source-ctg-observation-nct07803744-2026-09-23-f6e29c5089b8))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07803744-2026-09-23-f6e29c5089b8`](#source-ctg-observation-nct07803744-2026-09-23-f6e29c5089b8))

### Sources

<a id="source-ctg-observation-nct07803744-2026-09-23-f6e29c5089b8"></a>
- **ClinicalTrials.gov record NCT07803744 · retained source version 2026-09-23:f6e29c5089b80b1d5b79e0313a9329dc5d4cbc7e1aa86db19d3ec3fa6b04641e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07803744) (`ctg-observation-nct07803744-2026-09-23-f6e29c5089b8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07803744." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07803744-tirzepatide-v1 SHA-256: f1c626f078ebe894692b4923b9372306ee4e1c7ab3c814e19d36221501039a9d.

---

<a id="clinicaltrials-gov-nct07811895-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07811895

> PeptideScanner retained ClinicalTrials.gov record NCT07811895 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07811895-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-10
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07811895-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07811895-tirzepatide-v1
- Content SHA-256: `34178a47d1621dd5ba0726f4765026c0ea42f31d79fbc814ff319af5bbf6a23f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07811895 ([`ctg-observation-nct07811895-2026-09-10-e286584c4293`](#source-ctg-observation-nct07811895-2026-09-10-e286584c4293))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07811895 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07811895-2026-09-10-e286584c4293`](#source-ctg-observation-nct07811895-2026-09-10-e286584c4293))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07811895 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07811895-2026-09-10-e286584c4293`](#source-ctg-observation-nct07811895-2026-09-10-e286584c4293))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07811895-2026-09-10-e286584c4293`](#source-ctg-observation-nct07811895-2026-09-10-e286584c4293))

### Sources

<a id="source-ctg-observation-nct07811895-2026-09-10-e286584c4293"></a>
- **ClinicalTrials.gov record NCT07811895 · retained source version 2026-09-10:e286584c429373eaf92c7dc43d393d6981dcf6ccf9e103c03220e17ad3082607** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07811895) (`ctg-observation-nct07811895-2026-09-10-e286584c4293`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07811895." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07811895-tirzepatide-v1 SHA-256: 34178a47d1621dd5ba0726f4765026c0ea42f31d79fbc814ff319af5bbf6a23f.

---

<a id="clinicaltrials-gov-nct07812636-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07812636

> PeptideScanner retained ClinicalTrials.gov record NCT07812636 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07812636-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-10
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07812636-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07812636-tirzepatide-v1
- Content SHA-256: `26b4cf89c924caa1f23cf1144c1080c732ba81bfd9ea9655fdb6c73879bc36a9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07812636 ([`ctg-observation-nct07812636-2026-09-10-fee0cf88e603`](#source-ctg-observation-nct07812636-2026-09-10-fee0cf88e603))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07812636 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07812636-2026-09-10-fee0cf88e603`](#source-ctg-observation-nct07812636-2026-09-10-fee0cf88e603))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07812636 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07812636-2026-09-10-fee0cf88e603`](#source-ctg-observation-nct07812636-2026-09-10-fee0cf88e603))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07812636-2026-09-10-fee0cf88e603`](#source-ctg-observation-nct07812636-2026-09-10-fee0cf88e603))

### Sources

<a id="source-ctg-observation-nct07812636-2026-09-10-fee0cf88e603"></a>
- **ClinicalTrials.gov record NCT07812636 · retained source version 2026-09-10:fee0cf88e6030fae9324dd67baee3d012733ca68b55145ef87d37e29714261f2** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07812636) (`ctg-observation-nct07812636-2026-09-10-fee0cf88e603`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07812636." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07812636-tirzepatide-v1 SHA-256: 26b4cf89c924caa1f23cf1144c1080c732ba81bfd9ea9655fdb6c73879bc36a9.

---

<a id="clinicaltrials-gov-nct07817875-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07817875

> PeptideScanner retained ClinicalTrials.gov record NCT07817875 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07817875-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07817875-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07817875-tirzepatide-v1
- Content SHA-256: `90c6ee295b1d9d6fcdffe4dde8f3d6ca899c7d924093340e5593a2b3f8b8ce60`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07817875 ([`ctg-observation-nct07817875-2026-11-04-12298bac2fca`](#source-ctg-observation-nct07817875-2026-11-04-12298bac2fca))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07817875 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07817875-2026-11-04-12298bac2fca`](#source-ctg-observation-nct07817875-2026-11-04-12298bac2fca))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07817875 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07817875-2026-11-04-12298bac2fca`](#source-ctg-observation-nct07817875-2026-11-04-12298bac2fca))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07817875-2026-11-04-12298bac2fca`](#source-ctg-observation-nct07817875-2026-11-04-12298bac2fca))

### Sources

<a id="source-ctg-observation-nct07817875-2026-11-04-12298bac2fca"></a>
- **ClinicalTrials.gov record NCT07817875 · retained source version 2026-11-04:12298bac2fca58b51bf49b358bee5f348e93242ee7822e0040aa9cb6d7fd29ce** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07817875) (`ctg-observation-nct07817875-2026-11-04-12298bac2fca`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07817875." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07817875-tirzepatide-v1 SHA-256: 90c6ee295b1d9d6fcdffe4dde8f3d6ca899c7d924093340e5593a2b3f8b8ce60.

---

<a id="clinicaltrials-gov-nct07825857-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07825857

> PeptideScanner retained ClinicalTrials.gov record NCT07825857 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07825857-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-26
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07825857-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07825857-tirzepatide-v1
- Content SHA-256: `fa18598c1fcb71544186b550fa129e2f729dfe969f0929f4d4b483a774d2eb7b`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07825857 ([`ctg-observation-nct07825857-2026-10-26-1ca2c4b04d0a`](#source-ctg-observation-nct07825857-2026-10-26-1ca2c4b04d0a))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07825857 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07825857-2026-10-26-1ca2c4b04d0a`](#source-ctg-observation-nct07825857-2026-10-26-1ca2c4b04d0a))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07825857 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07825857-2026-10-26-1ca2c4b04d0a`](#source-ctg-observation-nct07825857-2026-10-26-1ca2c4b04d0a))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07825857-2026-10-26-1ca2c4b04d0a`](#source-ctg-observation-nct07825857-2026-10-26-1ca2c4b04d0a))

### Sources

<a id="source-ctg-observation-nct07825857-2026-10-26-1ca2c4b04d0a"></a>
- **ClinicalTrials.gov record NCT07825857 · retained source version 2026-10-26:1ca2c4b04d0a4814238a13dd3dc897e9caddc25a69c66d124fe23fdc283ea2e7** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07825857) (`ctg-observation-nct07825857-2026-10-26-1ca2c4b04d0a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07825857." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07825857-tirzepatide-v1 SHA-256: fa18598c1fcb71544186b550fa129e2f729dfe969f0929f4d4b483a774d2eb7b.

---

<a id="clinicaltrials-gov-nct07829198-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07829198

> PeptideScanner retained ClinicalTrials.gov record NCT07829198 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07829198-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-18
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07829198-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07829198-tirzepatide-v1
- Content SHA-256: `9a913fc1fe503107e5a2a7fcee519bf75b84b499a95d4b9d85e42d19dded049e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07829198 ([`ctg-observation-nct07829198-2026-09-18-100cea191384`](#source-ctg-observation-nct07829198-2026-09-18-100cea191384))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07829198 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07829198-2026-09-18-100cea191384`](#source-ctg-observation-nct07829198-2026-09-18-100cea191384))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07829198 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-18, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07829198-2026-09-18-100cea191384`](#source-ctg-observation-nct07829198-2026-09-18-100cea191384))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07829198-2026-09-18-100cea191384`](#source-ctg-observation-nct07829198-2026-09-18-100cea191384))

### Sources

<a id="source-ctg-observation-nct07829198-2026-09-18-100cea191384"></a>
- **ClinicalTrials.gov record NCT07829198 · retained source version 2026-09-18:100cea191384507ddb28d7d445b7d8a5a542577b96f8b33048fdfa223bcbbc4a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07829198) (`ctg-observation-nct07829198-2026-09-18-100cea191384`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07829198." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07829198-tirzepatide-v1 SHA-256: 9a913fc1fe503107e5a2a7fcee519bf75b84b499a95d4b9d85e42d19dded049e.

---

<a id="clinicaltrials-gov-nct07842640-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07842640

> PeptideScanner retained ClinicalTrials.gov record NCT07842640 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07842640-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-25
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07842640-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07842640-tirzepatide-v1
- Content SHA-256: `65b37a1271e4acb1eed7cbcc0be68578f62eeda1e39936a07b76e3fdd6fd044f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07842640 ([`ctg-observation-nct07842640-2026-09-25-a97412cfcd04`](#source-ctg-observation-nct07842640-2026-09-25-a97412cfcd04))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07842640 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07842640-2026-09-25-a97412cfcd04`](#source-ctg-observation-nct07842640-2026-09-25-a97412cfcd04))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07842640 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07842640-2026-09-25-a97412cfcd04`](#source-ctg-observation-nct07842640-2026-09-25-a97412cfcd04))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07842640-2026-09-25-a97412cfcd04`](#source-ctg-observation-nct07842640-2026-09-25-a97412cfcd04))

### Sources

<a id="source-ctg-observation-nct07842640-2026-09-25-a97412cfcd04"></a>
- **ClinicalTrials.gov record NCT07842640 · retained source version 2026-09-25:a97412cfcd0477439c35680ee006f9b81feca18d2dd268af30f69dd54f2ebb92** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07842640) (`ctg-observation-nct07842640-2026-09-25-a97412cfcd04`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07842640." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07842640-tirzepatide-v1 SHA-256: 65b37a1271e4acb1eed7cbcc0be68578f62eeda1e39936a07b76e3fdd6fd044f.

---

<a id="clinicaltrials-gov-nct07846865-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07846865

> PeptideScanner retained ClinicalTrials.gov record NCT07846865 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07846865-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-02
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07846865-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07846865-tirzepatide-v1
- Content SHA-256: `c6c801b8daf949582029988ea3e8d8659b7b773226b6c24410b5a7b74afd446d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07846865 ([`ctg-observation-nct07846865-2026-11-02-7344098b1121`](#source-ctg-observation-nct07846865-2026-11-02-7344098b1121))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07846865 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07846865-2026-11-02-7344098b1121`](#source-ctg-observation-nct07846865-2026-11-02-7344098b1121))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07846865 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07846865-2026-11-02-7344098b1121`](#source-ctg-observation-nct07846865-2026-11-02-7344098b1121))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07846865-2026-11-02-7344098b1121`](#source-ctg-observation-nct07846865-2026-11-02-7344098b1121))

### Sources

<a id="source-ctg-observation-nct07846865-2026-11-02-7344098b1121"></a>
- **ClinicalTrials.gov record NCT07846865 · retained source version 2026-11-02:7344098b11218dd47a91d6a6dfe721d845742fba107aa3c89c295ebfeb75f428** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07846865) (`ctg-observation-nct07846865-2026-11-02-7344098b1121`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07846865." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07846865-tirzepatide-v1 SHA-256: c6c801b8daf949582029988ea3e8d8659b7b773226b6c24410b5a7b74afd446d.

---

<a id="clinicaltrials-gov-nct07847515-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07847515

> PeptideScanner retained ClinicalTrials.gov record NCT07847515 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07847515-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-15
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07847515-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07847515-tirzepatide-v1
- Content SHA-256: `599ecf549278350ce09034140c4a24784f457dfd7ead8e4327328d4a3d388250`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07847515 ([`ctg-observation-nct07847515-2026-10-15-bc593e110bd7`](#source-ctg-observation-nct07847515-2026-10-15-bc593e110bd7))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07847515 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07847515-2026-10-15-bc593e110bd7`](#source-ctg-observation-nct07847515-2026-10-15-bc593e110bd7))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07847515 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-15, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07847515-2026-10-15-bc593e110bd7`](#source-ctg-observation-nct07847515-2026-10-15-bc593e110bd7))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07847515-2026-10-15-bc593e110bd7`](#source-ctg-observation-nct07847515-2026-10-15-bc593e110bd7))

### Sources

<a id="source-ctg-observation-nct07847515-2026-10-15-bc593e110bd7"></a>
- **ClinicalTrials.gov record NCT07847515 · retained source version 2026-10-15:bc593e110bd7ebaa8a15c9b3f39285fbaef324ed7eb65f01c5cad9b8a28b245c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07847515) (`ctg-observation-nct07847515-2026-10-15-bc593e110bd7`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07847515." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07847515-tirzepatide-v1 SHA-256: 599ecf549278350ce09034140c4a24784f457dfd7ead8e4327328d4a3d388250.

---

<a id="clinicaltrials-gov-nct07866183-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07866183

> PeptideScanner retained ClinicalTrials.gov record NCT07866183 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07866183-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-08
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07866183-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07866183-tirzepatide-v1
- Content SHA-256: `1515a74341f60ede6d03a2d1c06c97f834002c865f473cce9e8ea4360bc144a9`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07866183 ([`ctg-observation-nct07866183-2026-10-08-52a23c4bbaa5`](#source-ctg-observation-nct07866183-2026-10-08-52a23c4bbaa5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07866183 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07866183-2026-10-08-52a23c4bbaa5`](#source-ctg-observation-nct07866183-2026-10-08-52a23c4bbaa5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07866183 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-08, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07866183-2026-10-08-52a23c4bbaa5`](#source-ctg-observation-nct07866183-2026-10-08-52a23c4bbaa5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07866183-2026-10-08-52a23c4bbaa5`](#source-ctg-observation-nct07866183-2026-10-08-52a23c4bbaa5))

### Sources

<a id="source-ctg-observation-nct07866183-2026-10-08-52a23c4bbaa5"></a>
- **ClinicalTrials.gov record NCT07866183 · retained source version 2026-10-08:52a23c4bbaa58403705e29ca650dcfe02c7bf3f1ecdfedeca5f0601d6ad9e9c5** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07866183) (`ctg-observation-nct07866183-2026-10-08-52a23c4bbaa5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07866183." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07866183-tirzepatide-v1 SHA-256: 1515a74341f60ede6d03a2d1c06c97f834002c865f473cce9e8ea4360bc144a9.

---

<a id="clinicaltrials-gov-nct07868354-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07868354

> PeptideScanner retained ClinicalTrials.gov record NCT07868354 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07868354-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-16
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07868354-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07868354-tirzepatide-v1
- Content SHA-256: `1aa6ec4ad19ad6acbc009b5ad483f14b3c6466338a0de254a7816e990f67f309`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07868354 ([`ctg-observation-nct07868354-2026-10-16-0c567ff80aea`](#source-ctg-observation-nct07868354-2026-10-16-0c567ff80aea))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07868354 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07868354-2026-10-16-0c567ff80aea`](#source-ctg-observation-nct07868354-2026-10-16-0c567ff80aea))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07868354 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-16, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07868354-2026-10-16-0c567ff80aea`](#source-ctg-observation-nct07868354-2026-10-16-0c567ff80aea))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07868354-2026-10-16-0c567ff80aea`](#source-ctg-observation-nct07868354-2026-10-16-0c567ff80aea))

### Sources

<a id="source-ctg-observation-nct07868354-2026-10-16-0c567ff80aea"></a>
- **ClinicalTrials.gov record NCT07868354 · retained source version 2026-10-16:0c567ff80aeaa3b7a54731bf11068a634c59de2a2550524f240960d0f851d943** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07868354) (`ctg-observation-nct07868354-2026-10-16-0c567ff80aea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07868354." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07868354-tirzepatide-v1 SHA-256: 1aa6ec4ad19ad6acbc009b5ad483f14b3c6466338a0de254a7816e990f67f309.

---

<a id="clinicaltrials-gov-nct07874828-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07874828

> PeptideScanner retained ClinicalTrials.gov record NCT07874828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07874828-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-20
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07874828-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07874828-tirzepatide-v1
- Content SHA-256: `0ff6cf0da5ad974d16667b0c1c05d106fed70bc9831028257b2de93fd392f597`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07874828 ([`ctg-observation-nct07874828-2026-10-20-f393133f0211`](#source-ctg-observation-nct07874828-2026-10-20-f393133f0211))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07874828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07874828-2026-10-20-f393133f0211`](#source-ctg-observation-nct07874828-2026-10-20-f393133f0211))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07874828 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07874828-2026-10-20-f393133f0211`](#source-ctg-observation-nct07874828-2026-10-20-f393133f0211))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07874828-2026-10-20-f393133f0211`](#source-ctg-observation-nct07874828-2026-10-20-f393133f0211))

### Sources

<a id="source-ctg-observation-nct07874828-2026-10-20-f393133f0211"></a>
- **ClinicalTrials.gov record NCT07874828 · retained source version 2026-10-20:f393133f0211af6487f9860f297af77c2a9564db0a3b1106de216bb77a1ced89** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07874828) (`ctg-observation-nct07874828-2026-10-20-f393133f0211`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07874828." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07874828-tirzepatide-v1 SHA-256: 0ff6cf0da5ad974d16667b0c1c05d106fed70bc9831028257b2de93fd392f597.

---

<a id="clinicaltrials-gov-nct07881432-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07881432

> PeptideScanner retained ClinicalTrials.gov record NCT07881432 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07881432-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-03
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07881432-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07881432-tirzepatide-v1
- Content SHA-256: `6ac8a112192be79ceda5ea60af1f0ffe7fafd303eb7d73f1a4e23cfabbdc08b5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07881432 ([`ctg-observation-nct07881432-2026-11-03-951667ba3896`](#source-ctg-observation-nct07881432-2026-11-03-951667ba3896))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07881432 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07881432-2026-11-03-951667ba3896`](#source-ctg-observation-nct07881432-2026-11-03-951667ba3896))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07881432 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-03, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07881432-2026-11-03-951667ba3896`](#source-ctg-observation-nct07881432-2026-11-03-951667ba3896))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07881432-2026-11-03-951667ba3896`](#source-ctg-observation-nct07881432-2026-11-03-951667ba3896))

### Sources

<a id="source-ctg-observation-nct07881432-2026-11-03-951667ba3896"></a>
- **ClinicalTrials.gov record NCT07881432 · retained source version 2026-11-03:951667ba38962f568bf6580b3109f0283c7a89cefd9526b667db15addcc44f4e** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07881432) (`ctg-observation-nct07881432-2026-11-03-951667ba3896`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07881432." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07881432-tirzepatide-v1 SHA-256: 6ac8a112192be79ceda5ea60af1f0ffe7fafd303eb7d73f1a4e23cfabbdc08b5.

---

<a id="clinicaltrials-gov-nct07881458-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07881458

> PeptideScanner retained ClinicalTrials.gov record NCT07881458 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07881458-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-04
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07881458-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07881458-tirzepatide-v1
- Content SHA-256: `2e6a64e4b3348ec981146fd3e2b604ff3cf078bb348df79afbe05470009543c7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07881458 ([`ctg-observation-nct07881458-2026-11-04-306033a0e214`](#source-ctg-observation-nct07881458-2026-11-04-306033a0e214))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07881458 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07881458-2026-11-04-306033a0e214`](#source-ctg-observation-nct07881458-2026-11-04-306033a0e214))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07881458 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-04, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07881458-2026-11-04-306033a0e214`](#source-ctg-observation-nct07881458-2026-11-04-306033a0e214))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07881458-2026-11-04-306033a0e214`](#source-ctg-observation-nct07881458-2026-11-04-306033a0e214))

### Sources

<a id="source-ctg-observation-nct07881458-2026-11-04-306033a0e214"></a>
- **ClinicalTrials.gov record NCT07881458 · retained source version 2026-11-04:306033a0e2140203843e40570c06f470184abd84527bc1293bbcaf018cca41e8** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07881458) (`ctg-observation-nct07881458-2026-11-04-306033a0e214`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07881458." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07881458-tirzepatide-v1 SHA-256: 2e6a64e4b3348ec981146fd3e2b604ff3cf078bb348df79afbe05470009543c7.

---

<a id="clinicaltrials-gov-nct07889453-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07889453

> PeptideScanner retained ClinicalTrials.gov record NCT07889453 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07889453-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-22
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07889453-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07889453-tirzepatide-v1
- Content SHA-256: `73fcce5fa94002d8124d5b255f5a1b9c7f81c37db33745d76f3b4a39a83571fb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07889453 ([`ctg-observation-nct07889453-2026-10-22-843e9e7b086b`](#source-ctg-observation-nct07889453-2026-10-22-843e9e7b086b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07889453 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07889453-2026-10-22-843e9e7b086b`](#source-ctg-observation-nct07889453-2026-10-22-843e9e7b086b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07889453 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07889453-2026-10-22-843e9e7b086b`](#source-ctg-observation-nct07889453-2026-10-22-843e9e7b086b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07889453-2026-10-22-843e9e7b086b`](#source-ctg-observation-nct07889453-2026-10-22-843e9e7b086b))

### Sources

<a id="source-ctg-observation-nct07889453-2026-10-22-843e9e7b086b"></a>
- **ClinicalTrials.gov record NCT07889453 · retained source version 2026-10-22:843e9e7b086b7d9c219a61f6f7887dc1b454bc33935b230489c106954e248bdd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07889453) (`ctg-observation-nct07889453-2026-10-22-843e9e7b086b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07889453." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07889453-tirzepatide-v1 SHA-256: 73fcce5fa94002d8124d5b255f5a1b9c7f81c37db33745d76f3b4a39a83571fb.

---

<a id="clinicaltrials-gov-nct07889648-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07889648

> PeptideScanner retained ClinicalTrials.gov record NCT07889648 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07889648-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-22
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07889648-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07889648-tirzepatide-v1
- Content SHA-256: `cacf43967ac31502e8fa844fcd1fff6c41b5af4960ffee85a27a7c8bc80c1534`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07889648 ([`ctg-observation-nct07889648-2026-10-22-a110e6e1f232`](#source-ctg-observation-nct07889648-2026-10-22-a110e6e1f232))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07889648 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07889648-2026-10-22-a110e6e1f232`](#source-ctg-observation-nct07889648-2026-10-22-a110e6e1f232))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07889648 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-22, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07889648-2026-10-22-a110e6e1f232`](#source-ctg-observation-nct07889648-2026-10-22-a110e6e1f232))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07889648-2026-10-22-a110e6e1f232`](#source-ctg-observation-nct07889648-2026-10-22-a110e6e1f232))

### Sources

<a id="source-ctg-observation-nct07889648-2026-10-22-a110e6e1f232"></a>
- **ClinicalTrials.gov record NCT07889648 · retained source version 2026-10-22:a110e6e1f23260fd96e3002be7b803317d3ce24a510b1728f6d4154bfcfef9bc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07889648) (`ctg-observation-nct07889648-2026-10-22-a110e6e1f232`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07889648." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07889648-tirzepatide-v1 SHA-256: cacf43967ac31502e8fa844fcd1fff6c41b5af4960ffee85a27a7c8bc80c1534.

---

<a id="clinicaltrials-gov-nct07893457-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07893457

> PeptideScanner retained ClinicalTrials.gov record NCT07893457 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07893457-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-26
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07893457-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07893457-tirzepatide-v1
- Content SHA-256: `4a669384160d5d9ce8b04b787362aa177fdfca4cc0d8c4d3118311d0569974bf`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07893457 ([`ctg-observation-nct07893457-2026-10-26-fb09f765fdac`](#source-ctg-observation-nct07893457-2026-10-26-fb09f765fdac))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07893457 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07893457-2026-10-26-fb09f765fdac`](#source-ctg-observation-nct07893457-2026-10-26-fb09f765fdac))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07893457 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-10-26, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07893457-2026-10-26-fb09f765fdac`](#source-ctg-observation-nct07893457-2026-10-26-fb09f765fdac))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07893457-2026-10-26-fb09f765fdac`](#source-ctg-observation-nct07893457-2026-10-26-fb09f765fdac))

### Sources

<a id="source-ctg-observation-nct07893457-2026-10-26-fb09f765fdac"></a>
- **ClinicalTrials.gov record NCT07893457 · retained source version 2026-10-26:fb09f765fdacd64d140e11f55550a42b47a5e40daebb53294400c1b03c44eb09** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07893457) (`ctg-observation-nct07893457-2026-10-26-fb09f765fdac`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07893457." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07893457-tirzepatide-v1 SHA-256: 4a669384160d5d9ce8b04b787362aa177fdfca4cc0d8c4d3118311d0569974bf.

---

<a id="clinicaltrials-gov-nct07906041-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07906041

> PeptideScanner retained ClinicalTrials.gov record NCT07906041 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07906041-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-02
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07906041-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07906041-tirzepatide-v1
- Content SHA-256: `0dcd855ba886505f24286cd74b60e0e01d0c9f22fb854ca832ec141dd2859ee3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07906041 ([`ctg-observation-nct07906041-2026-11-02-97450fb00dc9`](#source-ctg-observation-nct07906041-2026-11-02-97450fb00dc9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07906041 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07906041-2026-11-02-97450fb00dc9`](#source-ctg-observation-nct07906041-2026-11-02-97450fb00dc9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07906041 at 2026-11-14T22:56:28.992Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07906041-2026-11-02-97450fb00dc9`](#source-ctg-observation-nct07906041-2026-11-02-97450fb00dc9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07906041-2026-11-02-97450fb00dc9`](#source-ctg-observation-nct07906041-2026-11-02-97450fb00dc9))

### Sources

<a id="source-ctg-observation-nct07906041-2026-11-02-97450fb00dc9"></a>
- **ClinicalTrials.gov record NCT07906041 · retained source version 2026-11-02:97450fb00dc9b7dd9ea959297226f405438be240a733758bf819ab51252911fe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07906041) (`ctg-observation-nct07906041-2026-11-02-97450fb00dc9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07906041." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07906041-tirzepatide-v1 SHA-256: 0dcd855ba886505f24286cd74b60e0e01d0c9f22fb854ca832ec141dd2859ee3.

---

<a id="clinicaltrials-gov-nct07929571-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07929571

> PeptideScanner retained ClinicalTrials.gov record NCT07929571 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07929571-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-10
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07929571-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07929571-tirzepatide-v1
- Content SHA-256: `71c78a9f6f3e401f2c4b854c528871a59bf8b06172546b9da159df9a647c59c8`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07929571 ([`ctg-observation-nct07929571-2026-11-10-78ff9d2c1ac1`](#source-ctg-observation-nct07929571-2026-11-10-78ff9d2c1ac1))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07929571 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07929571-2026-11-10-78ff9d2c1ac1`](#source-ctg-observation-nct07929571-2026-11-10-78ff9d2c1ac1))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07929571 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-10, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07929571-2026-11-10-78ff9d2c1ac1`](#source-ctg-observation-nct07929571-2026-11-10-78ff9d2c1ac1))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07929571-2026-11-10-78ff9d2c1ac1`](#source-ctg-observation-nct07929571-2026-11-10-78ff9d2c1ac1))

### Sources

<a id="source-ctg-observation-nct07929571-2026-11-10-78ff9d2c1ac1"></a>
- **ClinicalTrials.gov record NCT07929571 · retained source version 2026-11-10:78ff9d2c1ac134c58a9d13b1544f6d54cdfc7c8f2124271d0bc4a1655e98327a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07929571) (`ctg-observation-nct07929571-2026-11-10-78ff9d2c1ac1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07929571." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07929571-tirzepatide-v1 SHA-256: 71c78a9f6f3e401f2c4b854c528871a59bf8b06172546b9da159df9a647c59c8.

---

<a id="clinicaltrials-gov-nct07931235-tirzepatide-v1"></a>

## ClinicalTrials.gov record NCT07931235

> PeptideScanner retained ClinicalTrials.gov record NCT07931235 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide.

- Evidence object: `story:clinicaltrials-gov-nct07931235-tirzepatide:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07931235-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07931235-tirzepatide-v1
- Content SHA-256: `0361158e1750dc67f97c0f1a7e8d2a9664e4ba2642d2751611a401fa8c3515c3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07931235 ([`ctg-observation-nct07931235-2026-11-12-bcb3a34191ca`](#source-ctg-observation-nct07931235-2026-11-12-bcb3a34191ca))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07931235 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07931235-2026-11-12-bcb3a34191ca`](#source-ctg-observation-nct07931235-2026-11-12-bcb3a34191ca))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07931235 at 2026-11-14T22:51:22.481Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was tirzepatide. ([`ctg-observation-nct07931235-2026-11-12-bcb3a34191ca`](#source-ctg-observation-nct07931235-2026-11-12-bcb3a34191ca))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07931235-2026-11-12-bcb3a34191ca`](#source-ctg-observation-nct07931235-2026-11-12-bcb3a34191ca))

### Sources

<a id="source-ctg-observation-nct07931235-2026-11-12-bcb3a34191ca"></a>
- **ClinicalTrials.gov record NCT07931235 · retained source version 2026-11-12:bcb3a34191cafdded2f67389680e4e9cf3e705af53329808d5ce48aa0e01303a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07931235) (`ctg-observation-nct07931235-2026-11-12-bcb3a34191ca`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07931235." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#clinicaltrials-gov-nct07931235-tirzepatide-v1 SHA-256: 0361158e1750dc67f97c0f1a7e8d2a9664e4ba2642d2751611a401fa8c3515c3.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-v1"></a>

## Tirzepatide DailyMed SPL version 12

> DailyMed lists Structured Product Labeling version 12 for the reviewed Tirzepatide label family with a published date of 2024-11-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12:v1`
- Evidence domain: Regulatory
- Date in source: 2024-11-04
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-v1
- Content SHA-256: `6932f68a3584a584d3275540ec5bd94612f5318e018e7c87e81c42af6c7e4262`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 12 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-history))

#### Summary

DailyMed lists Structured Product Labeling version 12 for the reviewed Tirzepatide label family with a published date of 2024-11-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 12 for the reviewed Tirzepatide label family with a published date of 2024-11-04. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 12 · published 2024-11-04 · retained ZIP SHA-256 bea632d6b144f12170589de64dde6ec0ce693d9f5e1fd03087fea03aac28a8e7** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=12) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 12." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v12-v1 SHA-256: 6932f68a3584a584d3275540ec5bd94612f5318e018e7c87e81c42af6c7e4262.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-v1"></a>

## Tirzepatide DailyMed SPL version 14

> DailyMed lists Structured Product Labeling version 14 for the reviewed Tirzepatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14:v1`
- Evidence domain: Regulatory
- Date in source: 2024-12-30
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-v1
- Content SHA-256: `cda1a4ef1bb5c7fe5d5077cfdea7d691c98de68c8b9ca53ac6b33d56a3a1a3c9`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 14 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-history))

#### Summary

DailyMed lists Structured Product Labeling version 14 for the reviewed Tirzepatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 14 for the reviewed Tirzepatide label family with a published date of 2024-12-30. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 14 · published 2024-12-30 · retained ZIP SHA-256 7fdfcc0d79d5f1193b40fdf195f2cace562a0b15b7c961589e9710f6fedcd945** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=14) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 14." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v14-v1 SHA-256: cda1a4ef1bb5c7fe5d5077cfdea7d691c98de68c8b9ca53ac6b33d56a3a1a3c9.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-v1"></a>

## Tirzepatide DailyMed SPL version 15

> DailyMed lists Structured Product Labeling version 15 for the reviewed Tirzepatide label family with a published date of 2025-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15:v1`
- Evidence domain: Regulatory
- Date in source: 2025-01-06
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-v1
- Content SHA-256: `d62ef444f67ee0aeb3c973caefa483ba6654d24d68e622d91d1a7f4329d85c22`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 15 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-history))

#### Summary

DailyMed lists Structured Product Labeling version 15 for the reviewed Tirzepatide label family with a published date of 2025-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 15 for the reviewed Tirzepatide label family with a published date of 2025-01-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 15 · published 2025-01-06 · retained ZIP SHA-256 33353134b43f3ad7e39ae4eb9a51a1ab58b151a34764039a635ea68678d6e8d9** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=15) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 15." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v15-v1 SHA-256: d62ef444f67ee0aeb3c973caefa483ba6654d24d68e622d91d1a7f4329d85c22.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-v1"></a>

## Tirzepatide DailyMed SPL version 16

> DailyMed lists Structured Product Labeling version 16 for the reviewed Tirzepatide label family with a published date of 2025-02-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16:v1`
- Evidence domain: Regulatory
- Date in source: 2025-02-07
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-v1
- Content SHA-256: `2f5387ddb96fac226826cebffae42e80d4399f82db565332f0c78dbbbd7d3c29`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 16 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-history))

#### Summary

DailyMed lists Structured Product Labeling version 16 for the reviewed Tirzepatide label family with a published date of 2025-02-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 16 for the reviewed Tirzepatide label family with a published date of 2025-02-07. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 16 · published 2025-02-07 · retained ZIP SHA-256 caac6fd0ae226bb2739af361afb4ce966abb4c422d460789b7109bf70006f041** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=16) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 16." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v16-v1 SHA-256: 2f5387ddb96fac226826cebffae42e80d4399f82db565332f0c78dbbbd7d3c29.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-v1"></a>

## Tirzepatide DailyMed SPL version 17

> DailyMed lists Structured Product Labeling version 17 for the reviewed Tirzepatide label family with a published date of 2025-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17:v1`
- Evidence domain: Regulatory
- Date in source: 2025-02-27
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-v1
- Content SHA-256: `0d67b2245eb5839922af04b7cced3488ed25346195b6cb5d61d57b4f7687e0e3`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 17 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-history))

#### Summary

DailyMed lists Structured Product Labeling version 17 for the reviewed Tirzepatide label family with a published date of 2025-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 17 for the reviewed Tirzepatide label family with a published date of 2025-02-27. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 17 · published 2025-02-27 · retained ZIP SHA-256 998562479ae76fed929a66904d3b71368860a102786b98a806c90ffaee3d70b5** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=17) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 17." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v17-v1 SHA-256: 0d67b2245eb5839922af04b7cced3488ed25346195b6cb5d61d57b4f7687e0e3.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-v1"></a>

## Tirzepatide DailyMed SPL version 18

> DailyMed lists Structured Product Labeling version 18 for the reviewed Tirzepatide label family with a published date of 2025-03-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18:v1`
- Evidence domain: Regulatory
- Date in source: 2025-03-21
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-v1
- Content SHA-256: `0cdd8d3237fccf148401892d8d4b9a2f426e2725e0d70c8fbdeca72015eb1518`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 18 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-history))

#### Summary

DailyMed lists Structured Product Labeling version 18 for the reviewed Tirzepatide label family with a published date of 2025-03-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 18 for the reviewed Tirzepatide label family with a published date of 2025-03-21. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 18 · published 2025-03-21 · retained ZIP SHA-256 d6446805948a287eaf435b8335e8a0cd719fd4d8371e26f88be8ec529296a44e** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=18) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 18." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v18-v1 SHA-256: 0cdd8d3237fccf148401892d8d4b9a2f426e2725e0d70c8fbdeca72015eb1518.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-v1"></a>

## Tirzepatide DailyMed SPL version 19

> DailyMed lists Structured Product Labeling version 19 for the reviewed Tirzepatide label family with a published date of 2025-04-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19:v1`
- Evidence domain: Regulatory
- Date in source: 2025-04-14
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-v1
- Content SHA-256: `c3f781e96be3651afe578fab66a777cea97477b5229a3c94d546e570f8b03ca7`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 19 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-history))

#### Summary

DailyMed lists Structured Product Labeling version 19 for the reviewed Tirzepatide label family with a published date of 2025-04-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 19 for the reviewed Tirzepatide label family with a published date of 2025-04-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 19 · published 2025-04-14 · retained ZIP SHA-256 1be3bbbe854d8d05001ea4fd18f7b891720558736ed260cc2db738d1f0011766** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=19) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 19." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v19-v1 SHA-256: c3f781e96be3651afe578fab66a777cea97477b5229a3c94d546e570f8b03ca7.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-v1"></a>

## Tirzepatide DailyMed SPL version 21

> DailyMed lists Structured Product Labeling version 21 for the reviewed Tirzepatide label family with a published date of 2025-05-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21:v1`
- Evidence domain: Regulatory
- Date in source: 2025-05-05
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-v1
- Content SHA-256: `49ab850d4d51797404a702a9ef02b71b9a709985a4260ade97e25402b4269293`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 21 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-history))

#### Summary

DailyMed lists Structured Product Labeling version 21 for the reviewed Tirzepatide label family with a published date of 2025-05-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 21 for the reviewed Tirzepatide label family with a published date of 2025-05-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 21 · published 2025-05-05 · retained ZIP SHA-256 3baad4c13a1f1186332324990693e4314b7dc7c7b8651f59997777fecb827554** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=21) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 21." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v21-v1 SHA-256: 49ab850d4d51797404a702a9ef02b71b9a709985a4260ade97e25402b4269293.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-v1"></a>

## Tirzepatide DailyMed SPL version 22

> DailyMed lists Structured Product Labeling version 22 for the reviewed Tirzepatide label family with a published date of 2025-05-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22:v1`
- Evidence domain: Regulatory
- Date in source: 2025-05-29
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-v1
- Content SHA-256: `aad2b050032dab1eb4907165464bfd82eabfa661372f9e67e7b1b2909de2bf15`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 22 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-history))

#### Summary

DailyMed lists Structured Product Labeling version 22 for the reviewed Tirzepatide label family with a published date of 2025-05-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 22 for the reviewed Tirzepatide label family with a published date of 2025-05-29. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 22 · published 2025-05-29 · retained ZIP SHA-256 821ceedf603e4116cb52b52c0b3c2c39c95064f452318588cac03297dcf4797d** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=22) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 22." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v22-v1 SHA-256: aad2b050032dab1eb4907165464bfd82eabfa661372f9e67e7b1b2909de2bf15.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-v1"></a>

## Tirzepatide DailyMed SPL version 23

> DailyMed lists Structured Product Labeling version 23 for the reviewed Tirzepatide label family with a published date of 2025-07-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23:v1`
- Evidence domain: Regulatory
- Date in source: 2025-07-25
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-v1
- Content SHA-256: `77ec358bf3c842b21d88e7905890f427a50850ed7d71f27454d570183bca3428`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 23 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-history))

#### Summary

DailyMed lists Structured Product Labeling version 23 for the reviewed Tirzepatide label family with a published date of 2025-07-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 23 for the reviewed Tirzepatide label family with a published date of 2025-07-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 23 · published 2025-07-25 · retained ZIP SHA-256 db6e6804f6ab62108c3827c1acb45ba0662b600a8c8618995d4f18f374345a03** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=23) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 23." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v23-v1 SHA-256: 77ec358bf3c842b21d88e7905890f427a50850ed7d71f27454d570183bca3428.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-v1"></a>

## Tirzepatide DailyMed SPL version 28

> DailyMed lists Structured Product Labeling version 28 for the reviewed Tirzepatide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28:v1`
- Evidence domain: Regulatory
- Date in source: 2025-11-17
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-v1
- Content SHA-256: `338c5a1544a088e7b8be62b2601e8b61ef1298e6ab29c8566f739d0567fc4ea2`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 28 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-history))

#### Summary

DailyMed lists Structured Product Labeling version 28 for the reviewed Tirzepatide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 28 for the reviewed Tirzepatide label family with a published date of 2025-11-17. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 28 · published 2025-11-17 · retained ZIP SHA-256 c9ff3921c6c5369ca650731c3e9b05691b8104b11e8bd191743b59466981b915** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=28) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 28." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v28-v1 SHA-256: 338c5a1544a088e7b8be62b2601e8b61ef1298e6ab29c8566f739d0567fc4ea2.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-v1"></a>

## Tirzepatide DailyMed SPL version 2

> DailyMed lists Structured Product Labeling version 2 for the reviewed Tirzepatide label family with a published date of 2023-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-14
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-v1
- Content SHA-256: `3b4afd191a1ec4e45d0b95d1ed9cf9f108d7a17d77e3b2c8aa37d023db57c4f7`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 2 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-history))

#### Summary

DailyMed lists Structured Product Labeling version 2 for the reviewed Tirzepatide label family with a published date of 2023-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 2 for the reviewed Tirzepatide label family with a published date of 2023-11-14. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 2 · published 2023-11-14 · retained ZIP SHA-256 edc70712deba99f74df14f43774ddaf795765a0e59f85ec357494743b1c50288** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=2) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 2." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v2-v1 SHA-256: 3b4afd191a1ec4e45d0b95d1ed9cf9f108d7a17d77e3b2c8aa37d023db57c4f7.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-v1"></a>

## Tirzepatide DailyMed SPL version 30

> DailyMed lists Structured Product Labeling version 30 for the reviewed Tirzepatide label family with a published date of 2025-12-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30:v1`
- Evidence domain: Regulatory
- Date in source: 2025-12-31
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-v1
- Content SHA-256: `94803061b29a11e1dee07bc77f71d77b9a27f1f07569d0cf30eeb814f7011c8f`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 30 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-history))

#### Summary

DailyMed lists Structured Product Labeling version 30 for the reviewed Tirzepatide label family with a published date of 2025-12-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 30 for the reviewed Tirzepatide label family with a published date of 2025-12-31. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 30 · published 2025-12-31 · retained ZIP SHA-256 6b71c9728eb7ac5c698216b7f26e5a3432d9de2c28c2506da4154c4d48497800** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=30) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 30." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v30-v1 SHA-256: 94803061b29a11e1dee07bc77f71d77b9a27f1f07569d0cf30eeb814f7011c8f.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-v1"></a>

## Tirzepatide DailyMed SPL version 31

> DailyMed lists Structured Product Labeling version 31 for the reviewed Tirzepatide label family with a published date of 2026-01-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31:v1`
- Evidence domain: Regulatory
- Date in source: 2026-01-23
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-v1
- Content SHA-256: `541ba8bfa9a945d03e037e90a0849802fd14071de5f7ee58e8246b941a7338fb`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 31 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-history))

#### Summary

DailyMed lists Structured Product Labeling version 31 for the reviewed Tirzepatide label family with a published date of 2026-01-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 31 for the reviewed Tirzepatide label family with a published date of 2026-01-23. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 31 · published 2026-01-23 · retained ZIP SHA-256 9e59864e112960595f86985f382c788dd232ac47e9eae91e52ca51dbde9bc32d** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=31) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 31." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v31-v1 SHA-256: 541ba8bfa9a945d03e037e90a0849802fd14071de5f7ee58e8246b941a7338fb.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-v1"></a>

## Tirzepatide DailyMed SPL version 32

> DailyMed lists Structured Product Labeling version 32 for the reviewed Tirzepatide label family with a published date of 2026-02-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-05
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-v1
- Content SHA-256: `b41f5dc2a80852f57a0c28f9f4f1f3b12a5beb1289bd2cba38a28d7506d09f2f`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 32 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-history))

#### Summary

DailyMed lists Structured Product Labeling version 32 for the reviewed Tirzepatide label family with a published date of 2026-02-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 32 for the reviewed Tirzepatide label family with a published date of 2026-02-05. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 32 · published 2026-02-05 · retained ZIP SHA-256 67650e830f921f6f7a3841fa1bb22954df3637295b69b0a3528e5c92c190fca4** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=32) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 32." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v32-v1 SHA-256: b41f5dc2a80852f57a0c28f9f4f1f3b12a5beb1289bd2cba38a28d7506d09f2f.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-v1"></a>

## Tirzepatide DailyMed SPL version 36

> DailyMed lists Structured Product Labeling version 36 for the reviewed Tirzepatide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36:v1`
- Evidence domain: Regulatory
- Date in source: 2026-02-26
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-v1
- Content SHA-256: `af0b3107a743996e4477759611079a41e8af4937507b02435c9ace39ecf9f2bf`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 36 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-history))

#### Summary

DailyMed lists Structured Product Labeling version 36 for the reviewed Tirzepatide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 36 for the reviewed Tirzepatide label family with a published date of 2026-02-26. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 36 · published 2026-02-26 · retained ZIP SHA-256 024c61f53130c5050e495760f02cf67d97cca136e74a3db80d8f08bef1de8c48** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=36) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 36." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v36-v1 SHA-256: af0b3107a743996e4477759611079a41e8af4937507b02435c9ace39ecf9f2bf.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-v1"></a>

## Tirzepatide DailyMed SPL version 37

> DailyMed lists Structured Product Labeling version 37 for the reviewed Tirzepatide label family with a published date of 2026-03-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37:v1`
- Evidence domain: Regulatory
- Date in source: 2026-03-03
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-v1
- Content SHA-256: `dc67a41d304c40bc9c7414c577996bafacef1a17f3c60e33eb60ba61fd4ee006`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 37 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-history))

#### Summary

DailyMed lists Structured Product Labeling version 37 for the reviewed Tirzepatide label family with a published date of 2026-03-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 37 for the reviewed Tirzepatide label family with a published date of 2026-03-03. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 37 · published 2026-03-03 · retained ZIP SHA-256 f967eee30fbfac26fa5e12e5d5c1e1c1a70bf55ced90083116ef6db52d09ae9f** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=37) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 37." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v37-v1 SHA-256: dc67a41d304c40bc9c7414c577996bafacef1a17f3c60e33eb60ba61fd4ee006.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-v1"></a>

## Tirzepatide DailyMed SPL version 38

> DailyMed lists Structured Product Labeling version 38 for the reviewed Tirzepatide label family with a published date of 2026-05-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38:v1`
- Evidence domain: Regulatory
- Date in source: 2026-05-06
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-v1
- Content SHA-256: `77f6ad4bd0375d27883edef3d9eb569a9c955596010f8ede99079e2c2cd76429`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 38 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-history))

#### Summary

DailyMed lists Structured Product Labeling version 38 for the reviewed Tirzepatide label family with a published date of 2026-05-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 38 for the reviewed Tirzepatide label family with a published date of 2026-05-06. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 38 · published 2026-05-06 · retained ZIP SHA-256 8b4500aaf49b5c8bcc0c8dec4dc33c073826ef3ba80d0d8070dc39c5a2379c28** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=38) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 38." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v38-v1 SHA-256: 77f6ad4bd0375d27883edef3d9eb569a9c955596010f8ede99079e2c2cd76429.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-v1"></a>

## Tirzepatide DailyMed SPL version 3

> DailyMed lists Structured Product Labeling version 3 for the reviewed Tirzepatide label family with a published date of 2023-11-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-16
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-v1
- Content SHA-256: `3dac9753e2439a81ca565121b598b804da11c740d9c8d4e5223e2cbf12208ea4`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 3 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-history))

#### Summary

DailyMed lists Structured Product Labeling version 3 for the reviewed Tirzepatide label family with a published date of 2023-11-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 3 for the reviewed Tirzepatide label family with a published date of 2023-11-16. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 3 · published 2023-11-16 · retained ZIP SHA-256 aa527e5c3194250a76faea93454711e3b0abe8d07b6752cf58bde76345703e3b** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=3) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 3." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v3-v1 SHA-256: 3dac9753e2439a81ca565121b598b804da11c740d9c8d4e5223e2cbf12208ea4.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-v1"></a>

## Tirzepatide DailyMed SPL version 40

> DailyMed lists Structured Product Labeling version 40 for the reviewed Tirzepatide label family with a published date of 2026-09-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40:v1`
- Evidence domain: Regulatory
- Date in source: 2026-09-02
- Source checked: 2026-09-15
- Published by PeptideScanner: 2026-09-15
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-v1
- Content SHA-256: `1e7e9279688469b24409862709d99bb6a3997cf91ca43a9835464c9ff640fc93`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 40 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-history))

#### Summary

DailyMed lists Structured Product Labeling version 40 for the reviewed Tirzepatide label family with a published date of 2026-09-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 40 for the reviewed Tirzepatide label family with a published date of 2026-09-02. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 40 · published 2026-09-02 · retained ZIP SHA-256 4fe25d4173ba662adc2b4ac0653c09643bc7a9e883557286abe2c5d36f19d87e** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=40) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 40." Version 1, published 2026-09-15. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v40-v1 SHA-256: 1e7e9279688469b24409862709d99bb6a3997cf91ca43a9835464c9ff640fc93.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-v1"></a>

## Tirzepatide DailyMed SPL version 5

> DailyMed lists Structured Product Labeling version 5 for the reviewed Tirzepatide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5:v1`
- Evidence domain: Regulatory
- Date in source: 2024-04-12
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-v1
- Content SHA-256: `a4151f15b7447e85bb98e5a64c48bfac8de86b5625f9c6cf6c8b6c56245ef376`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 5 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-history))

#### Summary

DailyMed lists Structured Product Labeling version 5 for the reviewed Tirzepatide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 5 for the reviewed Tirzepatide label family with a published date of 2024-04-12. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 5 · published 2024-04-12 · retained ZIP SHA-256 e40834a6656d68f893a60cd89a35d64fce4c9641bddd2264eb1df526ea76d5d0** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=5) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 5." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v5-v1 SHA-256: a4151f15b7447e85bb98e5a64c48bfac8de86b5625f9c6cf6c8b6c56245ef376.

---

<a id="dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-v1"></a>

## Tirzepatide DailyMed SPL version 8

> DailyMed lists Structured Product Labeling version 8 for the reviewed Tirzepatide label family with a published date of 2024-08-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

- Evidence object: `story:dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8:v1`
- Evidence domain: Regulatory
- Date in source: 2024-08-08
- Source checked: 2026-08-22
- Published by PeptideScanner: 2026-08-22
- Story landing page: https://peptidescanner.com/stories/dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-v1
- Content SHA-256: `c0bdf33e2764276964b744ce2a8dc01a24f4e46078d013c2fb2a6b949e55be4f`

### Claims and source pins

#### Headline

Tirzepatide DailyMed SPL version 8 ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-history))

#### Summary

DailyMed lists Structured Product Labeling version 8 for the reviewed Tirzepatide label family with a published date of 2024-08-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-history))

#### Paragraph 1

DailyMed lists Structured Product Labeling version 8 for the reviewed Tirzepatide label family with a published date of 2024-08-08. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-history))

#### Paragraph 2

This page reports that DailyMed lists an available Structured Product Labeling version for the reviewed label family and links the exact historical ZIP. It does not reproduce label text, identify which sections changed, establish FDA approval, interpret safety or effectiveness, or provide medical guidance. ([`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-history`](#source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-history))

### Sources

<a id="source-dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-history"></a>
- **DailyMed SPL SET ID 487cd7e7-434c-4925-99fa-aa80b1cc776b · SPL version 8 · published 2024-08-08 · retained ZIP SHA-256 17a73d4d7b2602967f94af9b4c4ba951b014910d0363d7e15634f7504b1e4bf2** — DailyMed · U.S. National Library of Medicine; class A. [Open source](https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=487cd7e7-434c-4925-99fa-aa80b1cc776b&version=8) (`dailymed-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-history`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide DailyMed SPL version 8." Version 1, published 2026-08-22. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#dailymed-label-tirzepatide-487cd7e7-434c-4925-99fa-aa80b1cc776b-v8-v1 SHA-256: c0bdf33e2764276964b744ce2a8dc01a24f4e46078d013c2fb2a6b949e55be4f.

---

<a id="fda-drugs-nda215866-v1"></a>

## Drugs@FDA application NDA215866

> The official Drugs@FDA dataset lists original submission 1 for NDA 215866 with status AP dated 2022-05-13, and names tirzepatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda215866:v1`
- Evidence domain: Regulatory
- Date in source: 2022-05-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda215866/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#fda-drugs-nda215866-v1
- Content SHA-256: `60eba7db9841bfdeeb5dafffa1b37cf497f45cc319d0f163e33582063d05ae46`

### Claims and source pins

#### Headline

Drugs@FDA application NDA215866 ([`fda-drugs-nda215866-2022-05-13-20c7192d69ff`](#source-fda-drugs-nda215866-2022-05-13-20c7192d69ff))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 215866 with status AP dated 2022-05-13, and names tirzepatide among the application record's active ingredients. ([`fda-drugs-nda215866-2022-05-13-20c7192d69ff`](#source-fda-drugs-nda215866-2022-05-13-20c7192d69ff))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 215866 with status AP dated 2022-05-13, and names tirzepatide among the application record's active ingredients. ([`fda-drugs-nda215866-2022-05-13-20c7192d69ff`](#source-fda-drugs-nda215866-2022-05-13-20c7192d69ff))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda215866-2022-05-13-20c7192d69ff`](#source-fda-drugs-nda215866-2022-05-13-20c7192d69ff))

### Sources

<a id="source-fda-drugs-nda215866-2022-05-13-20c7192d69ff"></a>
- **Drugs@FDA application NDA215866 · original submission status AP · 2022-05-13 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA215866%22&limit=1) (`fda-drugs-nda215866-2022-05-13-20c7192d69ff`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA215866." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#fda-drugs-nda215866-v1 SHA-256: 60eba7db9841bfdeeb5dafffa1b37cf497f45cc319d0f163e33582063d05ae46.

---

<a id="fda-drugs-nda217806-v1"></a>

## Drugs@FDA application NDA217806

> The official Drugs@FDA dataset lists original submission 1 for NDA 217806 with status AP dated 2023-11-08, and names tirzepatide among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda217806:v1`
- Evidence domain: Regulatory
- Date in source: 2023-11-08
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda217806/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#fda-drugs-nda217806-v1
- Content SHA-256: `3599aff4548169ba93d07b23086faaeebf0ebd1500f8afc645689da462c1cb4e`

### Claims and source pins

#### Headline

Drugs@FDA application NDA217806 ([`fda-drugs-nda217806-2023-11-08-1fa405392d95`](#source-fda-drugs-nda217806-2023-11-08-1fa405392d95))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 217806 with status AP dated 2023-11-08, and names tirzepatide among the application record's active ingredients. ([`fda-drugs-nda217806-2023-11-08-1fa405392d95`](#source-fda-drugs-nda217806-2023-11-08-1fa405392d95))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 217806 with status AP dated 2023-11-08, and names tirzepatide among the application record's active ingredients. ([`fda-drugs-nda217806-2023-11-08-1fa405392d95`](#source-fda-drugs-nda217806-2023-11-08-1fa405392d95))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda217806-2023-11-08-1fa405392d95`](#source-fda-drugs-nda217806-2023-11-08-1fa405392d95))

### Sources

<a id="source-fda-drugs-nda217806-2023-11-08-1fa405392d95"></a>
- **Drugs@FDA application NDA217806 · original submission status AP · 2023-11-08 · dataset 2026-08-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA217806%22&limit=1) (`fda-drugs-nda217806-2023-11-08-1fa405392d95`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA217806." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#fda-drugs-nda217806-v1 SHA-256: 3599aff4548169ba93d07b23086faaeebf0ebd1500f8afc645689da462c1cb4e.

---

<a id="federal-register-2022-18523-v1"></a>

## Federal Register notice 2022-18523

> The Federal Register published notice 2022-18523, attributed to FDA and its parent HHS department, on 2022-08-29. Its official title is “Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide.

- Evidence object: `story:federal-register-2022-18523:v1`
- Evidence domain: Regulatory
- Date in source: 2022-08-29
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2022-18523/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#federal-register-2022-18523-v1
- Content SHA-256: `fb014951f4ee68b9db2af9f3381a4cbd6c55447835919955fb090c71b747b852`

### Claims and source pins

#### Headline

Federal Register notice 2022-18523 ([`federal-register-2022-18523-63c6d635b89e`](#source-federal-register-2022-18523-63c6d635b89e))

#### Summary

The Federal Register published notice 2022-18523, attributed to FDA and its parent HHS department, on 2022-08-29. Its official title is “Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide. ([`federal-register-2022-18523-63c6d635b89e`](#source-federal-register-2022-18523-63c6d635b89e))

#### Paragraph 1

The Federal Register published notice 2022-18523, attributed to FDA and its parent HHS department, on 2022-08-29. Its official title is “Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide. ([`federal-register-2022-18523-63c6d635b89e`](#source-federal-register-2022-18523-63c6d635b89e))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2022-18523-63c6d635b89e`](#source-federal-register-2022-18523-63c6d635b89e))

### Sources

<a id="source-federal-register-2022-18523-63c6d635b89e"></a>
- **Federal Register notice 2022-18523 · published 2022-08-29 · Notice of Approval of Product Under Voucher: Material Threat Medical Countermeasure Priority Review Voucher** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2022-08-29/pdf/2022-18523.pdf) (`federal-register-2022-18523-63c6d635b89e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2022-18523." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#federal-register-2022-18523-v1 SHA-256: fb014951f4ee68b9db2af9f3381a4cbd6c55447835919955fb090c71b747b852.

---

<a id="federal-register-2024-04157-v1"></a>

## Federal Register notice 2024-04157

> The Federal Register published notice 2024-04157, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MOUNJARO,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide.

- Evidence object: `story:federal-register-2024-04157:v1`
- Evidence domain: Regulatory
- Date in source: 2024-02-29
- Source checked: 2026-08-21
- Published by PeptideScanner: 2026-08-21
- Story landing page: https://peptidescanner.com/stories/federal-register-2024-04157/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#federal-register-2024-04157-v1
- Content SHA-256: `2b2136c31835c43276db7c352858315b628fd535a579249e9d0896e4a589acec`

### Claims and source pins

#### Headline

Federal Register notice 2024-04157 ([`federal-register-2024-04157-f2c8ee77a978`](#source-federal-register-2024-04157-f2c8ee77a978))

#### Summary

The Federal Register published notice 2024-04157, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MOUNJARO,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide. ([`federal-register-2024-04157-f2c8ee77a978`](#source-federal-register-2024-04157-f2c8ee77a978))

#### Paragraph 1

The Federal Register published notice 2024-04157, attributed to FDA and its parent HHS department, on 2024-02-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; MOUNJARO,” and PeptideScanner's exact reviewed identity mapping connects the document to Tirzepatide. ([`federal-register-2024-04157-f2c8ee77a978`](#source-federal-register-2024-04157-f2c8ee77a978))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2024-04157-f2c8ee77a978`](#source-federal-register-2024-04157-f2c8ee77a978))

### Sources

<a id="source-federal-register-2024-04157-f2c8ee77a978"></a>
- **Federal Register notice 2024-04157 · published 2024-02-29 · Determination of Regulatory Review Period for Purposes of Patent Extension; MOUNJARO** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2024-02-29/pdf/2024-04157.pdf) (`federal-register-2024-04157-f2c8ee77a978`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2024-04157." Version 1, published 2026-08-21. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#federal-register-2024-04157-v1 SHA-256: 2b2136c31835c43276db7c352858315b628fd535a579249e9d0896e4a589acec.

---

<a id="pubmed-pmid-37989596-tirzepatide-v1"></a>

## PubMed record PMID 37989596

> PeptideScanner retained PubMed bibliographic metadata for PMID 37989596 at 2026-08-10T10:49:06.851Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2023-11-21. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-37989596-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37989596-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-37989596-tirzepatide-v1
- Content SHA-256: `99ae11c38ec338faac45487b933c6d3c85d8052126ede95bc950ef6bbc71e32d`

### Claims and source pins

#### Headline

PubMed record PMID 37989596 ([`pubmed-observation-pmid-37989596-2026-07-30-16b987c55bc8`](#source-pubmed-observation-pmid-37989596-2026-07-30-16b987c55bc8))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 37989596 at 2026-08-10T10:49:06.851Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2023-11-21. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-37989596-2026-07-30-16b987c55bc8`](#source-pubmed-observation-pmid-37989596-2026-07-30-16b987c55bc8))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 37989596 at 2026-08-10T10:49:06.851Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2023-11-21. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-37989596-2026-07-30-16b987c55bc8`](#source-pubmed-observation-pmid-37989596-2026-07-30-16b987c55bc8))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37989596-2026-07-30-16b987c55bc8`](#source-pubmed-observation-pmid-37989596-2026-07-30-16b987c55bc8))

### Sources

<a id="source-pubmed-observation-pmid-37989596-2026-07-30-16b987c55bc8"></a>
- **PubMed record PMID 37989596 · retained source version 1:2026-07-30:current:16b987c55bc826175ba5bb59c7237e1d943ee2ca5873edc8dfe67243c85d8b00** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37989596/) (`pubmed-observation-pmid-37989596-2026-07-30-16b987c55bc8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 37989596." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-37989596-tirzepatide-v1 SHA-256: 99ae11c38ec338faac45487b933c6d3c85d8052126ede95bc950ef6bbc71e32d.

---

<a id="pubmed-pmid-38247052-tirzepatide-v1"></a>

## Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice.

> PubMed lists PMID 38247052 in The Annals of pharmacotherapy as Review, Letter, with publication-date metadata of 2024-01-21 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38247052-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38247052-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-38247052-tirzepatide-v1
- Content SHA-256: `6562a50c717ba129db50a4fd50334feadbeb8c4fd2e2c2cd82354f3d40281df0`

### Claims and source pins

#### Headline

Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. ([`pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db`](#source-pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db))

#### Summary

PubMed lists PMID 38247052 in The Annals of pharmacotherapy as Review, Letter, with publication-date metadata of 2024-01-21 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db`](#source-pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db))

#### Paragraph 1

PubMed lists PMID 38247052 in The Annals of pharmacotherapy as Review, Letter, with publication-date metadata of 2024-01-21 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db`](#source-pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db`](#source-pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db))

### Sources

<a id="source-pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db"></a>
- **Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice. · retained source version 1:2026-07-06:current:0be4c46fb1db5dd7a823239f52996064b0f0e5eb4c465d7a56b8e7eacf80a4db** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38247052/) (`pubmed-observation-pmid-38247052-2026-07-06-0be4c46fb1db`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide, the Newest Medication for Type 2 Diabetes: A Review of the Literature and Implications for Clinical Practice." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-38247052-tirzepatide-v1 SHA-256: 6562a50c717ba129db50a4fd50334feadbeb8c4fd2e2c2cd82354f3d40281df0.

---

<a id="pubmed-pmid-38302718-tirzepatide-v1"></a>

## PubMed record PMID 38302718

> PeptideScanner retained PubMed bibliographic metadata for PMID 38302718 at 2026-08-10T10:49:06.877Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2024-02-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-38302718-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38302718-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-38302718-tirzepatide-v1
- Content SHA-256: `58220063636e379f7fdd39a315081d91b4da379da94fe2d3264913693d93a628`

### Claims and source pins

#### Headline

PubMed record PMID 38302718 ([`pubmed-observation-pmid-38302718-2026-08-08-ddec51edf5c3`](#source-pubmed-observation-pmid-38302718-2026-08-08-ddec51edf5c3))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 38302718 at 2026-08-10T10:49:06.877Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2024-02-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38302718-2026-08-08-ddec51edf5c3`](#source-pubmed-observation-pmid-38302718-2026-08-08-ddec51edf5c3))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 38302718 at 2026-08-10T10:49:06.877Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2024-02-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-38302718-2026-08-08-ddec51edf5c3`](#source-pubmed-observation-pmid-38302718-2026-08-08-ddec51edf5c3))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38302718-2026-08-08-ddec51edf5c3`](#source-pubmed-observation-pmid-38302718-2026-08-08-ddec51edf5c3))

### Sources

<a id="source-pubmed-observation-pmid-38302718-2026-08-08-ddec51edf5c3"></a>
- **PubMed record PMID 38302718 · retained source version 1:2026-08-08:current:ddec51edf5c33918cdec15659cfcd257f47bdaaa78e71fe98d39e195cf604800** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38302718/) (`pubmed-observation-pmid-38302718-2026-08-08-ddec51edf5c3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 38302718." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-38302718-tirzepatide-v1 SHA-256: 58220063636e379f7fdd39a315081d91b4da379da94fe2d3264913693d93a628.

---

<a id="pubmed-pmid-38717708-tirzepatide-v1"></a>

## Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective.

> PubMed lists PMID 38717708 in PharmacoEconomics as Journal Article, with publication-date metadata of 2024-05-08 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38717708-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-12
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38717708-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-38717708-tirzepatide-v1
- Content SHA-256: `df6e268fc32c9d5eaaed6f5d1d151c118ed7a8bd849057630dd8a43cec0e34aa`

### Claims and source pins

#### Headline

Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective. ([`pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe`](#source-pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe))

#### Summary

PubMed lists PMID 38717708 in PharmacoEconomics as Journal Article, with publication-date metadata of 2024-05-08 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe`](#source-pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe))

#### Paragraph 1

PubMed lists PMID 38717708 in PharmacoEconomics as Journal Article, with publication-date metadata of 2024-05-08 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe`](#source-pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe`](#source-pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe))

### Sources

<a id="source-pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe"></a>
- **Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective. · retained source version 1:2026-07-12:current:52000ff1efbec556a2f29cded665122b740a254d664e7d9ab706c19f9735d7f6** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38717708/) (`pubmed-observation-pmid-38717708-2026-07-12-52000ff1efbe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Challenges in the Assessment of a Disease Model in the NICE Single Technology Appraisal of Tirzepatide for Treating Type 2 Diabetes: An External Assessment Group Perspective." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-38717708-tirzepatide-v1 SHA-256: df6e268fc32c9d5eaaed6f5d1d151c118ed7a8bd849057630dd8a43cec0e34aa.

---

<a id="pubmed-pmid-39018899-tirzepatide-v1"></a>

## Can tirzepatide untie the Gordian knot of eating disorders among individuals with type 2 diabetes and obesity?

> PubMed lists PMID 39018899 in Journal of diabetes and its complications as Editorial, with publication-date metadata of 2024-07-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-39018899-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-39018899-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-39018899-tirzepatide-v1
- Content SHA-256: `0b328c70045aa515f85ab949a1b2c99b1b11ebd3307fbff0753da743c1fbb7c7`

### Claims and source pins

#### Headline

Can tirzepatide untie the Gordian knot of eating disorders among individuals with type 2 diabetes and obesity? ([`pubmed-observation-pmid-39018899-2026-07-02-3eabe701c1e1`](#source-pubmed-observation-pmid-39018899-2026-07-02-3eabe701c1e1))

#### Summary

PubMed lists PMID 39018899 in Journal of diabetes and its complications as Editorial, with publication-date metadata of 2024-07-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39018899-2026-07-02-3eabe701c1e1`](#source-pubmed-observation-pmid-39018899-2026-07-02-3eabe701c1e1))

#### Paragraph 1

PubMed lists PMID 39018899 in Journal of diabetes and its complications as Editorial, with publication-date metadata of 2024-07-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-39018899-2026-07-02-3eabe701c1e1`](#source-pubmed-observation-pmid-39018899-2026-07-02-3eabe701c1e1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-39018899-2026-07-02-3eabe701c1e1`](#source-pubmed-observation-pmid-39018899-2026-07-02-3eabe701c1e1))

### Sources

<a id="source-pubmed-observation-pmid-39018899-2026-07-02-3eabe701c1e1"></a>
- **Can tirzepatide untie the Gordian knot of eating disorders among individuals with type 2 diabetes and obesity? · retained source version 1:2026-07-02:current:3eabe701c1e1d1e9133c3307bc6c006152a5047bc7c27e3849a6e87dbe0b73d5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/39018899/) (`pubmed-observation-pmid-39018899-2026-07-02-3eabe701c1e1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Can tirzepatide untie the Gordian knot of eating disorders among individuals with type 2 diabetes and obesity?" Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-39018899-tirzepatide-v1 SHA-256: 0b328c70045aa515f85ab949a1b2c99b1b11ebd3307fbff0753da743c1fbb7c7.

---

<a id="pubmed-pmid-40036855-tirzepatide-v1"></a>

## PubMed record PMID 40036855

> PeptideScanner retained PubMed bibliographic metadata for PMID 40036855 at 2026-08-10T10:49:06.932Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-03-04. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40036855-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40036855-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-40036855-tirzepatide-v1
- Content SHA-256: `c7bfdbfec7edd6daf541abe487cbb5cfe7b80bcd767b013602df388f7eb38cc8`

### Claims and source pins

#### Headline

PubMed record PMID 40036855 ([`pubmed-observation-pmid-40036855-2026-08-02-5ae32b82b67d`](#source-pubmed-observation-pmid-40036855-2026-08-02-5ae32b82b67d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40036855 at 2026-08-10T10:49:06.932Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-03-04. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40036855-2026-08-02-5ae32b82b67d`](#source-pubmed-observation-pmid-40036855-2026-08-02-5ae32b82b67d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40036855 at 2026-08-10T10:49:06.932Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-03-04. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40036855-2026-08-02-5ae32b82b67d`](#source-pubmed-observation-pmid-40036855-2026-08-02-5ae32b82b67d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40036855-2026-08-02-5ae32b82b67d`](#source-pubmed-observation-pmid-40036855-2026-08-02-5ae32b82b67d))

### Sources

<a id="source-pubmed-observation-pmid-40036855-2026-08-02-5ae32b82b67d"></a>
- **PubMed record PMID 40036855 · retained source version 1:2026-08-02:current:5ae32b82b67d5496b5fb837a58954befb874c2c13bb3d999a57161ab400772cd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40036855/) (`pubmed-observation-pmid-40036855-2026-08-02-5ae32b82b67d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40036855." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-40036855-tirzepatide-v1 SHA-256: c7bfdbfec7edd6daf541abe487cbb5cfe7b80bcd767b013602df388f7eb38cc8.

---

<a id="pubmed-pmid-40383978-tirzepatide-v1"></a>

## PubMed record PMID 40383978

> PeptideScanner retained PubMed bibliographic metadata for PMID 40383978 at 2026-08-10T10:49:06.944Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2025-05-19. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40383978-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-01
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40383978-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-40383978-tirzepatide-v1
- Content SHA-256: `d98d2fbf67f117471234ad06f1ceab9294f73ec96dbbf772a004a675f46404de`

### Claims and source pins

#### Headline

PubMed record PMID 40383978 ([`pubmed-observation-pmid-40383978-2026-08-01-4c5fe0eba646`](#source-pubmed-observation-pmid-40383978-2026-08-01-4c5fe0eba646))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40383978 at 2026-08-10T10:49:06.944Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2025-05-19. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40383978-2026-08-01-4c5fe0eba646`](#source-pubmed-observation-pmid-40383978-2026-08-01-4c5fe0eba646))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40383978 at 2026-08-10T10:49:06.944Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2025-05-19. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40383978-2026-08-01-4c5fe0eba646`](#source-pubmed-observation-pmid-40383978-2026-08-01-4c5fe0eba646))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40383978-2026-08-01-4c5fe0eba646`](#source-pubmed-observation-pmid-40383978-2026-08-01-4c5fe0eba646))

### Sources

<a id="source-pubmed-observation-pmid-40383978-2026-08-01-4c5fe0eba646"></a>
- **PubMed record PMID 40383978 · retained source version 1:2026-08-01:current:4c5fe0eba6462f5fc19e79a8aa3cc5e024dae2fa108d6916a13c6d68a8b8dd65** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40383978/) (`pubmed-observation-pmid-40383978-2026-08-01-4c5fe0eba646`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40383978." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-40383978-tirzepatide-v1 SHA-256: d98d2fbf67f117471234ad06f1ceab9294f73ec96dbbf772a004a675f46404de.

---

<a id="pubmed-pmid-40510020-tirzepatide-v1"></a>

## PubMed record PMID 40510020

> PeptideScanner retained PubMed bibliographic metadata for PMID 40510020 at 2026-08-10T10:49:06.950Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-06-13. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-40510020-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-40510020-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-40510020-tirzepatide-v1
- Content SHA-256: `998595dcde267b8cb7a051d7792aab110555b241cf202e8c1117b1f1d80b103a`

### Claims and source pins

#### Headline

PubMed record PMID 40510020 ([`pubmed-observation-pmid-40510020-2026-08-02-fc7dd0158141`](#source-pubmed-observation-pmid-40510020-2026-08-02-fc7dd0158141))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 40510020 at 2026-08-10T10:49:06.950Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-06-13. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40510020-2026-08-02-fc7dd0158141`](#source-pubmed-observation-pmid-40510020-2026-08-02-fc7dd0158141))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 40510020 at 2026-08-10T10:49:06.950Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-06-13. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-40510020-2026-08-02-fc7dd0158141`](#source-pubmed-observation-pmid-40510020-2026-08-02-fc7dd0158141))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-40510020-2026-08-02-fc7dd0158141`](#source-pubmed-observation-pmid-40510020-2026-08-02-fc7dd0158141))

### Sources

<a id="source-pubmed-observation-pmid-40510020-2026-08-02-fc7dd0158141"></a>
- **PubMed record PMID 40510020 · retained source version 1:2026-08-02:current:fc7dd01581411631945f9560c5b0e78ace473b68b511e443f436cf5bbdb2bc81** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/40510020/) (`pubmed-observation-pmid-40510020-2026-08-02-fc7dd0158141`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 40510020." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-40510020-tirzepatide-v1 SHA-256: 998595dcde267b8cb7a051d7792aab110555b241cf202e8c1117b1f1d80b103a.

---

<a id="pubmed-pmid-41032183-tirzepatide-v1"></a>

## PubMed record PMID 41032183

> PeptideScanner retained PubMed bibliographic metadata for PMID 41032183 at 2026-08-10T10:49:06.970Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2025-10-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41032183-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41032183-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41032183-tirzepatide-v1
- Content SHA-256: `e91d7451292d9227bc07173cd7b47b85a36806bc82179c8b494323df0e4b4f8b`

### Claims and source pins

#### Headline

PubMed record PMID 41032183 ([`pubmed-observation-pmid-41032183-2026-07-30-80bbab59d93c`](#source-pubmed-observation-pmid-41032183-2026-07-30-80bbab59d93c))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41032183 at 2026-08-10T10:49:06.970Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2025-10-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41032183-2026-07-30-80bbab59d93c`](#source-pubmed-observation-pmid-41032183-2026-07-30-80bbab59d93c))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41032183 at 2026-08-10T10:49:06.970Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2025-10-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41032183-2026-07-30-80bbab59d93c`](#source-pubmed-observation-pmid-41032183-2026-07-30-80bbab59d93c))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41032183-2026-07-30-80bbab59d93c`](#source-pubmed-observation-pmid-41032183-2026-07-30-80bbab59d93c))

### Sources

<a id="source-pubmed-observation-pmid-41032183-2026-07-30-80bbab59d93c"></a>
- **PubMed record PMID 41032183 · retained source version 1:2026-07-30:current:80bbab59d93c42686544859d4c11f7b52f3461ac92a3a89d0941426919f06e15** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41032183/) (`pubmed-observation-pmid-41032183-2026-07-30-80bbab59d93c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41032183." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41032183-tirzepatide-v1 SHA-256: e91d7451292d9227bc07173cd7b47b85a36806bc82179c8b494323df0e4b4f8b.

---

<a id="pubmed-pmid-41077767-tirzepatide-v1"></a>

## PubMed record PMID 41077767

> PeptideScanner retained PubMed bibliographic metadata for PMID 41077767 at 2026-08-10T10:49:06.977Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-10-13. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41077767-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41077767-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41077767-tirzepatide-v1
- Content SHA-256: `cd4e7295b04568a5e2007484c68988b36439ce1759a7ef3ffdd13964a63e5143`

### Claims and source pins

#### Headline

PubMed record PMID 41077767 ([`pubmed-observation-pmid-41077767-2026-08-02-3816fe2f719b`](#source-pubmed-observation-pmid-41077767-2026-08-02-3816fe2f719b))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41077767 at 2026-08-10T10:49:06.977Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-10-13. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41077767-2026-08-02-3816fe2f719b`](#source-pubmed-observation-pmid-41077767-2026-08-02-3816fe2f719b))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41077767 at 2026-08-10T10:49:06.977Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2025-10-13. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41077767-2026-08-02-3816fe2f719b`](#source-pubmed-observation-pmid-41077767-2026-08-02-3816fe2f719b))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41077767-2026-08-02-3816fe2f719b`](#source-pubmed-observation-pmid-41077767-2026-08-02-3816fe2f719b))

### Sources

<a id="source-pubmed-observation-pmid-41077767-2026-08-02-3816fe2f719b"></a>
- **PubMed record PMID 41077767 · retained source version 1:2026-08-02:current:3816fe2f719bf331785dd413c5661282704333a4d438daf3331aa5ff134ec7d7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41077767/) (`pubmed-observation-pmid-41077767-2026-08-02-3816fe2f719b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41077767." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41077767-tirzepatide-v1 SHA-256: cd4e7295b04568a5e2007484c68988b36439ce1759a7ef3ffdd13964a63e5143.

---

<a id="pubmed-pmid-41256163-tirzepatide-v1"></a>

## Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide.

> PubMed lists PMID 41256163 in medRxiv : the preprint server for health sciences as Journal Article, Preprint, with publication-date metadata of 2025-10-05 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41256163-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41256163-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41256163-tirzepatide-v1
- Content SHA-256: `6a2240d033dbb0c2fb1b2d6aa1a97f12eb3cdd128a3272cbad50607c01e36da9`

### Claims and source pins

#### Headline

Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide. ([`pubmed-observation-pmid-41256163-2026-06-26-972a07d8c39a`](#source-pubmed-observation-pmid-41256163-2026-06-26-972a07d8c39a))

#### Summary

PubMed lists PMID 41256163 in medRxiv : the preprint server for health sciences as Journal Article, Preprint, with publication-date metadata of 2025-10-05 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41256163-2026-06-26-972a07d8c39a`](#source-pubmed-observation-pmid-41256163-2026-06-26-972a07d8c39a))

#### Paragraph 1

PubMed lists PMID 41256163 in medRxiv : the preprint server for health sciences as Journal Article, Preprint, with publication-date metadata of 2025-10-05 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41256163-2026-06-26-972a07d8c39a`](#source-pubmed-observation-pmid-41256163-2026-06-26-972a07d8c39a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41256163-2026-06-26-972a07d8c39a`](#source-pubmed-observation-pmid-41256163-2026-06-26-972a07d8c39a))

### Sources

<a id="source-pubmed-observation-pmid-41256163-2026-06-26-972a07d8c39a"></a>
- **Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide. · retained source version 1:2026-06-26:current:972a07d8c39aec262c1fb4710b5a3bc67b9442d90a78531f2203140e2d7f672c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41256163/) (`pubmed-observation-pmid-41256163-2026-06-26-972a07d8c39a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Treatment Preferences For Comorbid Obesity and Obstructive Sleep Apnea (PRO-CON OSA) Survey: Patient and Provider Preferences for CPAP and/or Tirzepatide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41256163-tirzepatide-v1 SHA-256: 6a2240d033dbb0c2fb1b2d6aa1a97f12eb3cdd128a3272cbad50607c01e36da9.

---

<a id="pubmed-pmid-41258966-tirzepatide-v1"></a>

## Tirzepatide and metabolic surgery: complementary approaches for multimodal management of MASLD.

> PubMed lists PMID 41258966 in Hepatology international as Letter, Comment, with publication-date metadata of 2025-11-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41258966-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-04-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41258966-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41258966-tirzepatide-v1
- Content SHA-256: `715a9251fada59864320ddb0723ed40d6ca150520a7705db793de130d22f92fb`

### Claims and source pins

#### Headline

Tirzepatide and metabolic surgery: complementary approaches for multimodal management of MASLD. ([`pubmed-observation-pmid-41258966-2026-04-27-30178300daa1`](#source-pubmed-observation-pmid-41258966-2026-04-27-30178300daa1))

#### Summary

PubMed lists PMID 41258966 in Hepatology international as Letter, Comment, with publication-date metadata of 2025-11-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41258966-2026-04-27-30178300daa1`](#source-pubmed-observation-pmid-41258966-2026-04-27-30178300daa1))

#### Paragraph 1

PubMed lists PMID 41258966 in Hepatology international as Letter, Comment, with publication-date metadata of 2025-11-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41258966-2026-04-27-30178300daa1`](#source-pubmed-observation-pmid-41258966-2026-04-27-30178300daa1))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41258966-2026-04-27-30178300daa1`](#source-pubmed-observation-pmid-41258966-2026-04-27-30178300daa1))

### Sources

<a id="source-pubmed-observation-pmid-41258966-2026-04-27-30178300daa1"></a>
- **Tirzepatide and metabolic surgery: complementary approaches for multimodal management of MASLD. · retained source version 1:2026-04-27:current:30178300daa1e9698346f08b937a549c6c2bc040359d214907b0595b9ffdc852** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41258966/) (`pubmed-observation-pmid-41258966-2026-04-27-30178300daa1`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide and metabolic surgery: complementary approaches for multimodal management of MASLD." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41258966-tirzepatide-v1 SHA-256: 715a9251fada59864320ddb0723ed40d6ca150520a7705db793de130d22f92fb.

---

<a id="pubmed-pmid-41290555-tirzepatide-v1"></a>

## PubMed record PMID 41290555

> PeptideScanner retained PubMed bibliographic metadata for PMID 41290555 at 2026-08-10T10:49:07.005Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2025-11-25. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41290555-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41290555-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41290555-tirzepatide-v1
- Content SHA-256: `8a7a2ac7d3658f804437a79800f0a7886401f41ad288f2625a5d4263d035e37f`

### Claims and source pins

#### Headline

PubMed record PMID 41290555 ([`pubmed-observation-pmid-41290555-2026-08-07-eaa8e583594a`](#source-pubmed-observation-pmid-41290555-2026-08-07-eaa8e583594a))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41290555 at 2026-08-10T10:49:07.005Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2025-11-25. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41290555-2026-08-07-eaa8e583594a`](#source-pubmed-observation-pmid-41290555-2026-08-07-eaa8e583594a))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41290555 at 2026-08-10T10:49:07.005Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2025-11-25. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41290555-2026-08-07-eaa8e583594a`](#source-pubmed-observation-pmid-41290555-2026-08-07-eaa8e583594a))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41290555-2026-08-07-eaa8e583594a`](#source-pubmed-observation-pmid-41290555-2026-08-07-eaa8e583594a))

### Sources

<a id="source-pubmed-observation-pmid-41290555-2026-08-07-eaa8e583594a"></a>
- **PubMed record PMID 41290555 · retained source version 1:2026-08-07:current:eaa8e583594a7c6807f1fcb533acebe26d8ed7df2873b86525ecb487f44c5edf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41290555/) (`pubmed-observation-pmid-41290555-2026-08-07-eaa8e583594a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41290555." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41290555-tirzepatide-v1 SHA-256: 8a7a2ac7d3658f804437a79800f0a7886401f41ad288f2625a5d4263d035e37f.

---

<a id="pubmed-pmid-41342185-tirzepatide-v1"></a>

## PubMed record PMID 41342185

> PeptideScanner retained PubMed bibliographic metadata for PMID 41342185 at 2026-08-10T10:49:07.015Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2025-12-04. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41342185-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-08
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41342185-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41342185-tirzepatide-v1
- Content SHA-256: `b69800fe86aa2436b56474b71c5bf5ca26a3888416bdd1c13ea2c0ccb8ccf16d`

### Claims and source pins

#### Headline

PubMed record PMID 41342185 ([`pubmed-observation-pmid-41342185-2026-08-08-504fcd793c1f`](#source-pubmed-observation-pmid-41342185-2026-08-08-504fcd793c1f))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41342185 at 2026-08-10T10:49:07.015Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2025-12-04. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41342185-2026-08-08-504fcd793c1f`](#source-pubmed-observation-pmid-41342185-2026-08-08-504fcd793c1f))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41342185 at 2026-08-10T10:49:07.015Z. PubMed recorded a metadata revision date of 2026-08-08 and an Entrez history date of 2025-12-04. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41342185-2026-08-08-504fcd793c1f`](#source-pubmed-observation-pmid-41342185-2026-08-08-504fcd793c1f))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41342185-2026-08-08-504fcd793c1f`](#source-pubmed-observation-pmid-41342185-2026-08-08-504fcd793c1f))

### Sources

<a id="source-pubmed-observation-pmid-41342185-2026-08-08-504fcd793c1f"></a>
- **PubMed record PMID 41342185 · retained source version 1:2026-08-08:current:504fcd793c1f609cf3e11a7079a7bc6ead8c88e55d4071d9b15a15e4797efd22** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41342185/) (`pubmed-observation-pmid-41342185-2026-08-08-504fcd793c1f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41342185." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41342185-tirzepatide-v1 SHA-256: b69800fe86aa2436b56474b71c5bf5ca26a3888416bdd1c13ea2c0ccb8ccf16d.

---

<a id="pubmed-pmid-41540105-tirzepatide-v1"></a>

## PubMed record PMID 41540105

> PeptideScanner retained PubMed bibliographic metadata for PMID 41540105 at 2026-08-10T18:13:40.558Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-01-15. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41540105-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-27
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41540105-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41540105-tirzepatide-v1
- Content SHA-256: `610d22bb14a1c74b0590e005047fd96dfb5dca1ea5c1c486d62e9c004fbdf8f1`

### Claims and source pins

#### Headline

PubMed record PMID 41540105 ([`pubmed-observation-pmid-41540105-2026-07-27-2b847f26b385`](#source-pubmed-observation-pmid-41540105-2026-07-27-2b847f26b385))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41540105 at 2026-08-10T18:13:40.558Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-01-15. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41540105-2026-07-27-2b847f26b385`](#source-pubmed-observation-pmid-41540105-2026-07-27-2b847f26b385))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41540105 at 2026-08-10T18:13:40.558Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-01-15. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41540105-2026-07-27-2b847f26b385`](#source-pubmed-observation-pmid-41540105-2026-07-27-2b847f26b385))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41540105-2026-07-27-2b847f26b385`](#source-pubmed-observation-pmid-41540105-2026-07-27-2b847f26b385))

### Sources

<a id="source-pubmed-observation-pmid-41540105-2026-07-27-2b847f26b385"></a>
- **PubMed record PMID 41540105 · retained source version 1:2026-07-27:current:2b847f26b3853788eb58d4fb8a5e855a2927a9a60bc2f819742546e9add6ef17** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41540105/) (`pubmed-observation-pmid-41540105-2026-07-27-2b847f26b385`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41540105." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41540105-tirzepatide-v1 SHA-256: 610d22bb14a1c74b0590e005047fd96dfb5dca1ea5c1c486d62e9c004fbdf8f1.

---

<a id="pubmed-pmid-41705736-tirzepatide-v1"></a>

## Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis.

> PubMed lists PMID 41705736 in Diabetes, obesity & metabolism as Systematic Review, Journal Article, Meta-Analysis, with publication-date metadata of 2026-02-18 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41705736-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-21
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41705736-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41705736-tirzepatide-v1
- Content SHA-256: `b73b8bf6c56f46dd5b71c03c1414483daeae050e886e45029743fb3918a5d254`

### Claims and source pins

#### Headline

Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis. ([`pubmed-observation-pmid-41705736-2026-07-21-0c36391443de`](#source-pubmed-observation-pmid-41705736-2026-07-21-0c36391443de))

#### Summary

PubMed lists PMID 41705736 in Diabetes, obesity & metabolism as Systematic Review, Journal Article, Meta-Analysis, with publication-date metadata of 2026-02-18 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41705736-2026-07-21-0c36391443de`](#source-pubmed-observation-pmid-41705736-2026-07-21-0c36391443de))

#### Paragraph 1

PubMed lists PMID 41705736 in Diabetes, obesity & metabolism as Systematic Review, Journal Article, Meta-Analysis, with publication-date metadata of 2026-02-18 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41705736-2026-07-21-0c36391443de`](#source-pubmed-observation-pmid-41705736-2026-07-21-0c36391443de))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41705736-2026-07-21-0c36391443de`](#source-pubmed-observation-pmid-41705736-2026-07-21-0c36391443de))

### Sources

<a id="source-pubmed-observation-pmid-41705736-2026-07-21-0c36391443de"></a>
- **Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis. · retained source version 1:2026-07-21:current:0c36391443de329ea9a7675bab87c829513f88ce96911e839bd78d6c6f73931a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41705736/) (`pubmed-observation-pmid-41705736-2026-07-21-0c36391443de`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide on physical function in adults with overweight or obesity: A systematic review and meta-analysis." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41705736-tirzepatide-v1 SHA-256: b73b8bf6c56f46dd5b71c03c1414483daeae050e886e45029743fb3918a5d254.

---

<a id="pubmed-pmid-41776028-tirzepatide-v1"></a>

## Real world tirzepatide treatment for fatty liver disease.

> PubMed lists PMID 41776028 in Hepatology international as Editorial, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41776028-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-04-27
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41776028-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41776028-tirzepatide-v1
- Content SHA-256: `a7e08ce1229da1c9a33424595dcbbd7be8bf53784c049d2f2a172fd2b7bd8f5f`

### Claims and source pins

#### Headline

Real world tirzepatide treatment for fatty liver disease. ([`pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531`](#source-pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531))

#### Summary

PubMed lists PMID 41776028 in Hepatology international as Editorial, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531`](#source-pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531))

#### Paragraph 1

PubMed lists PMID 41776028 in Hepatology international as Editorial, with publication-date metadata of 2026-03-03 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531`](#source-pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531`](#source-pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531))

### Sources

<a id="source-pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531"></a>
- **Real world tirzepatide treatment for fatty liver disease. · retained source version 1:2026-04-27:current:3b5833d9453153cb871b177a7dbed1e756c477207b8a301d62526b955ba80697** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41776028/) (`pubmed-observation-pmid-41776028-2026-04-27-3b5833d94531`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real world tirzepatide treatment for fatty liver disease." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41776028-tirzepatide-v1 SHA-256: a7e08ce1229da1c9a33424595dcbbd7be8bf53784c049d2f2a172fd2b7bd8f5f.

---

<a id="pubmed-pmid-41802735-tirzepatide-v1"></a>

## PubMed record PMID 41802735

> PeptideScanner retained PubMed bibliographic metadata for PMID 41802735 at 2026-08-10T10:49:08.786Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41802735-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41802735-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41802735-tirzepatide-v1
- Content SHA-256: `6ad442e95ca8e12ff6601b5ad892b554c6e1ed96e931d80b08d31f87f0f281ae`

### Claims and source pins

#### Headline

PubMed record PMID 41802735 ([`pubmed-observation-pmid-41802735-2026-08-05-9d6d4be53414`](#source-pubmed-observation-pmid-41802735-2026-08-05-9d6d4be53414))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41802735 at 2026-08-10T10:49:08.786Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41802735-2026-08-05-9d6d4be53414`](#source-pubmed-observation-pmid-41802735-2026-08-05-9d6d4be53414))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41802735 at 2026-08-10T10:49:08.786Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-03-09. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41802735-2026-08-05-9d6d4be53414`](#source-pubmed-observation-pmid-41802735-2026-08-05-9d6d4be53414))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41802735-2026-08-05-9d6d4be53414`](#source-pubmed-observation-pmid-41802735-2026-08-05-9d6d4be53414))

### Sources

<a id="source-pubmed-observation-pmid-41802735-2026-08-05-9d6d4be53414"></a>
- **PubMed record PMID 41802735 · retained source version 1:2026-08-05:current:9d6d4be534147bcf1c4d5f6360cf3b2f65dda4465f892aa4dede27a796bc0935** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41802735/) (`pubmed-observation-pmid-41802735-2026-08-05-9d6d4be53414`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41802735." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41802735-tirzepatide-v1 SHA-256: 6ad442e95ca8e12ff6601b5ad892b554c6e1ed96e931d80b08d31f87f0f281ae.

---

<a id="pubmed-pmid-41804540-tirzepatide-v1"></a>

## PubMed record PMID 41804540

> PeptideScanner retained PubMed bibliographic metadata for PMID 41804540 at 2026-08-10T10:49:08.787Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-03-10. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41804540-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41804540-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41804540-tirzepatide-v1
- Content SHA-256: `4a5429d3fac3faf9352382c09a5ed22e3d4d3beb1530d301b3c733c51a22f5d2`

### Claims and source pins

#### Headline

PubMed record PMID 41804540 ([`pubmed-observation-pmid-41804540-2026-08-06-ba30891b2fe5`](#source-pubmed-observation-pmid-41804540-2026-08-06-ba30891b2fe5))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41804540 at 2026-08-10T10:49:08.787Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-03-10. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41804540-2026-08-06-ba30891b2fe5`](#source-pubmed-observation-pmid-41804540-2026-08-06-ba30891b2fe5))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41804540 at 2026-08-10T10:49:08.787Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-03-10. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41804540-2026-08-06-ba30891b2fe5`](#source-pubmed-observation-pmid-41804540-2026-08-06-ba30891b2fe5))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41804540-2026-08-06-ba30891b2fe5`](#source-pubmed-observation-pmid-41804540-2026-08-06-ba30891b2fe5))

### Sources

<a id="source-pubmed-observation-pmid-41804540-2026-08-06-ba30891b2fe5"></a>
- **PubMed record PMID 41804540 · retained source version 1:2026-08-06:current:ba30891b2fe5bedd1264ca3cb56a85e9a3d7a41aa4e1582b264607211d567071** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41804540/) (`pubmed-observation-pmid-41804540-2026-08-06-ba30891b2fe5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41804540." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41804540-tirzepatide-v1 SHA-256: 4a5429d3fac3faf9352382c09a5ed22e3d4d3beb1530d301b3c733c51a22f5d2.

---

<a id="pubmed-pmid-41862113-tirzepatide-v1"></a>

## Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study.

> PubMed lists PMID 41862113 in The American journal of cardiology as Journal Article, with publication-date metadata of 2026-03-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41862113-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-11
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41862113-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41862113-tirzepatide-v1
- Content SHA-256: `e3dd72f6be93fc3dacba79199565f9cada95ae9f6182e80a647340c784c84858`

### Claims and source pins

#### Headline

Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study. ([`pubmed-observation-pmid-41862113-2026-07-11-cb0ea16db9ea`](#source-pubmed-observation-pmid-41862113-2026-07-11-cb0ea16db9ea))

#### Summary

PubMed lists PMID 41862113 in The American journal of cardiology as Journal Article, with publication-date metadata of 2026-03-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41862113-2026-07-11-cb0ea16db9ea`](#source-pubmed-observation-pmid-41862113-2026-07-11-cb0ea16db9ea))

#### Paragraph 1

PubMed lists PMID 41862113 in The American journal of cardiology as Journal Article, with publication-date metadata of 2026-03-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41862113-2026-07-11-cb0ea16db9ea`](#source-pubmed-observation-pmid-41862113-2026-07-11-cb0ea16db9ea))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41862113-2026-07-11-cb0ea16db9ea`](#source-pubmed-observation-pmid-41862113-2026-07-11-cb0ea16db9ea))

### Sources

<a id="source-pubmed-observation-pmid-41862113-2026-07-11-cb0ea16db9ea"></a>
- **Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study. · retained source version 1:2026-07-11:current:cb0ea16db9ea9913d75b921176b4278f35948394b5a8e16bbfe383c39dfb36f4** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41862113/) (`pubmed-observation-pmid-41862113-2026-07-11-cb0ea16db9ea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Early Tirzepatide Use After Acute Myocardial Infarction or Ischemic Stroke in Patients Without Diabetes: A Real-World Propensity-Matched Study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41862113-tirzepatide-v1 SHA-256: e3dd72f6be93fc3dacba79199565f9cada95ae9f6182e80a647340c784c84858.

---

<a id="pubmed-pmid-41885866-tirzepatide-v1"></a>

## PubMed record PMID 41885866

> PeptideScanner retained PubMed bibliographic metadata for PMID 41885866 at 2026-08-10T10:49:08.813Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-03-26. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41885866-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-07
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41885866-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41885866-tirzepatide-v1
- Content SHA-256: `967dd437c8ed024257cef808b142cc2dbeb36a808ecae0f4216f884e4c951dec`

### Claims and source pins

#### Headline

PubMed record PMID 41885866 ([`pubmed-observation-pmid-41885866-2026-08-07-61975b0207f3`](#source-pubmed-observation-pmid-41885866-2026-08-07-61975b0207f3))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41885866 at 2026-08-10T10:49:08.813Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-03-26. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41885866-2026-08-07-61975b0207f3`](#source-pubmed-observation-pmid-41885866-2026-08-07-61975b0207f3))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41885866 at 2026-08-10T10:49:08.813Z. PubMed recorded a metadata revision date of 2026-08-07 and an Entrez history date of 2026-03-26. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41885866-2026-08-07-61975b0207f3`](#source-pubmed-observation-pmid-41885866-2026-08-07-61975b0207f3))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41885866-2026-08-07-61975b0207f3`](#source-pubmed-observation-pmid-41885866-2026-08-07-61975b0207f3))

### Sources

<a id="source-pubmed-observation-pmid-41885866-2026-08-07-61975b0207f3"></a>
- **PubMed record PMID 41885866 · retained source version 1:2026-08-07:current:61975b0207f3e9b11d8a28d8647c15c5115ad2e895836678da7a3d30181cc2c3** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41885866/) (`pubmed-observation-pmid-41885866-2026-08-07-61975b0207f3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41885866." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41885866-tirzepatide-v1 SHA-256: 967dd437c8ed024257cef808b142cc2dbeb36a808ecae0f4216f884e4c951dec.

---

<a id="pubmed-pmid-41917519-tirzepatide-v1"></a>

## PubMed record PMID 41917519

> PeptideScanner retained PubMed bibliographic metadata for PMID 41917519 at 2026-08-10T10:49:08.829Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-04-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41917519-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41917519-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41917519-tirzepatide-v1
- Content SHA-256: `8465026164de677e44145fcab567f1f450309c8086bdb4c83640b2a2e1ec5bf4`

### Claims and source pins

#### Headline

PubMed record PMID 41917519 ([`pubmed-observation-pmid-41917519-2026-07-30-bebbe8913ab5`](#source-pubmed-observation-pmid-41917519-2026-07-30-bebbe8913ab5))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41917519 at 2026-08-10T10:49:08.829Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-04-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41917519-2026-07-30-bebbe8913ab5`](#source-pubmed-observation-pmid-41917519-2026-07-30-bebbe8913ab5))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41917519 at 2026-08-10T10:49:08.829Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-04-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41917519-2026-07-30-bebbe8913ab5`](#source-pubmed-observation-pmid-41917519-2026-07-30-bebbe8913ab5))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41917519-2026-07-30-bebbe8913ab5`](#source-pubmed-observation-pmid-41917519-2026-07-30-bebbe8913ab5))

### Sources

<a id="source-pubmed-observation-pmid-41917519-2026-07-30-bebbe8913ab5"></a>
- **PubMed record PMID 41917519 · retained source version 1:2026-07-30:current:bebbe8913ab5dc29b443bf8207c28b8c170b57a24e73825ba8fe3a0596dd9185** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41917519/) (`pubmed-observation-pmid-41917519-2026-07-30-bebbe8913ab5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41917519." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41917519-tirzepatide-v1 SHA-256: 8465026164de677e44145fcab567f1f450309c8086bdb4c83640b2a2e1ec5bf4.

---

<a id="pubmed-pmid-41944182-tirzepatide-v1"></a>

## Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.

> PubMed lists PMID 41944182 in Diabetes, obesity & metabolism as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2026-04-07 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41944182-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-14
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41944182-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41944182-tirzepatide-v1
- Content SHA-256: `5eb4e3824961181d2e4249adecabb894524e0aa452717d60d072e0fc7ab2e148`

### Claims and source pins

#### Headline

Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study. ([`pubmed-observation-pmid-41944182-2026-07-14-9e8d0b6dc0ec`](#source-pubmed-observation-pmid-41944182-2026-07-14-9e8d0b6dc0ec))

#### Summary

PubMed lists PMID 41944182 in Diabetes, obesity & metabolism as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2026-04-07 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41944182-2026-07-14-9e8d0b6dc0ec`](#source-pubmed-observation-pmid-41944182-2026-07-14-9e8d0b6dc0ec))

#### Paragraph 1

PubMed lists PMID 41944182 in Diabetes, obesity & metabolism as Journal Article, Multicenter Study, Observational Study, with publication-date metadata of 2026-04-07 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41944182-2026-07-14-9e8d0b6dc0ec`](#source-pubmed-observation-pmid-41944182-2026-07-14-9e8d0b6dc0ec))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41944182-2026-07-14-9e8d0b6dc0ec`](#source-pubmed-observation-pmid-41944182-2026-07-14-9e8d0b6dc0ec))

### Sources

<a id="source-pubmed-observation-pmid-41944182-2026-07-14-9e8d0b6dc0ec"></a>
- **Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study. · retained source version 1:2026-07-14:current:9e8d0b6dc0ec5b29af04dce66a3650b6bec9431ade474120a354b9f8c093b70e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41944182/) (`pubmed-observation-pmid-41944182-2026-07-14-9e8d0b6dc0ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41944182-tirzepatide-v1 SHA-256: 5eb4e3824961181d2e4249adecabb894524e0aa452717d60d072e0fc7ab2e148.

---

<a id="pubmed-pmid-41945548-tirzepatide-v1"></a>

## Tirzepatide and Autonomic Dysfunction: Insights From Postural Orthostatic Tachycardia Syndrome.

> PubMed lists PMID 41945548 in JACC. Case reports as Letter, with publication-date metadata of 2025-12-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41945548-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41945548-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41945548-tirzepatide-v1
- Content SHA-256: `15a1f8b1a75aed0deecdf12fce0fe5b8acd256d4037fa932385778787a8d6629`

### Claims and source pins

#### Headline

Tirzepatide and Autonomic Dysfunction: Insights From Postural Orthostatic Tachycardia Syndrome. ([`pubmed-observation-pmid-41945548-2026-08-13-aab8d817e70d`](#source-pubmed-observation-pmid-41945548-2026-08-13-aab8d817e70d))

#### Summary

PubMed lists PMID 41945548 in JACC. Case reports as Letter, with publication-date metadata of 2025-12-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41945548-2026-08-13-aab8d817e70d`](#source-pubmed-observation-pmid-41945548-2026-08-13-aab8d817e70d))

#### Paragraph 1

PubMed lists PMID 41945548 in JACC. Case reports as Letter, with publication-date metadata of 2025-12-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41945548-2026-08-13-aab8d817e70d`](#source-pubmed-observation-pmid-41945548-2026-08-13-aab8d817e70d))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41945548-2026-08-13-aab8d817e70d`](#source-pubmed-observation-pmid-41945548-2026-08-13-aab8d817e70d))

### Sources

<a id="source-pubmed-observation-pmid-41945548-2026-08-13-aab8d817e70d"></a>
- **Tirzepatide and Autonomic Dysfunction: Insights From Postural Orthostatic Tachycardia Syndrome. · retained source version 1:2026-08-13:current:aab8d817e70dc63edc2c3bc3681b41d4d4a5173d99c09ad0ea8ff381a2ec2096** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41945548/) (`pubmed-observation-pmid-41945548-2026-08-13-aab8d817e70d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide and Autonomic Dysfunction: Insights From Postural Orthostatic Tachycardia Syndrome." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41945548-tirzepatide-v1 SHA-256: 15a1f8b1a75aed0deecdf12fce0fe5b8acd256d4037fa932385778787a8d6629.

---

<a id="pubmed-pmid-41962807-tirzepatide-v1"></a>

## PubMed record PMID 41962807

> PeptideScanner retained PubMed bibliographic metadata for PMID 41962807 at 2026-08-10T18:13:46.844Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-04-10. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-41962807-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-27
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41962807-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41962807-tirzepatide-v1
- Content SHA-256: `e25037178f5b7df6423957cd3df825ddfe493ecd4fd743af81e9eed5d2574c1e`

### Claims and source pins

#### Headline

PubMed record PMID 41962807 ([`pubmed-observation-pmid-41962807-2026-07-27-fa6ee9878d79`](#source-pubmed-observation-pmid-41962807-2026-07-27-fa6ee9878d79))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 41962807 at 2026-08-10T18:13:46.844Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-04-10. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41962807-2026-07-27-fa6ee9878d79`](#source-pubmed-observation-pmid-41962807-2026-07-27-fa6ee9878d79))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 41962807 at 2026-08-10T18:13:46.844Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-04-10. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-41962807-2026-07-27-fa6ee9878d79`](#source-pubmed-observation-pmid-41962807-2026-07-27-fa6ee9878d79))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41962807-2026-07-27-fa6ee9878d79`](#source-pubmed-observation-pmid-41962807-2026-07-27-fa6ee9878d79))

### Sources

<a id="source-pubmed-observation-pmid-41962807-2026-07-27-fa6ee9878d79"></a>
- **PubMed record PMID 41962807 · retained source version 1:2026-07-27:current:fa6ee9878d795ea8a067bda7a96aa340285e798b4fb6cd863d031895756e63f0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41962807/) (`pubmed-observation-pmid-41962807-2026-07-27-fa6ee9878d79`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 41962807." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-41962807-tirzepatide-v1 SHA-256: e25037178f5b7df6423957cd3df825ddfe493ecd4fd743af81e9eed5d2574c1e.

---

<a id="pubmed-pmid-42012431-tirzepatide-v1"></a>

## PubMed record PMID 42012431

> PeptideScanner retained PubMed bibliographic metadata for PMID 42012431 at 2026-08-10T10:49:08.852Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-04-21. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42012431-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42012431-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42012431-tirzepatide-v1
- Content SHA-256: `af65dec4e82931efb1c97e0b769972ff5b8e28a717260e7d69cbb6bea629f294`

### Claims and source pins

#### Headline

PubMed record PMID 42012431 ([`pubmed-observation-pmid-42012431-2026-08-03-4d5954376b21`](#source-pubmed-observation-pmid-42012431-2026-08-03-4d5954376b21))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42012431 at 2026-08-10T10:49:08.852Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-04-21. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42012431-2026-08-03-4d5954376b21`](#source-pubmed-observation-pmid-42012431-2026-08-03-4d5954376b21))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42012431 at 2026-08-10T10:49:08.852Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-04-21. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42012431-2026-08-03-4d5954376b21`](#source-pubmed-observation-pmid-42012431-2026-08-03-4d5954376b21))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42012431-2026-08-03-4d5954376b21`](#source-pubmed-observation-pmid-42012431-2026-08-03-4d5954376b21))

### Sources

<a id="source-pubmed-observation-pmid-42012431-2026-08-03-4d5954376b21"></a>
- **PubMed record PMID 42012431 · retained source version 1:2026-08-03:current:4d5954376b213dc20b93f1dc07def5deed37dec85fedc168f00425c7de3ed90f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42012431/) (`pubmed-observation-pmid-42012431-2026-08-03-4d5954376b21`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42012431." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42012431-tirzepatide-v1 SHA-256: af65dec4e82931efb1c97e0b769972ff5b8e28a717260e7d69cbb6bea629f294.

---

<a id="pubmed-pmid-42043833-tirzepatide-v1"></a>

## Understanding Weight Regain After Tirzepatide Withdrawal.

> PubMed lists PMID 42043833 in JAMA internal medicine as Journal Article, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42043833-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-01
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42043833-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42043833-tirzepatide-v1
- Content SHA-256: `9d59ca67cc3bf46f171fb01011b20fd53af6d027bd80cbbf1cd27e35dd5b2109`

### Claims and source pins

#### Headline

Understanding Weight Regain After Tirzepatide Withdrawal. ([`pubmed-observation-pmid-42043833-2026-06-01-9d04721a216f`](#source-pubmed-observation-pmid-42043833-2026-06-01-9d04721a216f))

#### Summary

PubMed lists PMID 42043833 in JAMA internal medicine as Journal Article, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42043833-2026-06-01-9d04721a216f`](#source-pubmed-observation-pmid-42043833-2026-06-01-9d04721a216f))

#### Paragraph 1

PubMed lists PMID 42043833 in JAMA internal medicine as Journal Article, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42043833-2026-06-01-9d04721a216f`](#source-pubmed-observation-pmid-42043833-2026-06-01-9d04721a216f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42043833-2026-06-01-9d04721a216f`](#source-pubmed-observation-pmid-42043833-2026-06-01-9d04721a216f))

### Sources

<a id="source-pubmed-observation-pmid-42043833-2026-06-01-9d04721a216f"></a>
- **Understanding Weight Regain After Tirzepatide Withdrawal. · retained source version 1:2026-06-01:current:9d04721a216ff4e95bbf2d266c3aed0b94d6e5aee47f97e709364f28a631eaf0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42043833/) (`pubmed-observation-pmid-42043833-2026-06-01-9d04721a216f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Understanding Weight Regain After Tirzepatide Withdrawal." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42043833-tirzepatide-v1 SHA-256: 9d59ca67cc3bf46f171fb01011b20fd53af6d027bd80cbbf1cd27e35dd5b2109.

---

<a id="pubmed-pmid-42075085-tirzepatide-v1"></a>

## Real-Life Data of Tirzepatide Use to Support Lifestyle Modification in Patients with Metabolic Syndrome.

> PubMed lists PMID 42075085 in Nutrients as Journal Article, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42075085-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-16
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42075085-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42075085-tirzepatide-v1
- Content SHA-256: `2453012af05bb263548ec8e70575dc4624e5343724594bc84aab329561d23aff`

### Claims and source pins

#### Headline

Real-Life Data of Tirzepatide Use to Support Lifestyle Modification in Patients with Metabolic Syndrome. ([`pubmed-observation-pmid-42075085-2026-07-16-b0a2ef558bea`](#source-pubmed-observation-pmid-42075085-2026-07-16-b0a2ef558bea))

#### Summary

PubMed lists PMID 42075085 in Nutrients as Journal Article, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42075085-2026-07-16-b0a2ef558bea`](#source-pubmed-observation-pmid-42075085-2026-07-16-b0a2ef558bea))

#### Paragraph 1

PubMed lists PMID 42075085 in Nutrients as Journal Article, with publication-date metadata of 2026-04-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42075085-2026-07-16-b0a2ef558bea`](#source-pubmed-observation-pmid-42075085-2026-07-16-b0a2ef558bea))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42075085-2026-07-16-b0a2ef558bea`](#source-pubmed-observation-pmid-42075085-2026-07-16-b0a2ef558bea))

### Sources

<a id="source-pubmed-observation-pmid-42075085-2026-07-16-b0a2ef558bea"></a>
- **Real-Life Data of Tirzepatide Use to Support Lifestyle Modification in Patients with Metabolic Syndrome. · retained source version 1:2026-07-16:current:b0a2ef558bea579f66d6855fb5f5ec4356393fc591f5218557d725856b6b5764** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42075085/) (`pubmed-observation-pmid-42075085-2026-07-16-b0a2ef558bea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Real-Life Data of Tirzepatide Use to Support Lifestyle Modification in Patients with Metabolic Syndrome." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42075085-tirzepatide-v1 SHA-256: 2453012af05bb263548ec8e70575dc4624e5343724594bc84aab329561d23aff.

---

<a id="pubmed-pmid-42082865-tirzepatide-v1"></a>

## Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1.

> PubMed lists PMID 42082865 in Journal of endocrinological investigation as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, with publication-date metadata of 2026-05-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42082865-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-16
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42082865-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42082865-tirzepatide-v1
- Content SHA-256: `00488bdfc10bd32e64ec8ed924bbe23f87be713efba258dbacbc8698620a54a1`

### Claims and source pins

#### Headline

Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1. ([`pubmed-observation-pmid-42082865-2026-07-16-62931f6734d2`](#source-pubmed-observation-pmid-42082865-2026-07-16-62931f6734d2))

#### Summary

PubMed lists PMID 42082865 in Journal of endocrinological investigation as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, with publication-date metadata of 2026-05-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42082865-2026-07-16-62931f6734d2`](#source-pubmed-observation-pmid-42082865-2026-07-16-62931f6734d2))

#### Paragraph 1

PubMed lists PMID 42082865 in Journal of endocrinological investigation as Journal Article, Randomized Controlled Trial, Clinical Trial, Phase III, with publication-date metadata of 2026-05-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42082865-2026-07-16-62931f6734d2`](#source-pubmed-observation-pmid-42082865-2026-07-16-62931f6734d2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42082865-2026-07-16-62931f6734d2`](#source-pubmed-observation-pmid-42082865-2026-07-16-62931f6734d2))

### Sources

<a id="source-pubmed-observation-pmid-42082865-2026-07-16-62931f6734d2"></a>
- **Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1. · retained source version 1:2026-07-16:current:62931f6734d20b2a14d7915bc2c92be693efcfa2c72a1a981b7358830d345b81** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42082865/) (`pubmed-observation-pmid-42082865-2026-07-16-62931f6734d2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Shifts in waist-to-height ratio categories within tirzepatide groups: a post-hoc analysis of SURMOUNT-1." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42082865-tirzepatide-v1 SHA-256: 00488bdfc10bd32e64ec8ed924bbe23f87be713efba258dbacbc8698620a54a1.

---

<a id="pubmed-pmid-42088720-tirzepatide-v1"></a>

## Facial nodules following filler injections after initiating compounded tirzepatide use.

> PubMed lists PMID 42088720 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-03-27 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42088720-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42088720-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42088720-tirzepatide-v1
- Content SHA-256: `87d5901e86e46cc665e2dbd19ea5685ca03c6339d7e999b2a824bfece5448a51`

### Claims and source pins

#### Headline

Facial nodules following filler injections after initiating compounded tirzepatide use. ([`pubmed-observation-pmid-42088720-2026-08-13-f19c1f56cf97`](#source-pubmed-observation-pmid-42088720-2026-08-13-f19c1f56cf97))

#### Summary

PubMed lists PMID 42088720 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-03-27 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42088720-2026-08-13-f19c1f56cf97`](#source-pubmed-observation-pmid-42088720-2026-08-13-f19c1f56cf97))

#### Paragraph 1

PubMed lists PMID 42088720 in JAAD case reports as Case Reports, Journal Article, with publication-date metadata of 2026-03-27 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42088720-2026-08-13-f19c1f56cf97`](#source-pubmed-observation-pmid-42088720-2026-08-13-f19c1f56cf97))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42088720-2026-08-13-f19c1f56cf97`](#source-pubmed-observation-pmid-42088720-2026-08-13-f19c1f56cf97))

### Sources

<a id="source-pubmed-observation-pmid-42088720-2026-08-13-f19c1f56cf97"></a>
- **Facial nodules following filler injections after initiating compounded tirzepatide use. · retained source version 1:2026-08-13:current:f19c1f56cf97585736ca43a7c637b247f65c571a0f50e378324f44bb1caa47c5** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42088720/) (`pubmed-observation-pmid-42088720-2026-08-13-f19c1f56cf97`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Facial nodules following filler injections after initiating compounded tirzepatide use." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42088720-tirzepatide-v1 SHA-256: 87d5901e86e46cc665e2dbd19ea5685ca03c6339d7e999b2a824bfece5448a51.

---

<a id="pubmed-pmid-42136855-tirzepatide-v1"></a>

## GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives.

> PubMed lists PMID 42136855 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2026-04-29 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42136855-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-05-15
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42136855-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42136855-tirzepatide-v1
- Content SHA-256: `24dbc98fa704a71e9cc02b578133e930825cb47e21fe59dffe304cc6aa89a257`

### Claims and source pins

#### Headline

GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives. ([`pubmed-observation-pmid-42136855-2026-05-15-8c651c83f6d4`](#source-pubmed-observation-pmid-42136855-2026-05-15-8c651c83f6d4))

#### Summary

PubMed lists PMID 42136855 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2026-04-29 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42136855-2026-05-15-8c651c83f6d4`](#source-pubmed-observation-pmid-42136855-2026-05-15-8c651c83f6d4))

#### Paragraph 1

PubMed lists PMID 42136855 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2026-04-29 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42136855-2026-05-15-8c651c83f6d4`](#source-pubmed-observation-pmid-42136855-2026-05-15-8c651c83f6d4))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42136855-2026-05-15-8c651c83f6d4`](#source-pubmed-observation-pmid-42136855-2026-05-15-8c651c83f6d4))

### Sources

<a id="source-pubmed-observation-pmid-42136855-2026-05-15-8c651c83f6d4"></a>
- **GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives. · retained source version 1:2026-05-15:current:8c651c83f6d4aaa37355c4997fdb7cfe04b16f75cc31c285049aa197191d917a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42136855/) (`pubmed-observation-pmid-42136855-2026-05-15-8c651c83f6d4`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "GLP-1/GIP dual agonist tirzepatide in obstructive sleep apnea syndrome: mechanisms, evidence, and clinical perspectives." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42136855-tirzepatide-v1 SHA-256: 24dbc98fa704a71e9cc02b578133e930825cb47e21fe59dffe304cc6aa89a257.

---

<a id="pubmed-pmid-42151574-tirzepatide-v1"></a>

## Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide.

> PubMed lists PMID 42151574 in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine as Published Erratum, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42151574-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-26
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42151574-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42151574-tirzepatide-v1
- Content SHA-256: `ccd53569f5d052c360c9bae3c1de01a4e52730f83cdb5c2f0f8fc15aefab93db`

### Claims and source pins

#### Headline

Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide. ([`pubmed-observation-pmid-42151574-2026-06-26-ac31cc7ff175`](#source-pubmed-observation-pmid-42151574-2026-06-26-ac31cc7ff175))

#### Summary

PubMed lists PMID 42151574 in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine as Published Erratum, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42151574-2026-06-26-ac31cc7ff175`](#source-pubmed-observation-pmid-42151574-2026-06-26-ac31cc7ff175))

#### Paragraph 1

PubMed lists PMID 42151574 in Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine as Published Erratum, with publication-date metadata of 2026-05-18 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42151574-2026-06-26-ac31cc7ff175`](#source-pubmed-observation-pmid-42151574-2026-06-26-ac31cc7ff175))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42151574-2026-06-26-ac31cc7ff175`](#source-pubmed-observation-pmid-42151574-2026-06-26-ac31cc7ff175))

### Sources

<a id="source-pubmed-observation-pmid-42151574-2026-06-26-ac31cc7ff175"></a>
- **Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide. · retained source version 1:2026-06-26:current:ac31cc7ff175cdb4039cbce8d233a7f5b3390d9c9f6c86ae33ccdf3240762921** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42151574/) (`pubmed-observation-pmid-42151574-2026-06-26-ac31cc7ff175`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Correction: Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42151574-tirzepatide-v1 SHA-256: ccd53569f5d052c360c9bae3c1de01a4e52730f83cdb5c2f0f8fc15aefab93db.

---

<a id="pubmed-pmid-42155604-tirzepatide-v1"></a>

## Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation.

> PubMed lists PMID 42155604 in Diabetes research and clinical practice as Letter, with publication-date metadata of 2026-05-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42155604-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-06
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42155604-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42155604-tirzepatide-v1
- Content SHA-256: `af8eca972f687400e4763ad8de3e57551409cf454bddaeb0075e29ccc33a919e`

### Claims and source pins

#### Headline

Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation. ([`pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39`](#source-pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39))

#### Summary

PubMed lists PMID 42155604 in Diabetes research and clinical practice as Letter, with publication-date metadata of 2026-05-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39`](#source-pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39))

#### Paragraph 1

PubMed lists PMID 42155604 in Diabetes research and clinical practice as Letter, with publication-date metadata of 2026-05-19 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39`](#source-pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39`](#source-pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39))

### Sources

<a id="source-pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39"></a>
- **Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation. · retained source version 1:2026-06-06:current:3ec65c22ac3905250f69163294adeb6b784d67850a8073ac13b1ae0550327d40** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42155604/) (`pubmed-observation-pmid-42155604-2026-06-06-3ec65c22ac39`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Early cardiovascular-kidney-metabolic progression with tirzepatide: population definition and clinical interpretation." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42155604-tirzepatide-v1 SHA-256: af8eca972f687400e4763ad8de3e57551409cf454bddaeb0075e29ccc33a919e.

---

<a id="pubmed-pmid-42233554-tirzepatide-v1"></a>

## On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT.

> PubMed lists PMID 42233554 in Journal of the American College of Cardiology as Journal Article, with publication-date metadata of 2026-06-02 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42233554-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-03
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42233554-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42233554-tirzepatide-v1
- Content SHA-256: `d07a2073af371a98e1fff2f751fb45b1a11b7a45ae597562ebee7c852f9c77bc`

### Claims and source pins

#### Headline

On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT. ([`pubmed-observation-pmid-42233554-2026-06-03-9f27e6800a3c`](#source-pubmed-observation-pmid-42233554-2026-06-03-9f27e6800a3c))

#### Summary

PubMed lists PMID 42233554 in Journal of the American College of Cardiology as Journal Article, with publication-date metadata of 2026-06-02 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42233554-2026-06-03-9f27e6800a3c`](#source-pubmed-observation-pmid-42233554-2026-06-03-9f27e6800a3c))

#### Paragraph 1

PubMed lists PMID 42233554 in Journal of the American College of Cardiology as Journal Article, with publication-date metadata of 2026-06-02 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42233554-2026-06-03-9f27e6800a3c`](#source-pubmed-observation-pmid-42233554-2026-06-03-9f27e6800a3c))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42233554-2026-06-03-9f27e6800a3c`](#source-pubmed-observation-pmid-42233554-2026-06-03-9f27e6800a3c))

### Sources

<a id="source-pubmed-observation-pmid-42233554-2026-06-03-9f27e6800a3c"></a>
- **On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT. · retained source version 1:2026-06-03:current:9f27e6800a3cff36bd0e6e2547002d20b2a5a3ffd2d59a42bab4aeb1b732099b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42233554/) (`pubmed-observation-pmid-42233554-2026-06-03-9f27e6800a3c`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "On the Noninferiority of Tirzepatide: Insights From SURPASS-CVOT." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42233554-tirzepatide-v1 SHA-256: d07a2073af371a98e1fff2f751fb45b1a11b7a45ae597562ebee7c852f9c77bc.

---

<a id="pubmed-pmid-42260100-tirzepatide-v1"></a>

## PubMed record PMID 42260100

> PeptideScanner retained PubMed bibliographic metadata for PMID 42260100 at 2026-08-10T18:13:52.233Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-08. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42260100-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42260100-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42260100-tirzepatide-v1
- Content SHA-256: `99e39758aeebdd79ecfab4f33aa28a67804d8473a0d18a4e9e4a3ef00abb2426`

### Claims and source pins

#### Headline

PubMed record PMID 42260100 ([`pubmed-observation-pmid-42260100-2026-07-26-51c81b27e479`](#source-pubmed-observation-pmid-42260100-2026-07-26-51c81b27e479))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42260100 at 2026-08-10T18:13:52.233Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-08. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42260100-2026-07-26-51c81b27e479`](#source-pubmed-observation-pmid-42260100-2026-07-26-51c81b27e479))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42260100 at 2026-08-10T18:13:52.233Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-08. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42260100-2026-07-26-51c81b27e479`](#source-pubmed-observation-pmid-42260100-2026-07-26-51c81b27e479))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42260100-2026-07-26-51c81b27e479`](#source-pubmed-observation-pmid-42260100-2026-07-26-51c81b27e479))

### Sources

<a id="source-pubmed-observation-pmid-42260100-2026-07-26-51c81b27e479"></a>
- **PubMed record PMID 42260100 · retained source version 1:2026-07-26:current:51c81b27e4798c80284502efc8d28cc02bccbe7f914749b4b7f53378b7fba0e7** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42260100/) (`pubmed-observation-pmid-42260100-2026-07-26-51c81b27e479`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42260100." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42260100-tirzepatide-v1 SHA-256: 99e39758aeebdd79ecfab4f33aa28a67804d8473a0d18a4e9e4a3ef00abb2426.

---

<a id="pubmed-pmid-42275945-tirzepatide-v1"></a>

## PubMed record PMID 42275945

> PeptideScanner retained PubMed bibliographic metadata for PMID 42275945 at 2026-08-10T10:49:10.676Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-06-11. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42275945-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42275945-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42275945-tirzepatide-v1
- Content SHA-256: `862f2774b1065656972a722a4138b5e93005ab8042e4874281975b873987ad5c`

### Claims and source pins

#### Headline

PubMed record PMID 42275945 ([`pubmed-observation-pmid-42275945-2026-08-05-02988959baba`](#source-pubmed-observation-pmid-42275945-2026-08-05-02988959baba))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42275945 at 2026-08-10T10:49:10.676Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-06-11. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42275945-2026-08-05-02988959baba`](#source-pubmed-observation-pmid-42275945-2026-08-05-02988959baba))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42275945 at 2026-08-10T10:49:10.676Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-06-11. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42275945-2026-08-05-02988959baba`](#source-pubmed-observation-pmid-42275945-2026-08-05-02988959baba))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42275945-2026-08-05-02988959baba`](#source-pubmed-observation-pmid-42275945-2026-08-05-02988959baba))

### Sources

<a id="source-pubmed-observation-pmid-42275945-2026-08-05-02988959baba"></a>
- **PubMed record PMID 42275945 · retained source version 1:2026-08-05:current:02988959baba2db6f3d7531e2adad183b9aa7998fc52f4c629b845eaa2072f3d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42275945/) (`pubmed-observation-pmid-42275945-2026-08-05-02988959baba`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42275945." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42275945-tirzepatide-v1 SHA-256: 862f2774b1065656972a722a4138b5e93005ab8042e4874281975b873987ad5c.

---

<a id="pubmed-pmid-42289805-tirzepatide-v1"></a>

## PubMed record PMID 42289805

> PeptideScanner retained PubMed bibliographic metadata for PMID 42289805 at 2026-08-10T10:49:10.680Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42289805-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42289805-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42289805-tirzepatide-v1
- Content SHA-256: `2ba0112e496eeb1e80e23f3aa6b4d7cd55dc260fc4a46a635f0f70dbd8bfb3e0`

### Claims and source pins

#### Headline

PubMed record PMID 42289805 ([`pubmed-observation-pmid-42289805-2026-08-03-7ce80318b3ce`](#source-pubmed-observation-pmid-42289805-2026-08-03-7ce80318b3ce))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42289805 at 2026-08-10T10:49:10.680Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42289805-2026-08-03-7ce80318b3ce`](#source-pubmed-observation-pmid-42289805-2026-08-03-7ce80318b3ce))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42289805 at 2026-08-10T10:49:10.680Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-06-15. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42289805-2026-08-03-7ce80318b3ce`](#source-pubmed-observation-pmid-42289805-2026-08-03-7ce80318b3ce))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42289805-2026-08-03-7ce80318b3ce`](#source-pubmed-observation-pmid-42289805-2026-08-03-7ce80318b3ce))

### Sources

<a id="source-pubmed-observation-pmid-42289805-2026-08-03-7ce80318b3ce"></a>
- **PubMed record PMID 42289805 · retained source version 1:2026-08-03:current:7ce80318b3ce111ba548b82bd0b9a31ff521bdb2e26b9bfabac6674c265fad02** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42289805/) (`pubmed-observation-pmid-42289805-2026-08-03-7ce80318b3ce`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42289805." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42289805-tirzepatide-v1 SHA-256: 2ba0112e496eeb1e80e23f3aa6b4d7cd55dc260fc4a46a635f0f70dbd8bfb3e0.

---

<a id="pubmed-pmid-42304199-tirzepatide-v1"></a>

## PubMed record PMID 42304199

> PeptideScanner retained PubMed bibliographic metadata for PMID 42304199 at 2026-08-10T10:49:10.691Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-16. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42304199-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42304199-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42304199-tirzepatide-v1
- Content SHA-256: `62ff99b5e332fcb452e5090a16fbc9b40b1a07cc0fa6b6e0a3afc153641af59f`

### Claims and source pins

#### Headline

PubMed record PMID 42304199 ([`pubmed-observation-pmid-42304199-2026-08-09-96a0c2b66905`](#source-pubmed-observation-pmid-42304199-2026-08-09-96a0c2b66905))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42304199 at 2026-08-10T10:49:10.691Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-16. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42304199-2026-08-09-96a0c2b66905`](#source-pubmed-observation-pmid-42304199-2026-08-09-96a0c2b66905))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42304199 at 2026-08-10T10:49:10.691Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-16. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42304199-2026-08-09-96a0c2b66905`](#source-pubmed-observation-pmid-42304199-2026-08-09-96a0c2b66905))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42304199-2026-08-09-96a0c2b66905`](#source-pubmed-observation-pmid-42304199-2026-08-09-96a0c2b66905))

### Sources

<a id="source-pubmed-observation-pmid-42304199-2026-08-09-96a0c2b66905"></a>
- **PubMed record PMID 42304199 · retained source version 1:2026-08-09:current:96a0c2b66905e2d95dcb27c128ad3ba1bfd3be05f093542c304fb53b35271d2b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42304199/) (`pubmed-observation-pmid-42304199-2026-08-09-96a0c2b66905`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42304199." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42304199-tirzepatide-v1 SHA-256: 62ff99b5e332fcb452e5090a16fbc9b40b1a07cc0fa6b6e0a3afc153641af59f.

---

<a id="pubmed-pmid-42307617-tirzepatide-v1"></a>

## PubMed record PMID 42307617

> PeptideScanner retained PubMed bibliographic metadata for PMID 42307617 at 2026-08-10T18:13:52.282Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-17. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42307617-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42307617-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42307617-tirzepatide-v1
- Content SHA-256: `7d67566c1ae2f7a7bddd5420303184be5dfb4254f205b87c2720970ad340c4ac`

### Claims and source pins

#### Headline

PubMed record PMID 42307617 ([`pubmed-observation-pmid-42307617-2026-07-26-29aff2e9b84f`](#source-pubmed-observation-pmid-42307617-2026-07-26-29aff2e9b84f))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42307617 at 2026-08-10T18:13:52.282Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-17. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42307617-2026-07-26-29aff2e9b84f`](#source-pubmed-observation-pmid-42307617-2026-07-26-29aff2e9b84f))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42307617 at 2026-08-10T18:13:52.282Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-06-17. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42307617-2026-07-26-29aff2e9b84f`](#source-pubmed-observation-pmid-42307617-2026-07-26-29aff2e9b84f))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42307617-2026-07-26-29aff2e9b84f`](#source-pubmed-observation-pmid-42307617-2026-07-26-29aff2e9b84f))

### Sources

<a id="source-pubmed-observation-pmid-42307617-2026-07-26-29aff2e9b84f"></a>
- **PubMed record PMID 42307617 · retained source version 1:2026-07-26:current:29aff2e9b84f7b71a16ef6358213b34aa736cca82fb0add318efc8ebd3d8fc73** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42307617/) (`pubmed-observation-pmid-42307617-2026-07-26-29aff2e9b84f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42307617." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42307617-tirzepatide-v1 SHA-256: 7d67566c1ae2f7a7bddd5420303184be5dfb4254f205b87c2720970ad340c4ac.

---

<a id="pubmed-pmid-42329593-tirzepatide-v1"></a>

## Residual gastric content after tirzepatide discontinuation: is one week enough?

> PubMed lists PMID 42329593 in Minerva anestesiologica as Journal Article, with publication-date metadata of 2026-06-22 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42329593-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-22
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42329593-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42329593-tirzepatide-v1
- Content SHA-256: `ba83d64f13cdfd12f6a94d181ad752988704e215767b470a0a4e0ec0eaa4ea6f`

### Claims and source pins

#### Headline

Residual gastric content after tirzepatide discontinuation: is one week enough? ([`pubmed-observation-pmid-42329593-2026-06-22-992ec890b43e`](#source-pubmed-observation-pmid-42329593-2026-06-22-992ec890b43e))

#### Summary

PubMed lists PMID 42329593 in Minerva anestesiologica as Journal Article, with publication-date metadata of 2026-06-22 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42329593-2026-06-22-992ec890b43e`](#source-pubmed-observation-pmid-42329593-2026-06-22-992ec890b43e))

#### Paragraph 1

PubMed lists PMID 42329593 in Minerva anestesiologica as Journal Article, with publication-date metadata of 2026-06-22 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42329593-2026-06-22-992ec890b43e`](#source-pubmed-observation-pmid-42329593-2026-06-22-992ec890b43e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42329593-2026-06-22-992ec890b43e`](#source-pubmed-observation-pmid-42329593-2026-06-22-992ec890b43e))

### Sources

<a id="source-pubmed-observation-pmid-42329593-2026-06-22-992ec890b43e"></a>
- **Residual gastric content after tirzepatide discontinuation: is one week enough? · retained source version 1:2026-06-22:current:992ec890b43eefa524f446c306c946ef7019d370c251e7903d960fd4e60e04f0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42329593/) (`pubmed-observation-pmid-42329593-2026-06-22-992ec890b43e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Residual gastric content after tirzepatide discontinuation: is one week enough?" Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42329593-tirzepatide-v1 SHA-256: ba83d64f13cdfd12f6a94d181ad752988704e215767b470a0a4e0ec0eaa4ea6f.

---

<a id="pubmed-pmid-42334799-tirzepatide-v1"></a>

## Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study.

> PubMed lists PMID 42334799 in Advances in therapy as Journal Article, with publication-date metadata of 2026-06-23 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42334799-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-23
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42334799-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42334799-tirzepatide-v1
- Content SHA-256: `f33bc3ebe5a08151bbed8e9c1747f67e667da97d28c84bc371caa2f63679c627`

### Claims and source pins

#### Headline

Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study. ([`pubmed-observation-pmid-42334799-2026-06-23-e4a6cca58758`](#source-pubmed-observation-pmid-42334799-2026-06-23-e4a6cca58758))

#### Summary

PubMed lists PMID 42334799 in Advances in therapy as Journal Article, with publication-date metadata of 2026-06-23 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42334799-2026-06-23-e4a6cca58758`](#source-pubmed-observation-pmid-42334799-2026-06-23-e4a6cca58758))

#### Paragraph 1

PubMed lists PMID 42334799 in Advances in therapy as Journal Article, with publication-date metadata of 2026-06-23 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42334799-2026-06-23-e4a6cca58758`](#source-pubmed-observation-pmid-42334799-2026-06-23-e4a6cca58758))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42334799-2026-06-23-e4a6cca58758`](#source-pubmed-observation-pmid-42334799-2026-06-23-e4a6cca58758))

### Sources

<a id="source-pubmed-observation-pmid-42334799-2026-06-23-e4a6cca58758"></a>
- **Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study. · retained source version 1:2026-06-23:current:e4a6cca587584fd8b898738be612b59523ff80703228ba0cb82d9f14b1027c56** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42334799/) (`pubmed-observation-pmid-42334799-2026-06-23-e4a6cca58758`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Experience with Tirzepatide and Weight Management During and After a Clinical Trial in Japanese Patients with Obesity Disease: A Qualitative Study." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42334799-tirzepatide-v1 SHA-256: f33bc3ebe5a08151bbed8e9c1747f67e667da97d28c84bc371caa2f63679c627.

---

<a id="pubmed-pmid-42348366-tirzepatide-v1"></a>

## PubMed record PMID 42348366

> PeptideScanner retained PubMed bibliographic metadata for PMID 42348366 at 2026-08-10T10:49:10.723Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-25. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42348366-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42348366-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42348366-tirzepatide-v1
- Content SHA-256: `4f63fdf77de2eec549d24307f0f32bbd81178ebfb4e75382d4401acca4d7e28c`

### Claims and source pins

#### Headline

PubMed record PMID 42348366 ([`pubmed-observation-pmid-42348366-2026-08-09-1392c988b9de`](#source-pubmed-observation-pmid-42348366-2026-08-09-1392c988b9de))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42348366 at 2026-08-10T10:49:10.723Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-25. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42348366-2026-08-09-1392c988b9de`](#source-pubmed-observation-pmid-42348366-2026-08-09-1392c988b9de))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42348366 at 2026-08-10T10:49:10.723Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-06-25. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42348366-2026-08-09-1392c988b9de`](#source-pubmed-observation-pmid-42348366-2026-08-09-1392c988b9de))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42348366-2026-08-09-1392c988b9de`](#source-pubmed-observation-pmid-42348366-2026-08-09-1392c988b9de))

### Sources

<a id="source-pubmed-observation-pmid-42348366-2026-08-09-1392c988b9de"></a>
- **PubMed record PMID 42348366 · retained source version 1:2026-08-09:current:1392c988b9de89d3b8ccb050d652bba047b1464bb0c51ef033fde4c6f30cb0b1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42348366/) (`pubmed-observation-pmid-42348366-2026-08-09-1392c988b9de`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42348366." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42348366-tirzepatide-v1 SHA-256: 4f63fdf77de2eec549d24307f0f32bbd81178ebfb4e75382d4401acca4d7e28c.

---

<a id="pubmed-pmid-42373101-tirzepatide-v1"></a>

## Can the NHS afford Mounjaro? It spent £574m on the jab last year despite most eligible patients not getting it.

> PubMed lists PMID 42373101 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-06-28 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42373101-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-06-29
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42373101-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42373101-tirzepatide-v1
- Content SHA-256: `5396770d507de826e5213ba1dd12904484bf2beb85ef25ee35d0a0c90d381a33`

### Claims and source pins

#### Headline

Can the NHS afford Mounjaro? It spent £574m on the jab last year despite most eligible patients not getting it. ([`pubmed-observation-pmid-42373101-2026-06-29-6b0d19232bf2`](#source-pubmed-observation-pmid-42373101-2026-06-29-6b0d19232bf2))

#### Summary

PubMed lists PMID 42373101 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-06-28 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42373101-2026-06-29-6b0d19232bf2`](#source-pubmed-observation-pmid-42373101-2026-06-29-6b0d19232bf2))

#### Paragraph 1

PubMed lists PMID 42373101 in BMJ (Clinical research ed.) as Journal Article, with publication-date metadata of 2026-06-28 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42373101-2026-06-29-6b0d19232bf2`](#source-pubmed-observation-pmid-42373101-2026-06-29-6b0d19232bf2))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42373101-2026-06-29-6b0d19232bf2`](#source-pubmed-observation-pmid-42373101-2026-06-29-6b0d19232bf2))

### Sources

<a id="source-pubmed-observation-pmid-42373101-2026-06-29-6b0d19232bf2"></a>
- **Can the NHS afford Mounjaro? It spent £574m on the jab last year despite most eligible patients not getting it. · retained source version 1:2026-06-29:current:6b0d19232bf2cb7bac16217fccab8b0e92ea721271146662626c21d172d03874** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42373101/) (`pubmed-observation-pmid-42373101-2026-06-29-6b0d19232bf2`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Can the NHS afford Mounjaro? It spent £574m on the jab last year despite most eligible patients not getting it." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42373101-tirzepatide-v1 SHA-256: 5396770d507de826e5213ba1dd12904484bf2beb85ef25ee35d0a0c90d381a33.

---

<a id="pubmed-pmid-42387290-tirzepatide-v1"></a>

## PubMed record PMID 42387290

> PeptideScanner retained PubMed bibliographic metadata for PMID 42387290 at 2026-08-10T10:49:10.738Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-02. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42387290-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-09
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42387290-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42387290-tirzepatide-v1
- Content SHA-256: `826cfc216405598d877b4875a55eed7765c8e519a322d98d05b8b8fcec362d53`

### Claims and source pins

#### Headline

PubMed record PMID 42387290 ([`pubmed-observation-pmid-42387290-2026-08-09-b5f916b37119`](#source-pubmed-observation-pmid-42387290-2026-08-09-b5f916b37119))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42387290 at 2026-08-10T10:49:10.738Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-02. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42387290-2026-08-09-b5f916b37119`](#source-pubmed-observation-pmid-42387290-2026-08-09-b5f916b37119))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42387290 at 2026-08-10T10:49:10.738Z. PubMed recorded a metadata revision date of 2026-08-09 and an Entrez history date of 2026-07-02. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42387290-2026-08-09-b5f916b37119`](#source-pubmed-observation-pmid-42387290-2026-08-09-b5f916b37119))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42387290-2026-08-09-b5f916b37119`](#source-pubmed-observation-pmid-42387290-2026-08-09-b5f916b37119))

### Sources

<a id="source-pubmed-observation-pmid-42387290-2026-08-09-b5f916b37119"></a>
- **PubMed record PMID 42387290 · retained source version 1:2026-08-09:current:b5f916b371196905e2dba3c1804ef9adecaae2421c2d2b6d236ad65b44f731d2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42387290/) (`pubmed-observation-pmid-42387290-2026-08-09-b5f916b37119`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42387290." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42387290-tirzepatide-v1 SHA-256: 826cfc216405598d877b4875a55eed7765c8e519a322d98d05b8b8fcec362d53.

---

<a id="pubmed-pmid-42388932-tirzepatide-v1"></a>

## Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review.

> PubMed lists PMID 42388932 in Cureus as Published Erratum, Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42388932-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42388932-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42388932-tirzepatide-v1
- Content SHA-256: `2ff3d6cea0ec10a31b0ff59b72d31fd9536937e805277ce86ce633213d73c3dd`

### Claims and source pins

#### Headline

Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review. ([`pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522`](#source-pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522))

#### Summary

PubMed lists PMID 42388932 in Cureus as Published Erratum, Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522`](#source-pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522))

#### Paragraph 1

PubMed lists PMID 42388932 in Cureus as Published Erratum, Journal Article, with publication-date metadata of 2026-06-30 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522`](#source-pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522`](#source-pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522))

### Sources

<a id="source-pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522"></a>
- **Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review. · retained source version 1:2026-07-06:current:5f567d3e452268241bfe8b38e9cb67d478ecfc199e088ed494e40b8723452f3b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42388932/) (`pubmed-observation-pmid-42388932-2026-07-06-5f567d3e4522`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Correction: Clinical Implications of Mounjaro (Tirzepatide) for Breast Cancer Detection and Management: A Narrative Review." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42388932-tirzepatide-v1 SHA-256: 2ff3d6cea0ec10a31b0ff59b72d31fd9536937e805277ce86ce633213d73c3dd.

---

<a id="pubmed-pmid-42464179-tirzepatide-v1"></a>

## PubMed record PMID 42464179

> PeptideScanner retained PubMed bibliographic metadata for PMID 42464179 at 2026-08-10T18:13:55.290Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-17. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42464179-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-26
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42464179-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42464179-tirzepatide-v1
- Content SHA-256: `d09dacd74369c614889c3206150c21f6047428c74cf377ced7444aff67605567`

### Claims and source pins

#### Headline

PubMed record PMID 42464179 ([`pubmed-observation-pmid-42464179-2026-07-26-9bdc2c8ad249`](#source-pubmed-observation-pmid-42464179-2026-07-26-9bdc2c8ad249))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42464179 at 2026-08-10T18:13:55.290Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-17. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42464179-2026-07-26-9bdc2c8ad249`](#source-pubmed-observation-pmid-42464179-2026-07-26-9bdc2c8ad249))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42464179 at 2026-08-10T18:13:55.290Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-07-17. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42464179-2026-07-26-9bdc2c8ad249`](#source-pubmed-observation-pmid-42464179-2026-07-26-9bdc2c8ad249))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42464179-2026-07-26-9bdc2c8ad249`](#source-pubmed-observation-pmid-42464179-2026-07-26-9bdc2c8ad249))

### Sources

<a id="source-pubmed-observation-pmid-42464179-2026-07-26-9bdc2c8ad249"></a>
- **PubMed record PMID 42464179 · retained source version 1:2026-07-26:current:9bdc2c8ad2496bcfdb96ca0b7cd0ed8269eb91873a39f43978359956af398c9e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42464179/) (`pubmed-observation-pmid-42464179-2026-07-26-9bdc2c8ad249`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42464179." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42464179-tirzepatide-v1 SHA-256: d09dacd74369c614889c3206150c21f6047428c74cf377ced7444aff67605567.

---

<a id="pubmed-pmid-42487213-tirzepatide-v1"></a>

## PubMed record PMID 42487213

> PeptideScanner retained PubMed bibliographic metadata for PMID 42487213 at 2026-08-10T10:49:10.780Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42487213-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42487213-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42487213-tirzepatide-v1
- Content SHA-256: `b7eadd3e9519e48078a6a1de4153c20be162b693db0ce97bcc602b34e3368d62`

### Claims and source pins

#### Headline

PubMed record PMID 42487213 ([`pubmed-observation-pmid-42487213-2026-07-30-adae24d2865f`](#source-pubmed-observation-pmid-42487213-2026-07-30-adae24d2865f))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42487213 at 2026-08-10T10:49:10.780Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42487213-2026-07-30-adae24d2865f`](#source-pubmed-observation-pmid-42487213-2026-07-30-adae24d2865f))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42487213 at 2026-08-10T10:49:10.780Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-23. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42487213-2026-07-30-adae24d2865f`](#source-pubmed-observation-pmid-42487213-2026-07-30-adae24d2865f))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42487213-2026-07-30-adae24d2865f`](#source-pubmed-observation-pmid-42487213-2026-07-30-adae24d2865f))

### Sources

<a id="source-pubmed-observation-pmid-42487213-2026-07-30-adae24d2865f"></a>
- **PubMed record PMID 42487213 · retained source version 1:2026-07-30:current:adae24d2865f99469e80dfd1de62f10b4128d0c1e0215f5f9645be7763add7e2** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42487213/) (`pubmed-observation-pmid-42487213-2026-07-30-adae24d2865f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42487213." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42487213-tirzepatide-v1 SHA-256: b7eadd3e9519e48078a6a1de4153c20be162b693db0ce97bcc602b34e3368d62.

---

<a id="pubmed-pmid-42507846-tirzepatide-v1"></a>

## PubMed record PMID 42507846

> PeptideScanner retained PubMed bibliographic metadata for PMID 42507846 at 2026-08-10T18:13:56.762Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-27. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42507846-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-27
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42507846-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42507846-tirzepatide-v1
- Content SHA-256: `d1dae50264fb0b0a8b8d9cb9fa2fb05bd5d41b3e3c072e35ac6689ad1645c0b0`

### Claims and source pins

#### Headline

PubMed record PMID 42507846 ([`pubmed-observation-pmid-42507846-2026-07-27-709b51685a39`](#source-pubmed-observation-pmid-42507846-2026-07-27-709b51685a39))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42507846 at 2026-08-10T18:13:56.762Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-27. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42507846-2026-07-27-709b51685a39`](#source-pubmed-observation-pmid-42507846-2026-07-27-709b51685a39))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42507846 at 2026-08-10T18:13:56.762Z. PubMed recorded a metadata revision date of 2026-07-27 and an Entrez history date of 2026-07-27. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42507846-2026-07-27-709b51685a39`](#source-pubmed-observation-pmid-42507846-2026-07-27-709b51685a39))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42507846-2026-07-27-709b51685a39`](#source-pubmed-observation-pmid-42507846-2026-07-27-709b51685a39))

### Sources

<a id="source-pubmed-observation-pmid-42507846-2026-07-27-709b51685a39"></a>
- **PubMed record PMID 42507846 · retained source version 1:2026-07-27:current:709b51685a39975069658b58dbcf07001423f886eeefff9fa2d12043be413c99** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42507846/) (`pubmed-observation-pmid-42507846-2026-07-27-709b51685a39`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42507846." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42507846-tirzepatide-v1 SHA-256: d1dae50264fb0b0a8b8d9cb9fa2fb05bd5d41b3e3c072e35ac6689ad1645c0b0.

---

<a id="pubmed-pmid-42516860-tirzepatide-v1"></a>

## PubMed record PMID 42516860

> PeptideScanner retained PubMed bibliographic metadata for PMID 42516860 at 2026-08-10T18:13:56.767Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42516860-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42516860-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42516860-tirzepatide-v1
- Content SHA-256: `c61f5849e441232bbf5173e3ff7d2264381e0b10165ce7516baa7013041d24dd`

### Claims and source pins

#### Headline

PubMed record PMID 42516860 ([`pubmed-observation-pmid-42516860-2026-07-29-70589183b2fe`](#source-pubmed-observation-pmid-42516860-2026-07-29-70589183b2fe))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42516860 at 2026-08-10T18:13:56.767Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42516860-2026-07-29-70589183b2fe`](#source-pubmed-observation-pmid-42516860-2026-07-29-70589183b2fe))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42516860 at 2026-08-10T18:13:56.767Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42516860-2026-07-29-70589183b2fe`](#source-pubmed-observation-pmid-42516860-2026-07-29-70589183b2fe))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42516860-2026-07-29-70589183b2fe`](#source-pubmed-observation-pmid-42516860-2026-07-29-70589183b2fe))

### Sources

<a id="source-pubmed-observation-pmid-42516860-2026-07-29-70589183b2fe"></a>
- **PubMed record PMID 42516860 · retained source version 1:2026-07-29:current:70589183b2fe736dd87cbacb3099dff29dc53f365f060937f616988bea8381c9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42516860/) (`pubmed-observation-pmid-42516860-2026-07-29-70589183b2fe`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42516860." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42516860-tirzepatide-v1 SHA-256: c61f5849e441232bbf5173e3ff7d2264381e0b10165ce7516baa7013041d24dd.

---

<a id="pubmed-pmid-42518363-tirzepatide-v1"></a>

## PubMed record PMID 42518363

> PeptideScanner retained PubMed bibliographic metadata for PMID 42518363 at 2026-08-10T18:13:56.773Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42518363-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42518363-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42518363-tirzepatide-v1
- Content SHA-256: `53e2b66ff8bb000ab24057db6cebf13d8052108a56bd479073b1f9221cbf2e13`

### Claims and source pins

#### Headline

PubMed record PMID 42518363 ([`pubmed-observation-pmid-42518363-2026-07-29-d0113b51f493`](#source-pubmed-observation-pmid-42518363-2026-07-29-d0113b51f493))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42518363 at 2026-08-10T18:13:56.773Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42518363-2026-07-29-d0113b51f493`](#source-pubmed-observation-pmid-42518363-2026-07-29-d0113b51f493))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42518363 at 2026-08-10T18:13:56.773Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42518363-2026-07-29-d0113b51f493`](#source-pubmed-observation-pmid-42518363-2026-07-29-d0113b51f493))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42518363-2026-07-29-d0113b51f493`](#source-pubmed-observation-pmid-42518363-2026-07-29-d0113b51f493))

### Sources

<a id="source-pubmed-observation-pmid-42518363-2026-07-29-d0113b51f493"></a>
- **PubMed record PMID 42518363 · retained source version 1:2026-07-29:current:d0113b51f4937ef084d7f18b5568a11a19471eaf45015af078f1fc6b8d176403** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42518363/) (`pubmed-observation-pmid-42518363-2026-07-29-d0113b51f493`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42518363." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42518363-tirzepatide-v1 SHA-256: 53e2b66ff8bb000ab24057db6cebf13d8052108a56bd479073b1f9221cbf2e13.

---

<a id="pubmed-pmid-42518535-tirzepatide-v1"></a>

## PubMed record PMID 42518535

> PeptideScanner retained PubMed bibliographic metadata for PMID 42518535 at 2026-08-10T18:13:56.774Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42518535-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42518535-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42518535-tirzepatide-v1
- Content SHA-256: `7721edcca8a99956c1f22f219fa7c9c6ea07b5f25fba0fa4c83486b88aa182be`

### Claims and source pins

#### Headline

PubMed record PMID 42518535 ([`pubmed-observation-pmid-42518535-2026-07-29-f510dcdbca4e`](#source-pubmed-observation-pmid-42518535-2026-07-29-f510dcdbca4e))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42518535 at 2026-08-10T18:13:56.774Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42518535-2026-07-29-f510dcdbca4e`](#source-pubmed-observation-pmid-42518535-2026-07-29-f510dcdbca4e))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42518535 at 2026-08-10T18:13:56.774Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42518535-2026-07-29-f510dcdbca4e`](#source-pubmed-observation-pmid-42518535-2026-07-29-f510dcdbca4e))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42518535-2026-07-29-f510dcdbca4e`](#source-pubmed-observation-pmid-42518535-2026-07-29-f510dcdbca4e))

### Sources

<a id="source-pubmed-observation-pmid-42518535-2026-07-29-f510dcdbca4e"></a>
- **PubMed record PMID 42518535 · retained source version 1:2026-07-29:current:f510dcdbca4ed3eefd3db6bd213ad5efdbe76106190e6a16b1d37cb24dfaa48d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42518535/) (`pubmed-observation-pmid-42518535-2026-07-29-f510dcdbca4e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42518535." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42518535-tirzepatide-v1 SHA-256: 7721edcca8a99956c1f22f219fa7c9c6ea07b5f25fba0fa4c83486b88aa182be.

---

<a id="pubmed-pmid-42521631-tirzepatide-v1"></a>

## PubMed record PMID 42521631

> PeptideScanner retained PubMed bibliographic metadata for PMID 42521631 at 2026-08-10T18:13:56.781Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42521631-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-28
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42521631-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42521631-tirzepatide-v1
- Content SHA-256: `67a9ec516753988098f8b53d032a4719bba04f9f674ccdf52b627d76c06c635e`

### Claims and source pins

#### Headline

PubMed record PMID 42521631 ([`pubmed-observation-pmid-42521631-2026-07-28-a237f4387efd`](#source-pubmed-observation-pmid-42521631-2026-07-28-a237f4387efd))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42521631 at 2026-08-10T18:13:56.781Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42521631-2026-07-28-a237f4387efd`](#source-pubmed-observation-pmid-42521631-2026-07-28-a237f4387efd))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42521631 at 2026-08-10T18:13:56.781Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-07-28. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42521631-2026-07-28-a237f4387efd`](#source-pubmed-observation-pmid-42521631-2026-07-28-a237f4387efd))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42521631-2026-07-28-a237f4387efd`](#source-pubmed-observation-pmid-42521631-2026-07-28-a237f4387efd))

### Sources

<a id="source-pubmed-observation-pmid-42521631-2026-07-28-a237f4387efd"></a>
- **PubMed record PMID 42521631 · retained source version 1:2026-07-28:current:a237f4387efdf52d3bd9c1e4b141cca62dcba1a562d9530750ec44050e25d464** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42521631/) (`pubmed-observation-pmid-42521631-2026-07-28-a237f4387efd`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42521631." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42521631-tirzepatide-v1 SHA-256: 67a9ec516753988098f8b53d032a4719bba04f9f674ccdf52b627d76c06c635e.

---

<a id="pubmed-pmid-42524366-tirzepatide-v1"></a>

## PubMed record PMID 42524366

> PeptideScanner retained PubMed bibliographic metadata for PMID 42524366 at 2026-08-10T18:13:56.785Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42524366-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42524366-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42524366-tirzepatide-v1
- Content SHA-256: `c22e3ce3eb97012c1eaf3f9b65c2639a177802c5337f520eba64df8f154fbb23`

### Claims and source pins

#### Headline

PubMed record PMID 42524366 ([`pubmed-observation-pmid-42524366-2026-07-29-f5e70ed401ea`](#source-pubmed-observation-pmid-42524366-2026-07-29-f5e70ed401ea))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42524366 at 2026-08-10T18:13:56.785Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42524366-2026-07-29-f5e70ed401ea`](#source-pubmed-observation-pmid-42524366-2026-07-29-f5e70ed401ea))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42524366 at 2026-08-10T18:13:56.785Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42524366-2026-07-29-f5e70ed401ea`](#source-pubmed-observation-pmid-42524366-2026-07-29-f5e70ed401ea))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42524366-2026-07-29-f5e70ed401ea`](#source-pubmed-observation-pmid-42524366-2026-07-29-f5e70ed401ea))

### Sources

<a id="source-pubmed-observation-pmid-42524366-2026-07-29-f5e70ed401ea"></a>
- **PubMed record PMID 42524366 · retained source version 1:2026-07-29:current:f5e70ed401eabc14734ab718e76b00e6842fa74677592b6f59cbd67d3105ce1b** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42524366/) (`pubmed-observation-pmid-42524366-2026-07-29-f5e70ed401ea`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42524366." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42524366-tirzepatide-v1 SHA-256: c22e3ce3eb97012c1eaf3f9b65c2639a177802c5337f520eba64df8f154fbb23.

---

<a id="pubmed-pmid-42526939-tirzepatide-v1"></a>

## PubMed record PMID 42526939

> PeptideScanner retained PubMed bibliographic metadata for PMID 42526939 at 2026-08-10T18:13:57.051Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42526939-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-29
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42526939-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42526939-tirzepatide-v1
- Content SHA-256: `87824a149261dcc12a3b453cf3ad5288b3a49e112d7e59df3b763b844044d0e0`

### Claims and source pins

#### Headline

PubMed record PMID 42526939 ([`pubmed-observation-pmid-42526939-2026-07-29-dc6dbab38dae`](#source-pubmed-observation-pmid-42526939-2026-07-29-dc6dbab38dae))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42526939 at 2026-08-10T18:13:57.051Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42526939-2026-07-29-dc6dbab38dae`](#source-pubmed-observation-pmid-42526939-2026-07-29-dc6dbab38dae))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42526939 at 2026-08-10T18:13:57.051Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42526939-2026-07-29-dc6dbab38dae`](#source-pubmed-observation-pmid-42526939-2026-07-29-dc6dbab38dae))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42526939-2026-07-29-dc6dbab38dae`](#source-pubmed-observation-pmid-42526939-2026-07-29-dc6dbab38dae))

### Sources

<a id="source-pubmed-observation-pmid-42526939-2026-07-29-dc6dbab38dae"></a>
- **PubMed record PMID 42526939 · retained source version 1:2026-07-29:current:dc6dbab38dae56b6cfc9436003cb4e71b4b782769409fc786a6f7bceec7134ba** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42526939/) (`pubmed-observation-pmid-42526939-2026-07-29-dc6dbab38dae`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42526939." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42526939-tirzepatide-v1 SHA-256: 87824a149261dcc12a3b453cf3ad5288b3a49e112d7e59df3b763b844044d0e0.

---

<a id="pubmed-pmid-42530904-tirzepatide-v1"></a>

## PubMed record PMID 42530904

> PeptideScanner retained PubMed bibliographic metadata for PMID 42530904 at 2026-08-10T10:49:12.922Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42530904-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42530904-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42530904-tirzepatide-v1
- Content SHA-256: `b35c530108cbd954a10e46df676c6c6c3fd3d1535a709187cb9cb057bdbe05a1`

### Claims and source pins

#### Headline

PubMed record PMID 42530904 ([`pubmed-observation-pmid-42530904-2026-07-30-365ce2931f64`](#source-pubmed-observation-pmid-42530904-2026-07-30-365ce2931f64))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42530904 at 2026-08-10T10:49:12.922Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42530904-2026-07-30-365ce2931f64`](#source-pubmed-observation-pmid-42530904-2026-07-30-365ce2931f64))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42530904 at 2026-08-10T10:49:12.922Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42530904-2026-07-30-365ce2931f64`](#source-pubmed-observation-pmid-42530904-2026-07-30-365ce2931f64))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42530904-2026-07-30-365ce2931f64`](#source-pubmed-observation-pmid-42530904-2026-07-30-365ce2931f64))

### Sources

<a id="source-pubmed-observation-pmid-42530904-2026-07-30-365ce2931f64"></a>
- **PubMed record PMID 42530904 · retained source version 1:2026-07-30:current:365ce2931f64cb1d4ec5a849cf662ffe5807f6474536131be001e5b2da120542** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42530904/) (`pubmed-observation-pmid-42530904-2026-07-30-365ce2931f64`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42530904." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42530904-tirzepatide-v1 SHA-256: b35c530108cbd954a10e46df676c6c6c3fd3d1535a709187cb9cb057bdbe05a1.

---

<a id="pubmed-pmid-42531456-tirzepatide-v1"></a>

## PubMed record PMID 42531456

> PeptideScanner retained PubMed bibliographic metadata for PMID 42531456 at 2026-08-10T10:49:12.922Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42531456-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-07-30
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42531456-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42531456-tirzepatide-v1
- Content SHA-256: `ffa566e8826a2ff90e02743844a03b3bb4c15b0caa4b1fc32d2274de5dd4866c`

### Claims and source pins

#### Headline

PubMed record PMID 42531456 ([`pubmed-observation-pmid-42531456-2026-07-30-753d5696ef91`](#source-pubmed-observation-pmid-42531456-2026-07-30-753d5696ef91))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42531456 at 2026-08-10T10:49:12.922Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42531456-2026-07-30-753d5696ef91`](#source-pubmed-observation-pmid-42531456-2026-07-30-753d5696ef91))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42531456 at 2026-08-10T10:49:12.922Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42531456-2026-07-30-753d5696ef91`](#source-pubmed-observation-pmid-42531456-2026-07-30-753d5696ef91))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42531456-2026-07-30-753d5696ef91`](#source-pubmed-observation-pmid-42531456-2026-07-30-753d5696ef91))

### Sources

<a id="source-pubmed-observation-pmid-42531456-2026-07-30-753d5696ef91"></a>
- **PubMed record PMID 42531456 · retained source version 1:2026-07-30:current:753d5696ef91a47900fc03b1ad196057657d58139508fb75537ccba1e5f17b72** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42531456/) (`pubmed-observation-pmid-42531456-2026-07-30-753d5696ef91`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42531456." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42531456-tirzepatide-v1 SHA-256: ffa566e8826a2ff90e02743844a03b3bb4c15b0caa4b1fc32d2274de5dd4866c.

---

<a id="pubmed-pmid-42532547-tirzepatide-v1"></a>

## PubMed record PMID 42532547

> PeptideScanner retained PubMed bibliographic metadata for PMID 42532547 at 2026-08-10T10:49:12.924Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42532547-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42532547-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42532547-tirzepatide-v1
- Content SHA-256: `4b37666b8b69a6e4a436f843aadb0ee1d7d21766702ec2626cace5a6d761c692`

### Claims and source pins

#### Headline

PubMed record PMID 42532547 ([`pubmed-observation-pmid-42532547-2026-08-02-8b333885c705`](#source-pubmed-observation-pmid-42532547-2026-08-02-8b333885c705))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42532547 at 2026-08-10T10:49:12.924Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42532547-2026-08-02-8b333885c705`](#source-pubmed-observation-pmid-42532547-2026-08-02-8b333885c705))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42532547 at 2026-08-10T10:49:12.924Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-07-30. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42532547-2026-08-02-8b333885c705`](#source-pubmed-observation-pmid-42532547-2026-08-02-8b333885c705))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42532547-2026-08-02-8b333885c705`](#source-pubmed-observation-pmid-42532547-2026-08-02-8b333885c705))

### Sources

<a id="source-pubmed-observation-pmid-42532547-2026-08-02-8b333885c705"></a>
- **PubMed record PMID 42532547 · retained source version 1:2026-08-02:current:8b333885c705a354f16ed91948afbc0a7cb9fcab19296a1e8538c27f73728c5a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42532547/) (`pubmed-observation-pmid-42532547-2026-08-02-8b333885c705`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42532547." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42532547-tirzepatide-v1 SHA-256: 4b37666b8b69a6e4a436f843aadb0ee1d7d21766702ec2626cace5a6d761c692.

---

<a id="pubmed-pmid-42533465-tirzepatide-v1"></a>

## PubMed record PMID 42533465

> PeptideScanner retained PubMed bibliographic metadata for PMID 42533465 at 2026-08-10T10:49:12.933Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-07-31. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42533465-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-02
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42533465-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42533465-tirzepatide-v1
- Content SHA-256: `72762bc6893f19b42705e67bd6ef2526d8e54dfdc6796f866205413a1fe9e377`

### Claims and source pins

#### Headline

PubMed record PMID 42533465 ([`pubmed-observation-pmid-42533465-2026-08-02-8bdac4261d56`](#source-pubmed-observation-pmid-42533465-2026-08-02-8bdac4261d56))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42533465 at 2026-08-10T10:49:12.933Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-07-31. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42533465-2026-08-02-8bdac4261d56`](#source-pubmed-observation-pmid-42533465-2026-08-02-8bdac4261d56))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42533465 at 2026-08-10T10:49:12.933Z. PubMed recorded a metadata revision date of 2026-08-02 and an Entrez history date of 2026-07-31. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42533465-2026-08-02-8bdac4261d56`](#source-pubmed-observation-pmid-42533465-2026-08-02-8bdac4261d56))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42533465-2026-08-02-8bdac4261d56`](#source-pubmed-observation-pmid-42533465-2026-08-02-8bdac4261d56))

### Sources

<a id="source-pubmed-observation-pmid-42533465-2026-08-02-8bdac4261d56"></a>
- **PubMed record PMID 42533465 · retained source version 1:2026-08-02:current:8bdac4261d5683adcc8a33891fac16753f9bb7d92d18f8e0364beb097b202ce9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42533465/) (`pubmed-observation-pmid-42533465-2026-08-02-8bdac4261d56`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42533465." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42533465-tirzepatide-v1 SHA-256: 72762bc6893f19b42705e67bd6ef2526d8e54dfdc6796f866205413a1fe9e377.

---

<a id="pubmed-pmid-42538551-tirzepatide-v1"></a>

## PubMed record PMID 42538551

> PeptideScanner retained PubMed bibliographic metadata for PMID 42538551 at 2026-08-10T10:49:12.951Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-07-31. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42538551-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-03
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42538551-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42538551-tirzepatide-v1
- Content SHA-256: `11220b17ca205b05060199e51d10ff5af34dd2643e9da439176602e57016d36d`

### Claims and source pins

#### Headline

PubMed record PMID 42538551 ([`pubmed-observation-pmid-42538551-2026-08-03-8485a2e1e748`](#source-pubmed-observation-pmid-42538551-2026-08-03-8485a2e1e748))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42538551 at 2026-08-10T10:49:12.951Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-07-31. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42538551-2026-08-03-8485a2e1e748`](#source-pubmed-observation-pmid-42538551-2026-08-03-8485a2e1e748))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42538551 at 2026-08-10T10:49:12.951Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-07-31. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42538551-2026-08-03-8485a2e1e748`](#source-pubmed-observation-pmid-42538551-2026-08-03-8485a2e1e748))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42538551-2026-08-03-8485a2e1e748`](#source-pubmed-observation-pmid-42538551-2026-08-03-8485a2e1e748))

### Sources

<a id="source-pubmed-observation-pmid-42538551-2026-08-03-8485a2e1e748"></a>
- **PubMed record PMID 42538551 · retained source version 1:2026-08-03:current:8485a2e1e74873657cba4c9b04cce99a43d7df0182458e5077a5d8d942a260c1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42538551/) (`pubmed-observation-pmid-42538551-2026-08-03-8485a2e1e748`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42538551." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42538551-tirzepatide-v1 SHA-256: 11220b17ca205b05060199e51d10ff5af34dd2643e9da439176602e57016d36d.

---

<a id="pubmed-pmid-42542297-tirzepatide-v1"></a>

## PubMed record PMID 42542297

> PeptideScanner retained PubMed bibliographic metadata for PMID 42542297 at 2026-08-10T10:49:12.964Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42542297-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-01
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-12
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42542297-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42542297-tirzepatide-v1
- Content SHA-256: `8579a939d713bb2e25bf086fb1c89cfe2c83911bf843f2e972a0f37886acc4c2`

### Claims and source pins

#### Headline

PubMed record PMID 42542297 ([`pubmed-observation-pmid-42542297-2026-08-01-7579fe13125d`](#source-pubmed-observation-pmid-42542297-2026-08-01-7579fe13125d))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42542297 at 2026-08-10T10:49:12.964Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42542297-2026-08-01-7579fe13125d`](#source-pubmed-observation-pmid-42542297-2026-08-01-7579fe13125d))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42542297 at 2026-08-10T10:49:12.964Z. PubMed recorded a metadata revision date of 2026-08-01 and an Entrez history date of 2026-08-01. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42542297-2026-08-01-7579fe13125d`](#source-pubmed-observation-pmid-42542297-2026-08-01-7579fe13125d))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42542297-2026-08-01-7579fe13125d`](#source-pubmed-observation-pmid-42542297-2026-08-01-7579fe13125d))

### Sources

<a id="source-pubmed-observation-pmid-42542297-2026-08-01-7579fe13125d"></a>
- **PubMed record PMID 42542297 · retained source version 1:2026-08-01:current:7579fe13125d64ddd38fa61f1fb6774769700e14207fbc641023c62327ecdabe** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42542297/) (`pubmed-observation-pmid-42542297-2026-08-01-7579fe13125d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42542297." Version 1, published 2026-08-12. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42542297-tirzepatide-v1 SHA-256: 8579a939d713bb2e25bf086fb1c89cfe2c83911bf843f2e972a0f37886acc4c2.

---

<a id="pubmed-pmid-42555072-tirzepatide-v1"></a>

## PubMed record PMID 42555072

> PeptideScanner retained PubMed bibliographic metadata for PMID 42555072 at 2026-08-10T10:49:12.992Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42555072-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42555072-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42555072-tirzepatide-v1
- Content SHA-256: `6c2099db13985a2bbcb6746a1258148987bfa89dd7fef8b9d52e23c90daff8c0`

### Claims and source pins

#### Headline

PubMed record PMID 42555072 ([`pubmed-observation-pmid-42555072-2026-08-05-ea4023d5acfc`](#source-pubmed-observation-pmid-42555072-2026-08-05-ea4023d5acfc))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42555072 at 2026-08-10T10:49:12.992Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42555072-2026-08-05-ea4023d5acfc`](#source-pubmed-observation-pmid-42555072-2026-08-05-ea4023d5acfc))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42555072 at 2026-08-10T10:49:12.992Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42555072-2026-08-05-ea4023d5acfc`](#source-pubmed-observation-pmid-42555072-2026-08-05-ea4023d5acfc))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42555072-2026-08-05-ea4023d5acfc`](#source-pubmed-observation-pmid-42555072-2026-08-05-ea4023d5acfc))

### Sources

<a id="source-pubmed-observation-pmid-42555072-2026-08-05-ea4023d5acfc"></a>
- **PubMed record PMID 42555072 · retained source version 1:2026-08-05:current:ea4023d5acfc215322e778e99ea8182ab0e04476795c9f77ba044050493e7b78** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42555072/) (`pubmed-observation-pmid-42555072-2026-08-05-ea4023d5acfc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42555072." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42555072-tirzepatide-v1 SHA-256: 6c2099db13985a2bbcb6746a1258148987bfa89dd7fef8b9d52e23c90daff8c0.

---

<a id="pubmed-pmid-42556854-tirzepatide-v1"></a>

## PubMed record PMID 42556854

> PeptideScanner retained PubMed bibliographic metadata for PMID 42556854 at 2026-08-10T10:49:12.998Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42556854-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42556854-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42556854-tirzepatide-v1
- Content SHA-256: `049f3aac2048eb6a60c8dd7b344a1eb0dabf7394ed81614892929b6852979e14`

### Claims and source pins

#### Headline

PubMed record PMID 42556854 ([`pubmed-observation-pmid-42556854-2026-08-05-6012bf9d564f`](#source-pubmed-observation-pmid-42556854-2026-08-05-6012bf9d564f))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42556854 at 2026-08-10T10:49:12.998Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42556854-2026-08-05-6012bf9d564f`](#source-pubmed-observation-pmid-42556854-2026-08-05-6012bf9d564f))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42556854 at 2026-08-10T10:49:12.998Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42556854-2026-08-05-6012bf9d564f`](#source-pubmed-observation-pmid-42556854-2026-08-05-6012bf9d564f))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42556854-2026-08-05-6012bf9d564f`](#source-pubmed-observation-pmid-42556854-2026-08-05-6012bf9d564f))

### Sources

<a id="source-pubmed-observation-pmid-42556854-2026-08-05-6012bf9d564f"></a>
- **PubMed record PMID 42556854 · retained source version 1:2026-08-05:current:6012bf9d564f8a9ac0107bd3b8457bcad134ad40ca3bd0d63f4d9b85b90dd314** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42556854/) (`pubmed-observation-pmid-42556854-2026-08-05-6012bf9d564f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42556854." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42556854-tirzepatide-v1 SHA-256: 049f3aac2048eb6a60c8dd7b344a1eb0dabf7394ed81614892929b6852979e14.

---

<a id="pubmed-pmid-42556867-tirzepatide-v1"></a>

## PubMed record PMID 42556867

> PeptideScanner retained PubMed bibliographic metadata for PMID 42556867 at 2026-08-10T10:49:12.998Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42556867-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-05
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-11
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42556867-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42556867-tirzepatide-v1
- Content SHA-256: `497bc9968690e444203245223d0dc22bb769914b9de208ee3271ea16458c330c`

### Claims and source pins

#### Headline

PubMed record PMID 42556867 ([`pubmed-observation-pmid-42556867-2026-08-05-17062e95c7fa`](#source-pubmed-observation-pmid-42556867-2026-08-05-17062e95c7fa))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42556867 at 2026-08-10T10:49:12.998Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42556867-2026-08-05-17062e95c7fa`](#source-pubmed-observation-pmid-42556867-2026-08-05-17062e95c7fa))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42556867 at 2026-08-10T10:49:12.998Z. PubMed recorded a metadata revision date of 2026-08-05 and an Entrez history date of 2026-08-05. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42556867-2026-08-05-17062e95c7fa`](#source-pubmed-observation-pmid-42556867-2026-08-05-17062e95c7fa))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42556867-2026-08-05-17062e95c7fa`](#source-pubmed-observation-pmid-42556867-2026-08-05-17062e95c7fa))

### Sources

<a id="source-pubmed-observation-pmid-42556867-2026-08-05-17062e95c7fa"></a>
- **PubMed record PMID 42556867 · retained source version 1:2026-08-05:current:17062e95c7fa6ddbc549152eea4ee69df7762cc234903e4dcf17fbaf867eb8c1** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42556867/) (`pubmed-observation-pmid-42556867-2026-08-05-17062e95c7fa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42556867." Version 1, published 2026-08-11. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42556867-tirzepatide-v1 SHA-256: 497bc9968690e444203245223d0dc22bb769914b9de208ee3271ea16458c330c.

---

<a id="pubmed-pmid-42560020-tirzepatide-v1"></a>

## PubMed record PMID 42560020

> PeptideScanner retained PubMed bibliographic metadata for PMID 42560020 at 2026-08-10T10:49:13.020Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-06. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date.

- Evidence object: `story:pubmed-pmid-42560020-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-06
- Source checked: 2026-08-10
- Published by PeptideScanner: 2026-08-10
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42560020-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42560020-tirzepatide-v1
- Content SHA-256: `7a5f73776ff9804e35d268d9a0ced2164f5013a6ffa2ef163b24c2e731d6a11a`

### Claims and source pins

#### Headline

PubMed record PMID 42560020 ([`pubmed-observation-pmid-42560020-2026-08-06-3be550e8f895`](#source-pubmed-observation-pmid-42560020-2026-08-06-3be550e8f895))

#### Summary

PeptideScanner retained PubMed bibliographic metadata for PMID 42560020 at 2026-08-10T10:49:13.020Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-06. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42560020-2026-08-06-3be550e8f895`](#source-pubmed-observation-pmid-42560020-2026-08-06-3be550e8f895))

#### Paragraph 1

PeptideScanner retained PubMed bibliographic metadata for PMID 42560020 at 2026-08-10T10:49:13.020Z. PubMed recorded a metadata revision date of 2026-08-06 and an Entrez history date of 2026-08-06. PeptideScanner associated this retained record with the identity slug tirzepatide. These dates describe PubMed metadata history, not the article's original publication date. ([`pubmed-observation-pmid-42560020-2026-08-06-3be550e8f895`](#source-pubmed-observation-pmid-42560020-2026-08-06-3be550e8f895))

#### Paragraph 2

This page reports retained PubMed bibliographic metadata. It does not summarize the article, establish the article's publication date, or assert safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42560020-2026-08-06-3be550e8f895`](#source-pubmed-observation-pmid-42560020-2026-08-06-3be550e8f895))

### Sources

<a id="source-pubmed-observation-pmid-42560020-2026-08-06-3be550e8f895"></a>
- **PubMed record PMID 42560020 · retained source version 1:2026-08-06:current:3be550e8f895013b35d32a38e8ea2d2f7f7261e8842ea02672edeb873f0d1072** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42560020/) (`pubmed-observation-pmid-42560020-2026-08-06-3be550e8f895`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PubMed record PMID 42560020." Version 1, published 2026-08-10. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42560020-tirzepatide-v1 SHA-256: 7a5f73776ff9804e35d268d9a0ced2164f5013a6ffa2ef163b24c2e731d6a11a.

---

<a id="pubmed-pmid-42598502-tirzepatide-v1"></a>

## Inflammation-mediated facial nodules to compounded tirzepatide.

> PubMed lists PMID 42598502 in JAAD case reports as Letter, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42598502-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-14
- Source checked: 2026-08-14
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42598502-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42598502-tirzepatide-v1
- Content SHA-256: `0c409847919dc518dbebadb236e6a447f3094f3e413f3c38b7b42ed23e4849fe`

### Claims and source pins

#### Headline

Inflammation-mediated facial nodules to compounded tirzepatide. ([`pubmed-observation-pmid-42598502-2026-08-14-2b079cc362b5`](#source-pubmed-observation-pmid-42598502-2026-08-14-2b079cc362b5))

#### Summary

PubMed lists PMID 42598502 in JAAD case reports as Letter, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42598502-2026-08-14-2b079cc362b5`](#source-pubmed-observation-pmid-42598502-2026-08-14-2b079cc362b5))

#### Paragraph 1

PubMed lists PMID 42598502 in JAAD case reports as Letter, with publication-date metadata of 2026-06-17 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42598502-2026-08-14-2b079cc362b5`](#source-pubmed-observation-pmid-42598502-2026-08-14-2b079cc362b5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42598502-2026-08-14-2b079cc362b5`](#source-pubmed-observation-pmid-42598502-2026-08-14-2b079cc362b5))

### Sources

<a id="source-pubmed-observation-pmid-42598502-2026-08-14-2b079cc362b5"></a>
- **Inflammation-mediated facial nodules to compounded tirzepatide. · retained source version 1:2026-08-14:current:2b079cc362b53630676caa02a1de041a7ab692c920125f3584f0ab06b4c3b041** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42598502/) (`pubmed-observation-pmid-42598502-2026-08-14-2b079cc362b5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Inflammation-mediated facial nodules to compounded tirzepatide." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42598502-tirzepatide-v1 SHA-256: 0c409847919dc518dbebadb236e6a447f3094f3e413f3c38b7b42ed23e4849fe.

---

<a id="pubmed-pmid-42695200-tirzepatide-v1"></a>

## Are We Asking About Tirzepatide? Emerging Oral Health Implications for Oral Medicine Practice.

> PubMed lists PMID 42695200 in Oral diseases as Letter, with publication-date metadata of 2026-09-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42695200-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-04
- Source checked: 2026-09-09
- Published by PeptideScanner: 2026-09-09
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42695200-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42695200-tirzepatide-v1
- Content SHA-256: `507e80a3d8148e990fcb93f2448bd6b83769612b09b468247fef9158f547bc30`

### Claims and source pins

#### Headline

Are We Asking About Tirzepatide? Emerging Oral Health Implications for Oral Medicine Practice. ([`pubmed-observation-pmid-42695200-2026-09-04-efd36a686ea8`](#source-pubmed-observation-pmid-42695200-2026-09-04-efd36a686ea8))

#### Summary

PubMed lists PMID 42695200 in Oral diseases as Letter, with publication-date metadata of 2026-09-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42695200-2026-09-04-efd36a686ea8`](#source-pubmed-observation-pmid-42695200-2026-09-04-efd36a686ea8))

#### Paragraph 1

PubMed lists PMID 42695200 in Oral diseases as Letter, with publication-date metadata of 2026-09-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42695200-2026-09-04-efd36a686ea8`](#source-pubmed-observation-pmid-42695200-2026-09-04-efd36a686ea8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42695200-2026-09-04-efd36a686ea8`](#source-pubmed-observation-pmid-42695200-2026-09-04-efd36a686ea8))

### Sources

<a id="source-pubmed-observation-pmid-42695200-2026-09-04-efd36a686ea8"></a>
- **Are We Asking About Tirzepatide? Emerging Oral Health Implications for Oral Medicine Practice. · retained source version 1:2026-09-04:current:efd36a686ea870ea3bcc1e2b23b3ec2c36225da13b15b4f30e2e699be45b7c82** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42695200/) (`pubmed-observation-pmid-42695200-2026-09-04-efd36a686ea8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Are We Asking About Tirzepatide? Emerging Oral Health Implications for Oral Medicine Practice." Version 1, published 2026-09-09. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42695200-tirzepatide-v1 SHA-256: 507e80a3d8148e990fcb93f2448bd6b83769612b09b468247fef9158f547bc30.

---

<a id="pubmed-pmid-42735799-tirzepatide-v1"></a>

## Anaphylaxis to tirzepatide confirmed by positive skin prick testing.

> PubMed lists PMID 42735799 in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology as Journal Article, with publication-date metadata of 2026-09-14 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42735799-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-09
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42735799-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42735799-tirzepatide-v1
- Content SHA-256: `0d3c034135c9b08ddfdd09bb0e281ff363667339ae655de83481f00d54a2406f`

### Claims and source pins

#### Headline

Anaphylaxis to tirzepatide confirmed by positive skin prick testing. ([`pubmed-observation-pmid-42735799-2026-10-09-b1d1ded8f67b`](#source-pubmed-observation-pmid-42735799-2026-10-09-b1d1ded8f67b))

#### Summary

PubMed lists PMID 42735799 in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology as Journal Article, with publication-date metadata of 2026-09-14 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42735799-2026-10-09-b1d1ded8f67b`](#source-pubmed-observation-pmid-42735799-2026-10-09-b1d1ded8f67b))

#### Paragraph 1

PubMed lists PMID 42735799 in Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology as Journal Article, with publication-date metadata of 2026-09-14 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42735799-2026-10-09-b1d1ded8f67b`](#source-pubmed-observation-pmid-42735799-2026-10-09-b1d1ded8f67b))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42735799-2026-10-09-b1d1ded8f67b`](#source-pubmed-observation-pmid-42735799-2026-10-09-b1d1ded8f67b))

### Sources

<a id="source-pubmed-observation-pmid-42735799-2026-10-09-b1d1ded8f67b"></a>
- **Anaphylaxis to tirzepatide confirmed by positive skin prick testing. · retained source version 1:2026-10-09:current:b1d1ded8f67b9a192fdab018a39529c5e6221998ccc11929f45fb98305462560** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42735799/) (`pubmed-observation-pmid-42735799-2026-10-09-b1d1ded8f67b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Anaphylaxis to tirzepatide confirmed by positive skin prick testing." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42735799-tirzepatide-v1 SHA-256: 0d3c034135c9b08ddfdd09bb0e281ff363667339ae655de83481f00d54a2406f.

---

<a id="pubmed-pmid-42810204-tirzepatide-v1"></a>

## Tirzepatide among patients with psoriasis and obesity.

> PubMed lists PMID 42810204 in Medicina clinica as Journal Article, with publication-date metadata of 2026-09-29 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42810204-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-29
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42810204-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42810204-tirzepatide-v1
- Content SHA-256: `6858ab84e098174b3a75a752869d20dabe276d7a560273babfea30355b237fe2`

### Claims and source pins

#### Headline

Tirzepatide among patients with psoriasis and obesity. ([`pubmed-observation-pmid-42810204-2026-09-29-85a64632acd3`](#source-pubmed-observation-pmid-42810204-2026-09-29-85a64632acd3))

#### Summary

PubMed lists PMID 42810204 in Medicina clinica as Journal Article, with publication-date metadata of 2026-09-29 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42810204-2026-09-29-85a64632acd3`](#source-pubmed-observation-pmid-42810204-2026-09-29-85a64632acd3))

#### Paragraph 1

PubMed lists PMID 42810204 in Medicina clinica as Journal Article, with publication-date metadata of 2026-09-29 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42810204-2026-09-29-85a64632acd3`](#source-pubmed-observation-pmid-42810204-2026-09-29-85a64632acd3))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42810204-2026-09-29-85a64632acd3`](#source-pubmed-observation-pmid-42810204-2026-09-29-85a64632acd3))

### Sources

<a id="source-pubmed-observation-pmid-42810204-2026-09-29-85a64632acd3"></a>
- **Tirzepatide among patients with psoriasis and obesity. · retained source version 1:2026-09-29:current:85a64632acd376f9579c7bb206f9f3131c21d34b1e028cbc408e17faa9b2454e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42810204/) (`pubmed-observation-pmid-42810204-2026-09-29-85a64632acd3`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide among patients with psoriasis and obesity." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42810204-tirzepatide-v1 SHA-256: 6858ab84e098174b3a75a752869d20dabe276d7a560273babfea30355b237fe2.

---

<a id="pubmed-pmid-42831032-tirzepatide-v1"></a>

## Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes.

> PubMed lists PMID 42831032 in Obesity pillars as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42831032-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-06
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42831032-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42831032-tirzepatide-v1
- Content SHA-256: `6d9f4b040e32c27d2be07dd330fdbf13ab7074fda128105dd60110a7da659fd0`

### Claims and source pins

#### Headline

Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes. ([`pubmed-observation-pmid-42831032-2026-10-06-e3c5c018481a`](#source-pubmed-observation-pmid-42831032-2026-10-06-e3c5c018481a))

#### Summary

PubMed lists PMID 42831032 in Obesity pillars as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42831032-2026-10-06-e3c5c018481a`](#source-pubmed-observation-pmid-42831032-2026-10-06-e3c5c018481a))

#### Paragraph 1

PubMed lists PMID 42831032 in Obesity pillars as Journal Article, with publication-date metadata of 2026-09-18 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42831032-2026-10-06-e3c5c018481a`](#source-pubmed-observation-pmid-42831032-2026-10-06-e3c5c018481a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42831032-2026-10-06-e3c5c018481a`](#source-pubmed-observation-pmid-42831032-2026-10-06-e3c5c018481a))

### Sources

<a id="source-pubmed-observation-pmid-42831032-2026-10-06-e3c5c018481a"></a>
- **Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes. · retained source version 1:2026-10-06:current:e3c5c018481af267418739a4db11b00c8f64ecf0eccfc818592ae3cda76321cd** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42831032/) (`pubmed-observation-pmid-42831032-2026-10-06-e3c5c018481a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Evaluation of clinical relevance of weight nadirs and weight regain during 3 years of treatment with tirzepatide in participants with obesity or overweight and prediabetes." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42831032-tirzepatide-v1 SHA-256: 6d9f4b040e32c27d2be07dd330fdbf13ab7074fda128105dd60110a7da659fd0.

---

<a id="pubmed-pmid-42922752-tirzepatide-v1"></a>

## Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese mice.

> PubMed lists PMID 42922752 in bioRxiv : the preprint server for biology as Journal Article, Preprint, with publication-date metadata of 2026-09-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42922752-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-30
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42922752-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42922752-tirzepatide-v1
- Content SHA-256: `de7f9c967786d4836bbce2b4198ddf66dbe30b02f2ddbd68cf165431a6fecf21`

### Claims and source pins

#### Headline

Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese mice. ([`pubmed-observation-pmid-42922752-2026-10-30-2a85124908d8`](#source-pubmed-observation-pmid-42922752-2026-10-30-2a85124908d8))

#### Summary

PubMed lists PMID 42922752 in bioRxiv : the preprint server for biology as Journal Article, Preprint, with publication-date metadata of 2026-09-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42922752-2026-10-30-2a85124908d8`](#source-pubmed-observation-pmid-42922752-2026-10-30-2a85124908d8))

#### Paragraph 1

PubMed lists PMID 42922752 in bioRxiv : the preprint server for biology as Journal Article, Preprint, with publication-date metadata of 2026-09-04 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42922752-2026-10-30-2a85124908d8`](#source-pubmed-observation-pmid-42922752-2026-10-30-2a85124908d8))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42922752-2026-10-30-2a85124908d8`](#source-pubmed-observation-pmid-42922752-2026-10-30-2a85124908d8))

### Sources

<a id="source-pubmed-observation-pmid-42922752-2026-10-30-2a85124908d8"></a>
- **Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese mice. · retained source version 1:2026-10-30:current:2a85124908d8c34c2bdbd67d6528170a10ffbc27977faf173f5bcead28d02741** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42922752/) (`pubmed-observation-pmid-42922752-2026-10-30-2a85124908d8`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide preserves hematopoietic stem and progenitor cycling while remodeling inflammatory monocytes in obese mice." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42922752-tirzepatide-v1 SHA-256: de7f9c967786d4836bbce2b4198ddf66dbe30b02f2ddbd68cf165431a6fecf21.

---

<a id="pubmed-pmid-42969740-tirzepatide-v1"></a>

## PET Imaging of Dual GLP-1R and GIPR Targeting with \[18F\]AlF-NOTA-Asp2-Tirzepatide.

> PubMed lists PMID 42969740 in Molecular pharmaceutics as Journal Article, with publication-date metadata of 2026-11-02 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-42969740-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-02
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-42969740-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42969740-tirzepatide-v1
- Content SHA-256: `df45cf182e8bd16cd0911c68eda187fc2b436732423e51904c3686e50352cda9`

### Claims and source pins

#### Headline

PET Imaging of Dual GLP-1R and GIPR Targeting with \[18F\]AlF-NOTA-Asp2-Tirzepatide. ([`pubmed-observation-pmid-42969740-2026-11-02-dae7d55a16de`](#source-pubmed-observation-pmid-42969740-2026-11-02-dae7d55a16de))

#### Summary

PubMed lists PMID 42969740 in Molecular pharmaceutics as Journal Article, with publication-date metadata of 2026-11-02 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42969740-2026-11-02-dae7d55a16de`](#source-pubmed-observation-pmid-42969740-2026-11-02-dae7d55a16de))

#### Paragraph 1

PubMed lists PMID 42969740 in Molecular pharmaceutics as Journal Article, with publication-date metadata of 2026-11-02 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-42969740-2026-11-02-dae7d55a16de`](#source-pubmed-observation-pmid-42969740-2026-11-02-dae7d55a16de))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-42969740-2026-11-02-dae7d55a16de`](#source-pubmed-observation-pmid-42969740-2026-11-02-dae7d55a16de))

### Sources

<a id="source-pubmed-observation-pmid-42969740-2026-11-02-dae7d55a16de"></a>
- **PET Imaging of Dual GLP-1R and GIPR Targeting with \[18F\]AlF-NOTA-Asp2-Tirzepatide. · retained source version 1:2026-11-02:current:dae7d55a16de351952089d0bad7230d02331aa8364ed9305e9054c3470affe3e** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/42969740/) (`pubmed-observation-pmid-42969740-2026-11-02-dae7d55a16de`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "PET Imaging of Dual GLP-1R and GIPR Targeting with \[18F\]AlF-NOTA-Asp2-Tirzepatide." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-42969740-tirzepatide-v1 SHA-256: df45cf182e8bd16cd0911c68eda187fc2b436732423e51904c3686e50352cda9.

---

<a id="pubmed-pmid-43009382-tirzepatide-v1"></a>

## Temporal dynamics and prognostic value of serum calcitonin during tirzepatide therapy in adults with obesity.

> PubMed lists PMID 43009382 in Obesity research & clinical practice as Journal Article, with publication-date metadata of 2026-11-10 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-43009382-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-10
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-43009382-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-43009382-tirzepatide-v1
- Content SHA-256: `c50f01b2908af86b72c250404d7f016c1a1cd1a56f57e7ba0837cefbf96c5036`

### Claims and source pins

#### Headline

Temporal dynamics and prognostic value of serum calcitonin during tirzepatide therapy in adults with obesity. ([`pubmed-observation-pmid-43009382-2026-11-10-0c03717a441a`](#source-pubmed-observation-pmid-43009382-2026-11-10-0c03717a441a))

#### Summary

PubMed lists PMID 43009382 in Obesity research & clinical practice as Journal Article, with publication-date metadata of 2026-11-10 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43009382-2026-11-10-0c03717a441a`](#source-pubmed-observation-pmid-43009382-2026-11-10-0c03717a441a))

#### Paragraph 1

PubMed lists PMID 43009382 in Obesity research & clinical practice as Journal Article, with publication-date metadata of 2026-11-10 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43009382-2026-11-10-0c03717a441a`](#source-pubmed-observation-pmid-43009382-2026-11-10-0c03717a441a))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-43009382-2026-11-10-0c03717a441a`](#source-pubmed-observation-pmid-43009382-2026-11-10-0c03717a441a))

### Sources

<a id="source-pubmed-observation-pmid-43009382-2026-11-10-0c03717a441a"></a>
- **Temporal dynamics and prognostic value of serum calcitonin during tirzepatide therapy in adults with obesity. · retained source version 1:2026-11-10:current:0c03717a441aca8831fe264814cefc20149fa9200186608a3f8e3522eddb640a** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/43009382/) (`pubmed-observation-pmid-43009382-2026-11-10-0c03717a441a`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Temporal dynamics and prognostic value of serum calcitonin during tirzepatide therapy in adults with obesity." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-43009382-tirzepatide-v1 SHA-256: c50f01b2908af86b72c250404d7f016c1a1cd1a56f57e7ba0837cefbf96c5036.

---

<a id="pubmed-pmid-43030521-tirzepatide-v1"></a>

## Early Body-Composition Trajectory During Tirzepatide Treatment for Obesity: A Real-World Bioimpedance Cohort Study.

> PubMed lists PMID 43030521 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-10-28 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-43030521-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-14
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-43030521-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-43030521-tirzepatide-v1
- Content SHA-256: `4b5d391e1ba08e74da3ac3f00cc007c69ff7143bdfdf3fe74347a7b874772981`

### Claims and source pins

#### Headline

Early Body-Composition Trajectory During Tirzepatide Treatment for Obesity: A Real-World Bioimpedance Cohort Study. ([`pubmed-observation-pmid-43030521-2026-11-14-7c529f235348`](#source-pubmed-observation-pmid-43030521-2026-11-14-7c529f235348))

#### Summary

PubMed lists PMID 43030521 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-10-28 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43030521-2026-11-14-7c529f235348`](#source-pubmed-observation-pmid-43030521-2026-11-14-7c529f235348))

#### Paragraph 1

PubMed lists PMID 43030521 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-10-28 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43030521-2026-11-14-7c529f235348`](#source-pubmed-observation-pmid-43030521-2026-11-14-7c529f235348))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-43030521-2026-11-14-7c529f235348`](#source-pubmed-observation-pmid-43030521-2026-11-14-7c529f235348))

### Sources

<a id="source-pubmed-observation-pmid-43030521-2026-11-14-7c529f235348"></a>
- **Early Body-Composition Trajectory During Tirzepatide Treatment for Obesity: A Real-World Bioimpedance Cohort Study. · retained source version 1:2026-11-14:current:7c529f2353488fb01ecde9809df1c70f7712b0637622d89f74a7c92a5f3beca0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/43030521/) (`pubmed-observation-pmid-43030521-2026-11-14-7c529f235348`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Early Body-Composition Trajectory During Tirzepatide Treatment for Obesity: A Real-World Bioimpedance Cohort Study." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-43030521-tirzepatide-v1 SHA-256: 4b5d391e1ba08e74da3ac3f00cc007c69ff7143bdfdf3fe74347a7b874772981.

---

<a id="pubmed-pmid-43030785-tirzepatide-v1"></a>

## A Multimodal Intervention Including Tirzepatide in Women with Lipedema and Excess Body Weight: A Pilot Case Series.

> PubMed lists PMID 43030785 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-06 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-43030785-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-14
- Source checked: 2026-11-14
- Published by PeptideScanner: 2026-11-14
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-43030785-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-43030785-tirzepatide-v1
- Content SHA-256: `54ee33201b907d0e3b9615d5bd573cdf9492beb43c850373f19bc065067db29e`

### Claims and source pins

#### Headline

A Multimodal Intervention Including Tirzepatide in Women with Lipedema and Excess Body Weight: A Pilot Case Series. ([`pubmed-observation-pmid-43030785-2026-11-14-4d986e252d9e`](#source-pubmed-observation-pmid-43030785-2026-11-14-4d986e252d9e))

#### Summary

PubMed lists PMID 43030785 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-06 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43030785-2026-11-14-4d986e252d9e`](#source-pubmed-observation-pmid-43030785-2026-11-14-4d986e252d9e))

#### Paragraph 1

PubMed lists PMID 43030785 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2026-11-06 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43030785-2026-11-14-4d986e252d9e`](#source-pubmed-observation-pmid-43030785-2026-11-14-4d986e252d9e))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-43030785-2026-11-14-4d986e252d9e`](#source-pubmed-observation-pmid-43030785-2026-11-14-4d986e252d9e))

### Sources

<a id="source-pubmed-observation-pmid-43030785-2026-11-14-4d986e252d9e"></a>
- **A Multimodal Intervention Including Tirzepatide in Women with Lipedema and Excess Body Weight: A Pilot Case Series. · retained source version 1:2026-11-14:current:4d986e252d9ee1b330372848e3932865994813c79b68fe53735f3fad8dbc316c** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/43030785/) (`pubmed-observation-pmid-43030785-2026-11-14-4d986e252d9e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A Multimodal Intervention Including Tirzepatide in Women with Lipedema and Excess Body Weight: A Pilot Case Series." Version 1, published 2026-11-14. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-43030785-tirzepatide-v1 SHA-256: 54ee33201b907d0e3b9615d5bd573cdf9492beb43c850373f19bc065067db29e.

---

<a id="pubmed-pmid-43035094-tirzepatide-v1"></a>

## Tirzepatide in Adolescents With Obesity: Research Summary.

> PubMed lists PMID 43035094 in JAMA as Journal Article, with publication-date metadata of 2026-11-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-43035094-tirzepatide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-43035094-tirzepatide/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-43035094-tirzepatide-v1
- Content SHA-256: `75686bacb842355fc968c173129b4878e1ae6e605fd93579bd38fd0c989c478f`

### Claims and source pins

#### Headline

Tirzepatide in Adolescents With Obesity: Research Summary. ([`pubmed-observation-pmid-43035094-2026-11-15-cc90af20c864`](#source-pubmed-observation-pmid-43035094-2026-11-15-cc90af20c864))

#### Summary

PubMed lists PMID 43035094 in JAMA as Journal Article, with publication-date metadata of 2026-11-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43035094-2026-11-15-cc90af20c864`](#source-pubmed-observation-pmid-43035094-2026-11-15-cc90af20c864))

#### Paragraph 1

PubMed lists PMID 43035094 in JAMA as Journal Article, with publication-date metadata of 2026-11-15 (day precision). PeptideScanner associated the retained record with the identity slug tirzepatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-43035094-2026-11-15-cc90af20c864`](#source-pubmed-observation-pmid-43035094-2026-11-15-cc90af20c864))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-43035094-2026-11-15-cc90af20c864`](#source-pubmed-observation-pmid-43035094-2026-11-15-cc90af20c864))

### Sources

<a id="source-pubmed-observation-pmid-43035094-2026-11-15-cc90af20c864"></a>
- **Tirzepatide in Adolescents With Obesity: Research Summary. · retained source version 1:2026-11-15:current:cc90af20c8646eeb5968abf14b2b52a110ca278ff20fa4878dfc37fbdb13ac72** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/43035094/) (`pubmed-observation-pmid-43035094-2026-11-15-cc90af20c864`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Tirzepatide in Adolescents With Obesity: Research Summary." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/tirzepatide.json#pubmed-pmid-43035094-tirzepatide-v1 SHA-256: 75686bacb842355fc968c173129b4878e1ae6e605fd93579bd38fd0c989c478f.

